Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cannabinoids in health and disease</title><author><name sortKey="Kogan, Natalya M" sort="Kogan, Natalya M" uniqKey="Kogan N" first="Natalya M." last="Kogan">Natalya M. Kogan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18286801</idno><idno type="pmc">3202504</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202504</idno><idno type="RBID">PMC:3202504</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">000276</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000276</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Cannabinoids in health and disease</title><author><name sortKey="Kogan, Natalya M" sort="Kogan, Natalya M" uniqKey="Kogan N" first="Natalya M." last="Kogan">Natalya M. Kogan</name></author></analytic><series><title level="j">Dialogues in Clinical Neuroscience</title><idno type="ISSN">1294-8322</idno><idno type="eISSN">1958-5969</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Cannabis sativa L. preparations have been used in medicine for millenia. However, concern over the dangers of abuse led to the banning of the medicinal use of marijuana in most countries in the 1930s. Only recently, marijuana and individual natural and synthetic cannabinoid receptor agonists and antagonists, as well as chemically related compounds, whose mechanism of action is still obscure, have come back to being considered of therapeutic value. However, their use is highly restricted. Despite the mild addiction to cannabis and the possible enhancement of addiction to other substances of abuse, when combined with cannabis, the therapeutic value of cannabinoids is too high to be put aside. Numerous diseases, such as anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Tourette's syndrome, Alzheimer's disease), epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders, to name just a few, are being treated or have the potential to be treated by cannabinoid agonists/antagonists/cannabinoid-related compounds. In view of the very low toxicity and the generally benign side effects of this group of compounds, neglecting or denying their clinical potential is unacceptable - instead, we need to work on the development of more selective cannabinoid receptor agonists/antagonists and related compounds, as well as on novel drugs of this family with better selectivity, distribution patterns, and pharmacokinetics, and - in cases where it is impossible to separate the desired clinical action and the psychoactivity - just to monitor these side effects carefully.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Zias, J" uniqKey="Zias J">J. Zias</name></author><author><name sortKey="Stark, H" uniqKey="Stark H">H. Stark</name></author><author><name sortKey="Sellgman, J" uniqKey="Sellgman J">J. Sellgman</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schlesinger, S" uniqKey="Schlesinger S">S. Schlesinger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Decourtive, E" uniqKey="Decourtive E">E. Decourtive</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author><author><name sortKey="Hanus, L" uniqKey="Hanus L">L. Hanus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gaoni, Y" uniqKey="Gaoni Y">Y. Gaoni</name></author><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Waller, Cw Jj" uniqKey="Waller C">CW. JJ. Waller</name></author><author><name sortKey="Buelke, J" uniqKey="Buelke J">J. Buelke</name></author><author><name sortKey="Turner, Ce" uniqKey="Turner C">CE. Turner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fraser, Jd" uniqKey="Fraser J">JD. Fraser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grinspoon, L" uniqKey="Grinspoon L">L. Grinspoon</name></author><author><name sortKey="Bakalar, Jb" uniqKey="Bakalar J">JB. Bakalar</name></author><author><name sortKey="Zimmer, L" uniqKey="Zimmer L">L. Zimmer</name></author><author><name sortKey="Morgan, Jp" uniqKey="Morgan J">JP. Morgan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kaymakcalan, S" uniqKey="Kaymakcalan S">S. Kaymakcalan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jones, Rt" uniqKey="Jones R">RT. Jones</name></author><author><name sortKey="Benowitz, N" uniqKey="Benowitz N">N. Benowitz</name></author><author><name sortKey="Bachman, J" uniqKey="Bachman J">J. Bachman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nordstrom, Br" uniqKey="Nordstrom B">BR. Nordstrom</name></author><author><name sortKey="Levin, Fr" uniqKey="Levin F">FR. Levin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bernoussi, A" uniqKey="Bernoussi A">A. Bernoussi</name></author><author><name sortKey="Brandibas, G" uniqKey="Brandibas G">G. Brandibas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Budney, Aj" uniqKey="Budney A">AJ. Budney</name></author><author><name sortKey="Moore, Ba" uniqKey="Moore B">BA. Moore</name></author><author><name sortKey="Rocha, Hl" uniqKey="Rocha H">HL. Rocha</name></author><author><name sortKey="Higgins, St" uniqKey="Higgins S">ST. Higgins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gardner, El" uniqKey="Gardner E">EL. Gardner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maldonado, R" uniqKey="Maldonado R">R. Maldonado</name></author><author><name sortKey="Rodriguez, De Fonseca F" uniqKey="Rodriguez D">de Fonseca F. Rodriguez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mansbach, Rs" uniqKey="Mansbach R">RS. Mansbach</name></author><author><name sortKey="Nicholson, Kl" uniqKey="Nicholson K">KL. Nicholson</name></author><author><name sortKey="Martin, Br" uniqKey="Martin B">BR. Martin</name></author><author><name sortKey="Balster, Rl" uniqKey="Balster R">RL. Balster</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Colombo, G" uniqKey="Colombo G">G. Colombo</name></author><author><name sortKey="Serra, S" uniqKey="Serra S">S. Serra</name></author><author><name sortKey="Vacca, G" uniqKey="Vacca G">G. Vacca</name></author><author><name sortKey="Carai, Ma" uniqKey="Carai M">MA. Carai</name></author><author><name sortKey="Gessa, Gl" uniqKey="Gessa G">GL. Gessa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, L" uniqKey="Wang L">L. Wang</name></author><author><name sortKey="Liu, J" uniqKey="Liu J">J. Liu</name></author><author><name sortKey="Harvey White, J" uniqKey="Harvey White J">J. Harvey-White</name></author><author><name sortKey="Zimmer, A" uniqKey="Zimmer A">A. Zimmer</name></author><author><name sortKey="Kunos, G" uniqKey="Kunos G">G. Kunos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cohen, C" uniqKey="Cohen C">C. Cohen</name></author><author><name sortKey="Perrault, G" uniqKey="Perrault G">G. Perrault</name></author><author><name sortKey="Voltz, C" uniqKey="Voltz C">C. Voltz</name></author><author><name sortKey="Steinberg, R" uniqKey="Steinberg R">R. Steinberg</name></author><author><name sortKey="Soubrie, P" uniqKey="Soubrie P">P. Soubrie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Miller, Ns" uniqKey="Miller N">NS. Miller</name></author><author><name sortKey="Gold, Ms" uniqKey="Gold M">MS. Gold</name></author><author><name sortKey="Klahr, Al" uniqKey="Klahr A">AL. Klahr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Foltin, Rw" uniqKey="Foltin R">RW. Foltin</name></author><author><name sortKey="Fischman, Mw" uniqKey="Fischman M">MW. Fischman</name></author><author><name sortKey="Pippen, Pa" uniqKey="Pippen P">PA. Pippen</name></author><author><name sortKey="Kelly, Th" uniqKey="Kelly T">TH. Kelly</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lukas, Se" uniqKey="Lukas S">SE. Lukas</name></author><author><name sortKey="Sholar, M" uniqKey="Sholar M">M. Sholar</name></author><author><name sortKey="Kouri, E" uniqKey="Kouri E">E. Kouri</name></author><author><name sortKey="Fukuzako, H" uniqKey="Fukuzako H">H. Fukuzako</name></author><author><name sortKey="Mendelson, Jh" uniqKey="Mendelson J">JH. Mendelson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ballon, N" uniqKey="Ballon N">N. Ballon</name></author><author><name sortKey="Leroy, S" uniqKey="Leroy S">S. Leroy</name></author><author><name sortKey="Roy, C" uniqKey="Roy C">C. Roy</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Filip, M" uniqKey="Filip M">M. Filip</name></author><author><name sortKey="Golda, A" uniqKey="Golda A">A. Golda</name></author><author><name sortKey="Zaniewska, M" uniqKey="Zaniewska M">M. Zaniewska</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Le Foll, B" uniqKey="Le Foll B">B. Le Foll</name></author><author><name sortKey="Goldberg, Sr" uniqKey="Goldberg S">SR. Goldberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cohen, C" uniqKey="Cohen C">C. Cohen</name></author><author><name sortKey="Perrault, G" uniqKey="Perrault G">G. Perrault</name></author><author><name sortKey="Griebel, G" uniqKey="Griebel G">G. Griebel</name></author><author><name sortKey="Soubrie, P" uniqKey="Soubrie P">P. Soubrie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Castane, A" uniqKey="Castane A">A. Castane</name></author><author><name sortKey="Berrendero, F" uniqKey="Berrendero F">F. Berrendero</name></author><author><name sortKey="Maldonado, R" uniqKey="Maldonado R">R. Maldonado</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Einecke, D" uniqKey="Einecke D">D. Einecke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Foulds, J" uniqKey="Foulds J">J. Foulds</name></author><author><name sortKey="Burke, M" uniqKey="Burke M">M. Burke</name></author><author><name sortKey="Steinberg, M" uniqKey="Steinberg M">M. Steinberg</name></author><author><name sortKey="Williams, Jm" uniqKey="Williams J">JM. Williams</name></author><author><name sortKey="Ziedonis, Dm" uniqKey="Ziedonis D">DM. Ziedonis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gelfand, Ev" uniqKey="Gelfand E">EV. Gelfand</name></author><author><name sortKey="Cannon, Cp" uniqKey="Cannon C">CP. Cannon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yao, L" uniqKey="Yao L">L. Yao</name></author><author><name sortKey="Mcfarland, K" uniqKey="Mcfarland K">K. McFarland</name></author><author><name sortKey="Fan, P" uniqKey="Fan P">P. Fan</name></author><author><name sortKey="Jiang, Z" uniqKey="Jiang Z">Z. Jiang</name></author><author><name sortKey="Ueda, T" uniqKey="Ueda T">T. Ueda</name></author><author><name sortKey="Diamond, I" uniqKey="Diamond I">I. Diamond</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ledent, C" uniqKey="Ledent C">C. Ledent</name></author><author><name sortKey="Valverde, O" uniqKey="Valverde O">O. Valverde</name></author><author><name sortKey="Cossu, G" uniqKey="Cossu G">G. Cossu</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laviolette, Sr" uniqKey="Laviolette S">SR. Laviolette</name></author><author><name sortKey="Grace, Aa" uniqKey="Grace A">AA. Grace</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Le Foll, B" uniqKey="Le Foll B">B. Le Foll</name></author><author><name sortKey="Goldberg, Sr" uniqKey="Goldberg S">SR. Goldberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Solowij, N" uniqKey="Solowij N">N. Solowij</name></author><author><name sortKey="Stephens, Rs" uniqKey="Stephens R">RS. Stephens</name></author><author><name sortKey="Roffman, Ra" uniqKey="Roffman R">RA. Roffman</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Klugman, A" uniqKey="Klugman A">A. Klugman</name></author><author><name sortKey="Gruzelier, J" uniqKey="Gruzelier J">J. Gruzelier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wadsworth, Ej" uniqKey="Wadsworth E">EJ. Wadsworth</name></author><author><name sortKey="Moss, Sc" uniqKey="Moss S">SC. Moss</name></author><author><name sortKey="Simpson, Sa" uniqKey="Simpson S">SA. Simpson</name></author><author><name sortKey="Smith, Ap" uniqKey="Smith A">AP. Smith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jager, G" uniqKey="Jager G">G. Jager</name></author><author><name sortKey="Kahn, Rs" uniqKey="Kahn R">RS. Kahn</name></author><author><name sortKey="Van Den Brink, W" uniqKey="Van Den Brink W">W. Van Den Brink</name></author><author><name sortKey="Van Ree, Jm" uniqKey="Van Ree J">JM. Van Ree</name></author><author><name sortKey="Ramsey, Nf" uniqKey="Ramsey N">NF. Ramsey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maj, Pf" uniqKey="Maj P">PF. Maj</name></author><author><name sortKey="Collu, M" uniqKey="Collu M">M. Collu</name></author><author><name sortKey="Fadda, P" uniqKey="Fadda P">P. Fadda</name></author><author><name sortKey="Cattaneo, A" uniqKey="Cattaneo A">A. Cattaneo</name></author><author><name sortKey="Racagni, G" uniqKey="Racagni G">G. Racagni</name></author><author><name sortKey="Riva, Ma" uniqKey="Riva M">MA. Riva</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huizink, Ac" uniqKey="Huizink A">AC. Huizink</name></author><author><name sortKey="Mulder, Ej" uniqKey="Mulder E">EJ. Mulder</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fried, Pa" uniqKey="Fried P">PA. Fried</name></author><author><name sortKey="Smith, Am" uniqKey="Smith A">AM. Smith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Murray, Rm" uniqKey="Murray R">RM. Murray</name></author><author><name sortKey="Morrison, Pd" uniqKey="Morrison P">PD. Morrison</name></author><author><name sortKey="Henquet, C" uniqKey="Henquet C">C. Henquet</name></author><author><name sortKey="Di Forti, M" uniqKey="Di Forti M">M. Di Forti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Solowij, N" uniqKey="Solowij N">N. Solowij</name></author><author><name sortKey="Michie, Pt" uniqKey="Michie P">PT. Michie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Favrat, B" uniqKey="Favrat B">B. Favrat</name></author><author><name sortKey="Menetrey, A" uniqKey="Menetrey A">A. Menetrey</name></author><author><name sortKey="Augsburger, M" uniqKey="Augsburger M">M. Augsburger</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="D Souza, Dc" uniqKey="D Souza D">DC. D'Souza</name></author><author><name sortKey="Perry, E" uniqKey="Perry E">E. Perry</name></author><author><name sortKey="Macdougall, L" uniqKey="Macdougall L">L. MacDougall</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ozaki, S" uniqKey="Ozaki S">S. Ozaki</name></author><author><name sortKey="Wada, K" uniqKey="Wada K">K. Wada</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fujiwara, M" uniqKey="Fujiwara M">M. Fujiwara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tunving, K" uniqKey="Tunving K">K. Tunving</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laqueille, X" uniqKey="Laqueille X">X. Laqueille</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mendelson, Jh" uniqKey="Mendelson J">JH. Mendelson</name></author><author><name sortKey="Kuehnle, Jc" uniqKey="Kuehnle J">JC. Kuehnle</name></author><author><name sortKey="Greenberg, I" uniqKey="Greenberg I">I. Greenberg</name></author><author><name sortKey="Mello, Nk" uniqKey="Mello N">NK. Mello</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barnwell, Ss" uniqKey="Barnwell S">SS. Barnwell</name></author><author><name sortKey="Earleywine, M" uniqKey="Earleywine M">M. Earleywine</name></author><author><name sortKey="Wilcox, R" uniqKey="Wilcox R">R. Wilcox</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wargo, Ka" uniqKey="Wargo K">KA. Wargo</name></author><author><name sortKey="Geveden, Bn" uniqKey="Geveden B">BN. Geveden</name></author><author><name sortKey="Mcconnell, Vj" uniqKey="Mcconnell V">VJ. McConnell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kirkham, Tc" uniqKey="Kirkham T">TC. Kirkham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kirkham, Tc" uniqKey="Kirkham T">TC. Kirkham</name></author><author><name sortKey="Tucci, Sa" uniqKey="Tucci S">SA. Tucci</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Russo, P" uniqKey="Russo P">P. Russo</name></author><author><name sortKey="Strazzullo, P" uniqKey="Strazzullo P">P. Strazzullo</name></author><author><name sortKey="Cappuccio, Fp" uniqKey="Cappuccio F">FP. Cappuccio</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gessa, Gl" uniqKey="Gessa G">GL. Gessa</name></author><author><name sortKey="Orru, A" uniqKey="Orru A">A. Orru</name></author><author><name sortKey="Lai, P" uniqKey="Lai P">P. Lai</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ward, Sj" uniqKey="Ward S">SJ. Ward</name></author><author><name sortKey="Dykstra, La" uniqKey="Dykstra L">LA. Dykstra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Simiand, J" uniqKey="Simiand J">J. Simiand</name></author><author><name sortKey="Keane, M" uniqKey="Keane M">M. Keane</name></author><author><name sortKey="Keane, Pe" uniqKey="Keane P">PE. Keane</name></author><author><name sortKey="Soubrie, P" uniqKey="Soubrie P">P. Soubrie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carai, Ma" uniqKey="Carai M">MA. Carai</name></author><author><name sortKey="Colombo, G" uniqKey="Colombo G">G Colombo</name></author><author><name sortKey="Maccioni, P" uniqKey="Maccioni P">P. Maccioni</name></author><author><name sortKey="Gessa, Gl" uniqKey="Gessa G">GL. Gessa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pagotto, U" uniqKey="Pagotto U">U. Pagotto</name></author><author><name sortKey="Pasquali, R" uniqKey="Pasquali R">R. Pasquali</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Despres, Jp" uniqKey="Despres J">JP. Despres</name></author><author><name sortKey="Golay, A" uniqKey="Golay A">A. Golay</name></author><author><name sortKey="Sjostrom, L" uniqKey="Sjostrom L">L. Sjostrom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pi Sunyer, Fx" uniqKey="Pi Sunyer F">FX. Pi-Sunyer</name></author><author><name sortKey="Aronne, Lj" uniqKey="Aronne L">LJ. Aronne</name></author><author><name sortKey="Heshmati, Hm" uniqKey="Heshmati H">HM. Heshmati</name></author><author><name sortKey="Devin, J" uniqKey="Devin J">J. Devin</name></author><author><name sortKey="Rosenstock, J" uniqKey="Rosenstock J">J. Rosenstock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Gaal, Lf" uniqKey="Van Gaal L">LF. Van Gaal</name></author><author><name sortKey="Rissanen, Am" uniqKey="Rissanen A">AM. Rissanen</name></author><author><name sortKey="Scheen, Aj" uniqKey="Scheen A">AJ. Scheen</name></author><author><name sortKey="Ziegler, O" uniqKey="Ziegler O">O. Ziegler</name></author><author><name sortKey="Rossner, S" uniqKey="Rossner S">S. Rossner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cleland, Jg" uniqKey="Cleland J">JG. Cleland</name></author><author><name sortKey="Ghosh, J" uniqKey="Ghosh J">J. Ghosh</name></author><author><name sortKey="Freemantle, N" uniqKey="Freemantle N">N. Freemantle</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scheen, Aj" uniqKey="Scheen A">AJ. Scheen</name></author><author><name sortKey="Van Gaal, Lg" uniqKey="Van Gaal L">LG. Van Gaal</name></author><author><name sortKey="Despres, Jp" uniqKey="Despres J">JP. Despres</name></author><author><name sortKey="Pi Sunyer, X" uniqKey="Pi Sunyer X">X. Pi-Sunyer</name></author><author><name sortKey="Golay, A" uniqKey="Golay A">A. Golay</name></author><author><name sortKey="Hanotin, C" uniqKey="Hanotin C">C. Hanotin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shapiro, H" uniqKey="Shapiro H">H. Shapiro</name></author><author><name sortKey="Singer, P" uniqKey="Singer P">P. Singer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Patel, Pn" uniqKey="Patel P">PN. Patel</name></author><author><name sortKey="Pathak, R" uniqKey="Pathak R">R. Pathak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beal, Je" uniqKey="Beal J">JE. Beal</name></author><author><name sortKey="Olson, R" uniqKey="Olson R">R. Olson</name></author><author><name sortKey="Lefkowitz, L" uniqKey="Lefkowitz L">L. Lefkowitz</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beal, Je" uniqKey="Beal J">JE. Beal</name></author><author><name sortKey="Olson, R" uniqKey="Olson R">R. Olson</name></author><author><name sortKey="Laubenstein, L" uniqKey="Laubenstein L">L. Laubenstein</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gorter, R" uniqKey="Gorter R">R. Gorter</name></author><author><name sortKey="Seefried, M" uniqKey="Seefried M">M. Seefried</name></author><author><name sortKey="Volberding, P" uniqKey="Volberding P">P. Volberding</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Timpone, Jg" uniqKey="Timpone J">JG. Timpone</name></author><author><name sortKey="Wright, Dj" uniqKey="Wright D">DJ. Wright</name></author><author><name sortKey="Li, N" uniqKey="Li N">N. Li</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nauck, F" uniqKey="Nauck F">F. Nauck</name></author><author><name sortKey="Klaschik, E" uniqKey="Klaschik E">E. Klaschik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nelson, K" uniqKey="Nelson K">K. Nelson</name></author><author><name sortKey="Walsh, D" uniqKey="Walsh D">D. Walsh</name></author><author><name sortKey="Deeter, P" uniqKey="Deeter P">P. Deeter</name></author><author><name sortKey="Sheehan, F" uniqKey="Sheehan F">F. Sheehan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martin, Br" uniqKey="Martin B">BR. Martin</name></author><author><name sortKey="Wiley, Jl" uniqKey="Wiley J">JL. Wiley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abrahamov, A" uniqKey="Abrahamov A">A. Abrahamov</name></author><author><name sortKey="Abrahamov, A" uniqKey="Abrahamov A">A. Abrahamov</name></author><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tramer, Mr" uniqKey="Tramer M">MR. Tramer</name></author><author><name sortKey="Carroll, D" uniqKey="Carroll D">D. Carroll</name></author><author><name sortKey="Campbell, Fa" uniqKey="Campbell F">FA. Campbell</name></author><author><name sortKey="Reynolds, Dj" uniqKey="Reynolds D">DJ. Reynolds</name></author><author><name sortKey="Moore, Ra" uniqKey="Moore R">RA. Moore</name></author><author><name sortKey="Mcquay, Hj" uniqKey="Mcquay H">HJ. McQuay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liang, Yc" uniqKey="Liang Y">YC. Liang</name></author><author><name sortKey="Huang, Cc" uniqKey="Huang C">CC. Huang</name></author><author><name sortKey="Hsu, Ks" uniqKey="Hsu K">KS. Hsu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Volfe, Z" uniqKey="Volfe Z">Z. Volfe</name></author><author><name sortKey="Dvilansky, A" uniqKey="Dvilansky A">A. Dvilansky</name></author><author><name sortKey="Nathan, I" uniqKey="Nathan I">I. Nathan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Attal, N" uniqKey="Attal N">N. Attal</name></author><author><name sortKey="Brasseur, L" uniqKey="Brasseur L">L. Brasseur</name></author><author><name sortKey="Guirimand, D" uniqKey="Guirimand D">D. Guirimand</name></author><author><name sortKey="Clermond Gnamien, S" uniqKey="Clermond Gnamien S">S. Clermond-Gnamien</name></author><author><name sortKey="Atlami, S" uniqKey="Atlami S">S. Atlami</name></author><author><name sortKey="Bouhassira, D" uniqKey="Bouhassira D">D. Bouhassira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buggy, Dj" uniqKey="Buggy D">DJ. Buggy</name></author><author><name sortKey="Toogood, L" uniqKey="Toogood L">L. Toogood</name></author><author><name sortKey="Marie, S" uniqKey="Marie S">S. Marie</name></author><author><name sortKey="Sharpe, P" uniqKey="Sharpe P">P. Sharpe</name></author><author><name sortKey="Lambert, Dg" uniqKey="Lambert D">DG. Lambert</name></author><author><name sortKey="Rowbotham, Dj" uniqKey="Rowbotham D">DJ. Rowbotham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Holdcroft, A" uniqKey="Holdcroft A">A. Holdcroft</name></author><author><name sortKey="Smith, M" uniqKey="Smith M">M. Smith</name></author><author><name sortKey="Jacklin, A" uniqKey="Jacklin A">A. Jacklin</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Berman, Js" uniqKey="Berman J">JS. Berman</name></author><author><name sortKey="Symonds, C" uniqKey="Symonds C">C. Symonds</name></author><author><name sortKey="Birch, R" uniqKey="Birch R">R. Birch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Svendsen, Kb" uniqKey="Svendsen K">KB. Svendsen</name></author><author><name sortKey="Jensen, Ts" uniqKey="Jensen T">TS. Jensen</name></author><author><name sortKey="Bach, Fw" uniqKey="Bach F">FW. Bach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Svendsen, Kb" uniqKey="Svendsen K">KB. Svendsen</name></author><author><name sortKey="Jensen, Ts" uniqKey="Jensen T">TS. Jensen</name></author><author><name sortKey="Bach, Fw" uniqKey="Bach F">FW. Bach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Noyes, R" uniqKey="Noyes R">R. Noyes</name></author><author><name sortKey="Jr" uniqKey="Jr">Jr.</name></author><author><name sortKey="Brunk, Sf" uniqKey="Brunk S">SF. Brunk</name></author><author><name sortKey="Avery, Da" uniqKey="Avery D">DA. Avery</name></author><author><name sortKey="Canter, Ac" uniqKey="Canter A">AC. Canter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Noyes, R" uniqKey="Noyes R">R. Noyes</name></author><author><name sortKey="Jr" uniqKey="Jr">Jr.</name></author><author><name sortKey="Brunk, Sf" uniqKey="Brunk S">SF. Brunk</name></author><author><name sortKey="Baram, Da" uniqKey="Baram D">DA. Baram</name></author><author><name sortKey="Canter, A" uniqKey="Canter A">A. Canter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ware, Ma" uniqKey="Ware M">MA. Ware</name></author><author><name sortKey="Doyle, Cr" uniqKey="Doyle C">CR. Doyle</name></author><author><name sortKey="Woods, R" uniqKey="Woods R">R. Woods</name></author><author><name sortKey="Lynch, Me" uniqKey="Lynch M">ME. Lynch</name></author><author><name sortKey="Clark, Aj" uniqKey="Clark A">AJ. Clark</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Woolridge, E" uniqKey="Woolridge E">E. Woolridge</name></author><author><name sortKey="Barton, S" uniqKey="Barton S">S. Barton</name></author><author><name sortKey="Samuel, J" uniqKey="Samuel J">J. Samuel</name></author><author><name sortKey="Osorio, J" uniqKey="Osorio J">J. Osorio</name></author><author><name sortKey="Dougherty, A" uniqKey="Dougherty A">A. Dougherty</name></author><author><name sortKey="Holdcroft, A" uniqKey="Holdcroft A">A. Holdcroft</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Berlach, Dm" uniqKey="Berlach D">DM. Berlach</name></author><author><name sortKey="Shir, Y" uniqKey="Shir Y">Y. Shir</name></author><author><name sortKey="Ware, Ma" uniqKey="Ware M">MA. Ware</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wissel, J" uniqKey="Wissel J">J. Wissel</name></author><author><name sortKey="Haydn, T" uniqKey="Haydn T">T. Haydn</name></author><author><name sortKey="Muiier, J" uniqKey="Muiier J">J. MuIIer</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karst, M" uniqKey="Karst M">M. Karst</name></author><author><name sortKey="Salim, K" uniqKey="Salim K">K. Salim</name></author><author><name sortKey="Burstein, S" uniqKey="Burstein S">S. Burstein</name></author><author><name sortKey="Conrad, I" uniqKey="Conrad I">I. Conrad</name></author><author><name sortKey="Hoy, L" uniqKey="Hoy L">L. Hoy</name></author><author><name sortKey="Schneider, U" uniqKey="Schneider U">U. Schneider</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vann, Re" uniqKey="Vann R">RE. Vann</name></author><author><name sortKey="Cook, Cd" uniqKey="Cook C">CD. Cook</name></author><author><name sortKey="Martin, Br" uniqKey="Martin B">BR. Martin</name></author><author><name sortKey="Jenny, L" uniqKey="Jenny L">L. Jenny</name></author><author><name sortKey="Wiley, Jl" uniqKey="Wiley J">JL. Wiley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Russo, E" uniqKey="Russo E">E. Russo</name></author><author><name sortKey="Guy, Gw" uniqKey="Guy G">GW. Guy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iskedjian, M" uniqKey="Iskedjian M">M. Iskedjian</name></author><author><name sortKey="Bereza, B" uniqKey="Bereza B">B. Bereza</name></author><author><name sortKey="Gordon, A" uniqKey="Gordon A">A. Gordon</name></author><author><name sortKey="Piwko, C" uniqKey="Piwko C">C. Piwko</name></author><author><name sortKey="Einarson, Tr" uniqKey="Einarson T">TR. Einarson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Notcutt, W" uniqKey="Notcutt W">W. Notcutt</name></author><author><name sortKey="Price, M" uniqKey="Price M">M. Price</name></author><author><name sortKey="Miller, R" uniqKey="Miller R">R. Miller</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rog, Dj" uniqKey="Rog D">DJ. Rog</name></author><author><name sortKey="Nurmikko, Tj" uniqKey="Nurmikko T">TJ. Nurmikko</name></author><author><name sortKey="Friede, T" uniqKey="Friede T">T. Friede</name></author><author><name sortKey="Young, Ca" uniqKey="Young C">CA. Young</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barnes, Mp" uniqKey="Barnes M">MP. Barnes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Perez, J" uniqKey="Perez J">J. Perez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ware, M" uniqKey="Ware M">M. Ware</name></author><author><name sortKey="Beaulieu, P" uniqKey="Beaulieu P">P. Beaulieu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Achiron, A" uniqKey="Achiron A">A. Achiron</name></author><author><name sortKey="Miron, S" uniqKey="Miron S">S. Miron</name></author><author><name sortKey="Lavie, V" uniqKey="Lavie V">V. Lavie</name></author><author><name sortKey="Margalit, R" uniqKey="Margalit R">R. Margalit</name></author><author><name sortKey="Biegon, A" uniqKey="Biegon A">A. Biegon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lyman, Wd" uniqKey="Lyman W">WD. Lyman</name></author><author><name sortKey="Sonett, Jr" uniqKey="Sonett J">JR. Sonett</name></author><author><name sortKey="Brosnan, Cf" uniqKey="Brosnan C">CF. Brosnan</name></author><author><name sortKey="Elkin, R" uniqKey="Elkin R">R. Elkin</name></author><author><name sortKey="Bornstein, Mb" uniqKey="Bornstein M">MB. Bornstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sanchez, Aj" uniqKey="Sanchez A">AJ. Sanchez</name></author><author><name sortKey="Gonzalez Perez, P" uniqKey="Gonzalez Perez P">P. Gonzalez-Perez</name></author><author><name sortKey="Galve Roperh, I" uniqKey="Galve Roperh I">I. Galve-Roperh</name></author><author><name sortKey="Garcia Merino, A" uniqKey="Garcia Merino A">A. Garcia-Merino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Docagne, F" uniqKey="Docagne F">F. Docagne</name></author><author><name sortKey="Muneton, V" uniqKey="Muneton V">V. Muneton</name></author><author><name sortKey="Clemente, D" uniqKey="Clemente D">D. Clemente</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benito, C" uniqKey="Benito C">C. Benito</name></author><author><name sortKey="Romero, Jp" uniqKey="Romero J">JP. Romero</name></author><author><name sortKey="Tolon, Rm" uniqKey="Tolon R">RM. Tolon</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cabranes, A" uniqKey="Cabranes A">A. Cabranes</name></author><author><name sortKey="Pryce, G" uniqKey="Pryce G">G. Pryce</name></author><author><name sortKey="Baker, D" uniqKey="Baker D">D. Baker</name></author><author><name sortKey="Fernandez Ruiz, J" uniqKey="Fernandez Ruiz J">J. Fernandez-Ruiz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Petro, Dj" uniqKey="Petro D">DJ. Petro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pryce, G" uniqKey="Pryce G">G. Pryce</name></author><author><name sortKey="Baker, D" uniqKey="Baker D">D. Baker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ungerieider, Jt" uniqKey="Ungerieider J">JT. UngerIeider</name></author><author><name sortKey="Andyrsiak, T" uniqKey="Andyrsiak T">T. Andyrsiak</name></author><author><name sortKey="Fairbanks, L" uniqKey="Fairbanks L">L. Fairbanks</name></author><author><name sortKey="Ellison, Gw" uniqKey="Ellison G">GW. Ellison</name></author><author><name sortKey="Myers, Lw" uniqKey="Myers L">LW. Myers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martyn, Cn" uniqKey="Martyn C">CN. Martyn</name></author><author><name sortKey="Lllis, Ls" uniqKey="Lllis L">LS. lllis</name></author><author><name sortKey="Thom, J" uniqKey="Thom J">J. Thom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meinck, Hm" uniqKey="Meinck H">HM. Meinck</name></author><author><name sortKey="Schonle, Pw" uniqKey="Schonle P">PW. Schonle</name></author><author><name sortKey="Conrad, B" uniqKey="Conrad B">B. Conrad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Petro, Dj" uniqKey="Petro D">DJ. Petro</name></author><author><name sortKey="Ellenberger, C" uniqKey="Ellenberger C">C. Ellenberger</name></author><author><name sortKey="Jr" uniqKey="Jr">Jr.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brenneisen, R" uniqKey="Brenneisen R">R. Brenneisen</name></author><author><name sortKey="Egli, A" uniqKey="Egli A">A. Egli</name></author><author><name sortKey="Elsohly, Ma" uniqKey="Elsohly M">MA. Elsohly</name></author><author><name sortKey="Henn, V" uniqKey="Henn V">V. Henn</name></author><author><name sortKey="Spiess, Y" uniqKey="Spiess Y">Y. Spiess</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koch, M" uniqKey="Koch M">M. Koch</name></author><author><name sortKey="Mostert, J" uniqKey="Mostert J">J. Mostert</name></author><author><name sortKey="Heersema, D" uniqKey="Heersema D">D. Heersema</name></author><author><name sortKey="De Keyser, J" uniqKey="De Keyser J">J. De Keyser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Killestein, J" uniqKey="Killestein J">J. Killestein</name></author><author><name sortKey="Hoogervorst, El" uniqKey="Hoogervorst E">EL. Hoogervorst</name></author><author><name sortKey="Reif, M" uniqKey="Reif M">M. Reif</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greenberg, Hs" uniqKey="Greenberg H">HS. Greenberg</name></author><author><name sortKey="Werness, Sa" uniqKey="Werness S">SA. Werness</name></author><author><name sortKey="Pugh, Je" uniqKey="Pugh J">JE. Pugh</name></author><author><name sortKey="Andrus, Ro" uniqKey="Andrus R">RO. Andrus</name></author><author><name sortKey="Anderson, Dj" uniqKey="Anderson D">DJ. Anderson</name></author><author><name sortKey="Domino, Ef" uniqKey="Domino E">EF. Domino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clifford, Db" uniqKey="Clifford D">DB. Clifford</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fox, P" uniqKey="Fox P">P. Fox</name></author><author><name sortKey="Bain, Pg" uniqKey="Bain P">PG. Bain</name></author><author><name sortKey="Glickman, S" uniqKey="Glickman S">S. Glickman</name></author><author><name sortKey="Carroll, C" uniqKey="Carroll C">C. Carroll</name></author><author><name sortKey="Zajicek, J" uniqKey="Zajicek J">J. Zajicek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schon, F" uniqKey="Schon F">F. Schon</name></author><author><name sortKey="Hart, Pe" uniqKey="Hart P">PE. Hart</name></author><author><name sortKey="Hodgson, Tl" uniqKey="Hodgson T">TL. Hodgson</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Freeman, Rm" uniqKey="Freeman R">RM. Freeman</name></author><author><name sortKey="Adekanmi, O" uniqKey="Adekanmi O">O. Adekanmi</name></author><author><name sortKey="Waterfield, Mr" uniqKey="Waterfield M">MR. Waterfield</name></author><author><name sortKey="Waterfield, Ae" uniqKey="Waterfield A">AE. Waterfield</name></author><author><name sortKey="Wright, D" uniqKey="Wright D">D. Wright</name></author><author><name sortKey="Zajicek, J" uniqKey="Zajicek J">J. Zajicek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, Pf" uniqKey="Smith P">PF. Smith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vaney, C" uniqKey="Vaney C">C. Vaney</name></author><author><name sortKey="Heinzel Gutenbrunner, M" uniqKey="Heinzel Gutenbrunner M">M. Heinzel-Gutenbrunner</name></author><author><name sortKey="Jobin, P" uniqKey="Jobin P">P. Jobin</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wade, Dt" uniqKey="Wade D">DT. Wade</name></author><author><name sortKey="Makela, P" uniqKey="Makela P">P. Makela</name></author><author><name sortKey="Robson, P" uniqKey="Robson P">P. Robson</name></author><author><name sortKey="House, H" uniqKey="House H">H. House</name></author><author><name sortKey="Bateman, C" uniqKey="Bateman C">C. Bateman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wade, Dt" uniqKey="Wade D">DT. Wade</name></author><author><name sortKey="Makela, Pm" uniqKey="Makela P">PM. Makela</name></author><author><name sortKey="House, H" uniqKey="House H">H. House</name></author><author><name sortKey="Bateman, C" uniqKey="Bateman C">C. Bateman</name></author><author><name sortKey="Robson, P" uniqKey="Robson P">P. Robson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zajicek, J" uniqKey="Zajicek J">J. Zajicek</name></author><author><name sortKey="Fox, P" uniqKey="Fox P">P. Fox</name></author><author><name sortKey="Sanders, H" uniqKey="Sanders H">H. Sanders</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zajicek, Jp" uniqKey="Zajicek J">JP. Zajicek</name></author><author><name sortKey="Sanders, Hp" uniqKey="Sanders H">HP. Sanders</name></author><author><name sortKey="Wright, De" uniqKey="Wright D">DE. Wright</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bifuico, M" uniqKey="Bifuico M">M. BifuIco</name></author><author><name sortKey="Laezza, C" uniqKey="Laezza C">C. Laezza</name></author><author><name sortKey="Malfitano, Am" uniqKey="Malfitano A">AM. Malfitano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bowiing, A" uniqKey="Bowiing A">A. BowIing</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maccarrone, M" uniqKey="Maccarrone M">M. Maccarrone</name></author><author><name sortKey="Battista, N" uniqKey="Battista N">N. Battista</name></author><author><name sortKey="Centonze, D" uniqKey="Centonze D">D. Centonze</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mestre, L" uniqKey="Mestre L">L. Mestre</name></author><author><name sortKey="Correa, F" uniqKey="Correa F">F. Correa</name></author><author><name sortKey="Docagne, F" uniqKey="Docagne F">F. Docagne</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lastres Becker, I" uniqKey="Lastres Becker I">I. Lastres-Becker</name></author><author><name sortKey="Molina Holgado, F" uniqKey="Molina Holgado F">F. Molina-Holgado</name></author><author><name sortKey="Ramos, Ja" uniqKey="Ramos J">JA. Ramos</name></author><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author><author><name sortKey="Fernandez Ruiz, J" uniqKey="Fernandez Ruiz J">J. Fernandez-Ruiz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sommer, C" uniqKey="Sommer C">C. Sommer</name></author><author><name sortKey="Schomacher, M" uniqKey="Schomacher M">M. Schomacher</name></author><author><name sortKey="Berger, C" uniqKey="Berger C">C. Berger</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Knoiler, N" uniqKey="Knoiler N">N. KnoIler</name></author><author><name sortKey="Levi, L" uniqKey="Levi L">L. Levi</name></author><author><name sortKey="Shoshan, I" uniqKey="Shoshan I">I. Shoshan</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maas, Ai" uniqKey="Maas A">AI. Maas</name></author><author><name sortKey="Murray, G" uniqKey="Murray G">G. Murray</name></author><author><name sortKey="Henney, H" uniqKey="Henney H">H. Henney</name></author><author><name sortKey="3rd" uniqKey="3rd">3rd.</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Klein, Tw" uniqKey="Klein T">TW. Klein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walter, L" uniqKey="Walter L">L. Walter</name></author><author><name sortKey="Stella, N" uniqKey="Stella N">N. Stella</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marchalant, Y" uniqKey="Marchalant Y">Y. Marchalant</name></author><author><name sortKey="Rosi, S" uniqKey="Rosi S">S. Rosi</name></author><author><name sortKey="Wenk, Gl" uniqKey="Wenk G">GL. Wenk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maresz, K" uniqKey="Maresz K">K. Maresz</name></author><author><name sortKey="Pryce, G" uniqKey="Pryce G">G. Pryce</name></author><author><name sortKey="Ponomarev, Ed" uniqKey="Ponomarev E">ED. Ponomarev</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steffens, S" uniqKey="Steffens S">S. Steffens</name></author><author><name sortKey="Veillard, Nr" uniqKey="Veillard N">NR. Veillard</name></author><author><name sortKey="Arnaud, C" uniqKey="Arnaud C">C. Arnaud</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Darmani, Na" uniqKey="Darmani N">NA. Darmani</name></author><author><name sortKey="Izzo, Aa" uniqKey="Izzo A">AA. Izzo</name></author><author><name sortKey="Degenhardt, B" uniqKey="Degenhardt B">B. Degenhardt</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rajesh, M" uniqKey="Rajesh M">M. Rajesh</name></author><author><name sortKey="Mukhopadhyay, P" uniqKey="Mukhopadhyay P">P. Mukhopadhyay</name></author><author><name sortKey="Batkai, S" uniqKey="Batkai S">S. Batkai</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Croci, T" uniqKey="Croci T">T. Croci</name></author><author><name sortKey="Zarini, E" uniqKey="Zarini E">E. Zarini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brotchie, Jm" uniqKey="Brotchie J">JM. Brotchie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maneuf, Yp" uniqKey="Maneuf Y">YP. Maneuf</name></author><author><name sortKey="Crossman, Ar" uniqKey="Crossman A">AR. Crossman</name></author><author><name sortKey="Brotchie, Jm" uniqKey="Brotchie J">JM. Brotchie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferrer, B" uniqKey="Ferrer B">B. Ferrer</name></author><author><name sortKey="Asbrock, N" uniqKey="Asbrock N">N. Asbrock</name></author><author><name sortKey="Kathuria, S" uniqKey="Kathuria S">S. Kathuria</name></author><author><name sortKey="Piomelli, D" uniqKey="Piomelli D">D. Piomelli</name></author><author><name sortKey="Giuffrida, A" uniqKey="Giuffrida A">A. Giuffrida</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gonzalez, S" uniqKey="Gonzalez S">S. Gonzalez</name></author><author><name sortKey="Scorticati, C" uniqKey="Scorticati C">C. Scorticati</name></author><author><name sortKey="Garcia Arencibia, M" uniqKey="Garcia Arencibia M">M. Garcia-Arencibia</name></author><author><name sortKey="De Miguel, R" uniqKey="De Miguel R">R. de Miguel</name></author><author><name sortKey="Ramos, Ja" uniqKey="Ramos J">JA. Ramos</name></author><author><name sortKey="Fernandez Ruiz, J" uniqKey="Fernandez Ruiz J">J. Fernandez-Ruiz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lastres Becker, I" uniqKey="Lastres Becker I">I. Lastres-Becker</name></author><author><name sortKey="Cebeira, M" uniqKey="Cebeira M">M. Cebeira</name></author><author><name sortKey="De Ceballos, Ml" uniqKey="De Ceballos M">ML. de Ceballos</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pisani, A" uniqKey="Pisani A">A. Pisani</name></author><author><name sortKey="Fezza, F" uniqKey="Fezza F">F. Fezza</name></author><author><name sortKey="Galati, S" uniqKey="Galati S">S. Galati</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kreitzer, Ac" uniqKey="Kreitzer A">AC. Kreitzer</name></author><author><name sortKey="Malenka, Rc" uniqKey="Malenka R">RC. Malenka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sieradzan, Ka" uniqKey="Sieradzan K">KA. Sieradzan</name></author><author><name sortKey="Fox, Sh" uniqKey="Fox S">SH. Fox</name></author><author><name sortKey="Hill, M" uniqKey="Hill M">M. Hill</name></author><author><name sortKey="Dick, Jp" uniqKey="Dick J">JP. Dick</name></author><author><name sortKey="Crossman, Ar" uniqKey="Crossman A">AR. Crossman</name></author><author><name sortKey="Brotchie, Jm" uniqKey="Brotchie J">JM. Brotchie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jabusch, Hc" uniqKey="Jabusch H">HC. Jabusch</name></author><author><name sortKey="Schneider, U" uniqKey="Schneider U">U. Schneider</name></author><author><name sortKey="Altenmuiier, E" uniqKey="Altenmuiier E">E. AltenmuIIer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carroll, Cb" uniqKey="Carroll C">CB. Carroll</name></author><author><name sortKey="Bain, Pg" uniqKey="Bain P">PG. Bain</name></author><author><name sortKey="Teare, L" uniqKey="Teare L">L. Teare</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fox, Sh" uniqKey="Fox S">SH. Fox</name></author><author><name sortKey="Kellett, M" uniqKey="Kellett M">M. Kellett</name></author><author><name sortKey="Moore, Ap" uniqKey="Moore A">AP. Moore</name></author><author><name sortKey="Crossman, Ar" uniqKey="Crossman A">AR. Crossman</name></author><author><name sortKey="Brotchie, Jm" uniqKey="Brotchie J">JM. Brotchie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mesnage, V" uniqKey="Mesnage V">V. Mesnage</name></author><author><name sortKey="Houeto, Jl" uniqKey="Houeto J">JL. Houeto</name></author><author><name sortKey="Bonnet, Am" uniqKey="Bonnet A">AM. Bonnet</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Venderova, K" uniqKey="Venderova K">K. Venderova</name></author><author><name sortKey="Ruzicka, E" uniqKey="Ruzicka E">E. Ruzicka</name></author><author><name sortKey="Vorisek, V" uniqKey="Vorisek V">V. Vorisek</name></author><author><name sortKey="Visnovsky, P" uniqKey="Visnovsky P">P. Visnovsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aisasua, Del Valle A" uniqKey="Aisasua D">del Valle A. AIsasua</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lastres Becker, I" uniqKey="Lastres Becker I">I. Lastres-Becker</name></author><author><name sortKey="Fernandez Ruiz, J" uniqKey="Fernandez Ruiz J">J. Fernandez-Ruiz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sevcik, J" uniqKey="Sevcik J">J. Sevcik</name></author><author><name sortKey="Masek, K" uniqKey="Masek K">K. Masek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glass, M" uniqKey="Glass M">M. Glass</name></author><author><name sortKey="Dragunow, M" uniqKey="Dragunow M">M. Dragunow</name></author><author><name sortKey="Faull, Rl" uniqKey="Faull R">RL. Faull</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Richfield, Ek" uniqKey="Richfield E">EK. Richfield</name></author><author><name sortKey="Herkenham, M" uniqKey="Herkenham M">M. Herkenham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glass, M" uniqKey="Glass M">M. Glass</name></author><author><name sortKey="Faull, Rl" uniqKey="Faull R">RL. Faull</name></author><author><name sortKey="Dragunow, M" uniqKey="Dragunow M">M. Dragunow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Lago, E" uniqKey="De Lago E">E. de Lago</name></author><author><name sortKey="Urbani, P" uniqKey="Urbani P">P. Urbani</name></author><author><name sortKey="Ramos, Ja" uniqKey="Ramos J">JA. Ramos</name></author><author><name sortKey="Di Marzo, V" uniqKey="Di Marzo V">V. Di Marzo</name></author><author><name sortKey="Fernandez Ruiz, J" uniqKey="Fernandez Ruiz J">J. Fernandez-Ruiz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lastres Becker, I" uniqKey="Lastres Becker I">I. Lastres-Becker</name></author><author><name sortKey="De Miguel, R" uniqKey="De Miguel R">R. de Miguel</name></author><author><name sortKey="De Petrocellis, L" uniqKey="De Petrocellis L">L. De Petrocellis</name></author><author><name sortKey="Makriyannis, A" uniqKey="Makriyannis A">A. Makriyannis</name></author><author><name sortKey="Di Marzo, V" uniqKey="Di Marzo V">V. Di Marzo</name></author><author><name sortKey="Fernandez Ruiz, J" uniqKey="Fernandez Ruiz J">J. Fernandez-Ruiz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pintor, A" uniqKey="Pintor A">A. Pintor</name></author><author><name sortKey="Tebano, Mt" uniqKey="Tebano M">MT. Tebano</name></author><author><name sortKey="Martire, A" uniqKey="Martire A">A. Martire</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Consroe, P" uniqKey="Consroe P">P. Consroe</name></author><author><name sortKey="Laguna, J" uniqKey="Laguna J">J. Laguna</name></author><author><name sortKey="Ahender, J" uniqKey="Ahender J">J. AHender</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mulier Vahl, Kr" uniqKey="Mulier Vahl K">KR. MulIer-Vahl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller Vahl, Kr" uniqKey="Muller Vahl K">KR. Muller-Vahl</name></author><author><name sortKey="Prevedel, H" uniqKey="Prevedel H">H. Prevedel</name></author><author><name sortKey="Theloe, K" uniqKey="Theloe K">K. Theloe</name></author><author><name sortKey="Kolbe, H" uniqKey="Kolbe H">H. Kolbe</name></author><author><name sortKey="Emrich, Hm" uniqKey="Emrich H">HM. Emrich</name></author><author><name sortKey="Schneider, U" uniqKey="Schneider U">U. Schneider</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muiier Vahi, Kr" uniqKey="Muiier Vahi K">KR. MuIIer-VahI</name></author><author><name sortKey="Schneider, U" uniqKey="Schneider U">U. Schneider</name></author><author><name sortKey="Koblenz, A" uniqKey="Koblenz A">A. Koblenz</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muiier Vahl, Kr" uniqKey="Muiier Vahl K">KR. MuIIer-Vahl</name></author><author><name sortKey="Schneider, U" uniqKey="Schneider U">U. Schneider</name></author><author><name sortKey="Prevedel, H" uniqKey="Prevedel H">H. Prevedel</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gadzicki, D" uniqKey="Gadzicki D">D. Gadzicki</name></author><author><name sortKey="Muiier Vahl, Kr" uniqKey="Muiier Vahl K">KR. MuIIer-Vahl</name></author><author><name sortKey="Heller, D" uniqKey="Heller D">D. Heller</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, Gt" uniqKey="Carter G">GT. Carter</name></author><author><name sortKey="Rosen, Bs" uniqKey="Rosen B">BS. Rosen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bilsland, Lg" uniqKey="Bilsland L">LG. Bilsland</name></author><author><name sortKey="Dick, Jr" uniqKey="Dick J">JR. Dick</name></author><author><name sortKey="Pryce, G" uniqKey="Pryce G">G. Pryce</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raman, C" uniqKey="Raman C">C. Raman</name></author><author><name sortKey="Mcallister, Sd" uniqKey="Mcallister S">SD. McAllister</name></author><author><name sortKey="Rizvi, G" uniqKey="Rizvi G">G. Rizvi</name></author><author><name sortKey="Patel, Sg" uniqKey="Patel S">SG. Patel</name></author><author><name sortKey="Moore, Dh" uniqKey="Moore D">DH. Moore</name></author><author><name sortKey="Abood, Me" uniqKey="Abood M">ME. Abood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weydt, P" uniqKey="Weydt P">P. Weydt</name></author><author><name sortKey="Hong, S" uniqKey="Hong S">S. Hong</name></author><author><name sortKey="Witting, A" uniqKey="Witting A">A. Witting</name></author><author><name sortKey="Moiier, T" uniqKey="Moiier T">T. MoIIer</name></author><author><name sortKey="Stella, N" uniqKey="Stella N">N. Stella</name></author><author><name sortKey="Kliot, M" uniqKey="Kliot M">M. Kliot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, K" uniqKey="Kim K">K. Kim</name></author><author><name sortKey="Moore, Dh" uniqKey="Moore D">DH. Moore</name></author><author><name sortKey="Makriyannis, A" uniqKey="Makriyannis A">A. Makriyannis</name></author><author><name sortKey="Abood, Me" uniqKey="Abood M">ME. Abood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shoemaker, Jl" uniqKey="Shoemaker J">JL. Shoemaker</name></author><author><name sortKey="Seely, Ka" uniqKey="Seely K">KA. Seely</name></author><author><name sortKey="Reed, Rl" uniqKey="Reed R">RL. Reed</name></author><author><name sortKey="Crow, Jp" uniqKey="Crow J">JP. Crow</name></author><author><name sortKey="Prather, Pl" uniqKey="Prather P">PL. Prather</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Amtmann, D" uniqKey="Amtmann D">D. Amtmann</name></author><author><name sortKey="Weydt, P" uniqKey="Weydt P">P. Weydt</name></author><author><name sortKey="Johnson, Kl" uniqKey="Johnson K">KL. Johnson</name></author><author><name sortKey="Jensen, Mp" uniqKey="Jensen M">MP. Jensen</name></author><author><name sortKey="Carter, Gt" uniqKey="Carter G">GT. Carter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eubanks, Lm" uniqKey="Eubanks L">LM. Eubanks</name></author><author><name sortKey="Rogers, Cj" uniqKey="Rogers C">CJ. Rogers</name></author><author><name sortKey="Beuscher, Ae Th" uniqKey="Beuscher A">AE. 4th. Beuscher</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Voiicer, L" uniqKey="Voiicer L">L. VoIicer</name></author><author><name sortKey="Stelly, M" uniqKey="Stelly M">M. Stelly</name></author><author><name sortKey="Morris, J" uniqKey="Morris J">J. Morris</name></author><author><name sortKey="Mclaughlin, J" uniqKey="Mclaughlin J">J. McLaughlin</name></author><author><name sortKey="Volicer, Bj" uniqKey="Volicer B">BJ. Volicer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Waither, S" uniqKey="Waither S">S. WaIther</name></author><author><name sortKey="Mahlberg, R" uniqKey="Mahlberg R">R. Mahlberg</name></author><author><name sortKey="Eichmann, U" uniqKey="Eichmann U">U. Eichmann</name></author><author><name sortKey="Kunz, D" uniqKey="Kunz D">D. Kunz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carlini, Ea" uniqKey="Carlini E">EA. Carlini</name></author><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author><author><name sortKey="Lander, N" uniqKey="Lander N">N. Lander</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Consroe, P" uniqKey="Consroe P">P. Consroe</name></author><author><name sortKey="Martin, A" uniqKey="Martin A">A. Martin</name></author><author><name sortKey="Singh, V" uniqKey="Singh V">V. Singh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martin, Ar" uniqKey="Martin A">AR. Martin</name></author><author><name sortKey="Consroe, P" uniqKey="Consroe P">P. Consroe</name></author><author><name sortKey="Kane, W" uniqKey="Kane W">W. Kane</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ames, Fr" uniqKey="Ames F">FR. Ames</name></author><author><name sortKey="Cridland, S" uniqKey="Cridland S">S. Cridland</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Consroe, P" uniqKey="Consroe P">P. Consroe</name></author><author><name sortKey="Wolkin, A" uniqKey="Wolkin A">A. Wolkin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Consroe, Pf" uniqKey="Consroe P">PF. Consroe</name></author><author><name sortKey="Wolkin, Al" uniqKey="Wolkin A">AL. Wolkin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cortesi, M" uniqKey="Cortesi M">M. Cortesi</name></author><author><name sortKey="Fusar Poli, P" uniqKey="Fusar Poli P">P. Fusar-Poli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deshpande, Ls" uniqKey="Deshpande L">LS. Deshpande</name></author><author><name sortKey="Sombati, S" uniqKey="Sombati S">S. Sombati</name></author><author><name sortKey="Blair, Re" uniqKey="Blair R">RE. Blair</name></author><author><name sortKey="Carter, Ds" uniqKey="Carter D">DS. Carter</name></author><author><name sortKey="Martin, Br" uniqKey="Martin B">BR. Martin</name></author><author><name sortKey="Delorenzo, Rj" uniqKey="Delorenzo R">RJ. DeLorenzo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Luszczki, Jj" uniqKey="Luszczki J">JJ. Luszczki</name></author><author><name sortKey="Czuczwar, P" uniqKey="Czuczwar P">P. Czuczwar</name></author><author><name sortKey="Cioczek Czuczwar, A" uniqKey="Cioczek Czuczwar A">A. Cioczek-Czuczwar</name></author><author><name sortKey="Czuczwar, Sj" uniqKey="Czuczwar S">SJ. Czuczwar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gordon, E" uniqKey="Gordon E">E. Gordon</name></author><author><name sortKey="Devinsky, O" uniqKey="Devinsky O">O. Devinsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keeler, Mh" uniqKey="Keeler M">MH. Keeler</name></author><author><name sortKey="Reifler, Cb" uniqKey="Reifler C">CB. Reifler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cunha, Jm" uniqKey="Cunha J">JM. Cunha</name></author><author><name sortKey="Carlini, Ea" uniqKey="Carlini E">EA. Carlini</name></author><author><name sortKey="Pereira, Ae" uniqKey="Pereira A">AE. Pereira</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ashton, Ch" uniqKey="Ashton C">CH. Ashton</name></author><author><name sortKey="Moore, Pb" uniqKey="Moore P">PB. Moore</name></author><author><name sortKey="Gallagher, P" uniqKey="Gallagher P">P. Gallagher</name></author><author><name sortKey="Young, Ah" uniqKey="Young A">AH. Young</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grinspoon, L" uniqKey="Grinspoon L">L. Grinspoon</name></author><author><name sortKey="Bakalar, Jb" uniqKey="Bakalar J">JB. Bakalar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Emrich, Hm" uniqKey="Emrich H">HM. Emrich</name></author><author><name sortKey="Leweke, Fm" uniqKey="Leweke F">FM. Leweke</name></author><author><name sortKey="Schneider, U" uniqKey="Schneider U">U. Schneider</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leweke, Fm" uniqKey="Leweke F">FM. Leweke</name></author><author><name sortKey="Giuffrida, A" uniqKey="Giuffrida A">A. Giuffrida</name></author><author><name sortKey="Koethe, D" uniqKey="Koethe D">D. Koethe</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kenchadze, Vg" uniqKey="Kenchadze V">VG. Kenchadze</name></author><author><name sortKey="Chkoniia, Ed" uniqKey="Chkoniia E">ED. Chkoniia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcguire, Pk" uniqKey="Mcguire P">PK. McGuire</name></author><author><name sortKey="Jones, P" uniqKey="Jones P">P. Jones</name></author><author><name sortKey="Harvey, I" uniqKey="Harvey I">I. Harvey</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jockers Scherubl, Mc" uniqKey="Jockers Scherubl M">MC. Jockers-Scherubl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boydeii, J" uniqKey="Boydeii J">J. BoydeII</name></author><author><name sortKey="Dean, K" uniqKey="Dean K">K. Dean</name></author><author><name sortKey="Dutta, R" uniqKey="Dutta R">R. Dutta</name></author><author><name sortKey="Giouroukou, E" uniqKey="Giouroukou E">E. Giouroukou</name></author><author><name sortKey="Fearon, P" uniqKey="Fearon P">P. Fearon</name></author><author><name sortKey="Murray, R" uniqKey="Murray R">R. Murray</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dubertret, C" uniqKey="Dubertret C">C. Dubertret</name></author><author><name sortKey="Bidard, I" uniqKey="Bidard I">I. Bidard</name></author><author><name sortKey="Ades, J" uniqKey="Ades J">J. Ades</name></author><author><name sortKey="Gorwood, P" uniqKey="Gorwood P">P. Gorwood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meltzer, Hy" uniqKey="Meltzer H">HY. Meltzer</name></author><author><name sortKey="Arvanitis, L" uniqKey="Arvanitis L">L. Arvanitis</name></author><author><name sortKey="Bauer, D" uniqKey="Bauer D">D. Bauer</name></author><author><name sortKey="Rein, W" uniqKey="Rein W">W. Rein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zuardi, Aw" uniqKey="Zuardi A">AW. Zuardi</name></author><author><name sortKey="Morais, Sl" uniqKey="Morais S">SL. Morais</name></author><author><name sortKey="Guimaraes, Fs" uniqKey="Guimaraes F">FS. Guimaraes</name></author><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zuardi, Aw" uniqKey="Zuardi A">AW. Zuardi</name></author><author><name sortKey="Crippa, Ja" uniqKey="Crippa J">JA. Crippa</name></author><author><name sortKey="Hallak, Je" uniqKey="Hallak J">JE. Hallak</name></author><author><name sortKey="Moreira, Fa" uniqKey="Moreira F">FA. Moreira</name></author><author><name sortKey="Guimaraes, Fs" uniqKey="Guimaraes F">FS. Guimaraes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zuardi, Aw" uniqKey="Zuardi A">AW. Zuardi</name></author><author><name sortKey="Hallak, Je" uniqKey="Hallak J">JE. Hallak</name></author><author><name sortKey="Dursun, Sm" uniqKey="Dursun S">SM. Dursun</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chhatwal, Jp" uniqKey="Chhatwal J">JP. Chhatwal</name></author><author><name sortKey="Davis, M" uniqKey="Davis M">M. Davis</name></author><author><name sortKey="Maguschak, Ka" uniqKey="Maguschak K">KA. Maguschak</name></author><author><name sortKey="Ressler, Kj" uniqKey="Ressler K">KJ. Ressler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Varvel, Sa" uniqKey="Varvel S">SA. Varvel</name></author><author><name sortKey="Wise, Le" uniqKey="Wise L">LE. Wise</name></author><author><name sortKey="Niyuhire, F" uniqKey="Niyuhire F">F. Niyuhire</name></author><author><name sortKey="Cravatt, Bf" uniqKey="Cravatt B">BF. Cravatt</name></author><author><name sortKey="Lichtman, Ah" uniqKey="Lichtman A">AH. Lichtman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fride, E" uniqKey="Fride E">E. Fride</name></author><author><name sortKey="Suris, R" uniqKey="Suris R">R. Suris</name></author><author><name sortKey="Weidenfeld, J" uniqKey="Weidenfeld J">J. Weidenfeld</name></author><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Calhoun, Ps" uniqKey="Calhoun P">PS. Calhoun</name></author><author><name sortKey="Sampson, Ws" uniqKey="Sampson W">WS. Sampson</name></author><author><name sortKey="Bosworth, Hb" uniqKey="Bosworth H">HB. Bosworth</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barrero, Fj" uniqKey="Barrero F">FJ. Barrero</name></author><author><name sortKey="Ampuero, I" uniqKey="Ampuero I">I. Ampuero</name></author><author><name sortKey="Morales, B" uniqKey="Morales B">B. Morales</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guimaraes, Fs" uniqKey="Guimaraes F">FS. Guimaraes</name></author><author><name sortKey="Chiaretti, Tm" uniqKey="Chiaretti T">TM. Chiaretti</name></author><author><name sortKey="Graeff, Fg" uniqKey="Graeff F">FG. Graeff</name></author><author><name sortKey="Zuardi, Aw" uniqKey="Zuardi A">AW. Zuardi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guimaraes, Fs" uniqKey="Guimaraes F">FS. Guimaraes</name></author><author><name sortKey="De Aguiar, Jc" uniqKey="De Aguiar J">JC. de Aguiar</name></author><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author><author><name sortKey="Breuer, A" uniqKey="Breuer A">A. Breuer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glass, Rm" uniqKey="Glass R">RM. Glass</name></author><author><name sortKey="Uhlenhuth, Eh" uniqKey="Uhlenhuth E">EH. Uhlenhuth</name></author><author><name sortKey="Hartel, Fw" uniqKey="Hartel F">FW. Hartel</name></author><author><name sortKey="Schuster, Cr" uniqKey="Schuster C">CR. Schuster</name></author><author><name sortKey="Fischman, Mw" uniqKey="Fischman M">MW. Fischman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fabre, Lf" uniqKey="Fabre L">LF. Fabre</name></author><author><name sortKey="Mclendon, D" uniqKey="Mclendon D">D. McLendon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barratt, Es" uniqKey="Barratt E">ES. Barratt</name></author><author><name sortKey="Beaver, W" uniqKey="Beaver W">W. Beaver</name></author><author><name sortKey="White, R" uniqKey="White R">R. White</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Freemon, Fr" uniqKey="Freemon F">FR. Freemon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pivik, Rt" uniqKey="Pivik R">RT. Pivik</name></author><author><name sortKey="Zarcone, V" uniqKey="Zarcone V">V. Zarcone</name></author><author><name sortKey="Dement, Wc" uniqKey="Dement W">WC. Dement</name></author><author><name sortKey="Hollister, Le" uniqKey="Hollister L">LE. Hollister</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feinberg, I" uniqKey="Feinberg I">I. Feinberg</name></author><author><name sortKey="Jones, R" uniqKey="Jones R">R. Jones</name></author><author><name sortKey="Walker, J" uniqKey="Walker J">J. Walker</name></author><author><name sortKey="Cavness, C" uniqKey="Cavness C">C. Cavness</name></author><author><name sortKey="Floyd, T" uniqKey="Floyd T">T. Floyd</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feinberg, I" uniqKey="Feinberg I">I. Feinberg</name></author><author><name sortKey="Jones, R" uniqKey="Jones R">R. Jones</name></author><author><name sortKey="Walker, Jm" uniqKey="Walker J">JM. Walker</name></author><author><name sortKey="Cavness, C" uniqKey="Cavness C">C. Cavness</name></author><author><name sortKey="March, J" uniqKey="March J">J. March</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nicholson, An" uniqKey="Nicholson A">AN. Nicholson</name></author><author><name sortKey="Turner, C" uniqKey="Turner C">C. Turner</name></author><author><name sortKey="Stone, Bm" uniqKey="Stone B">BM. Stone</name></author><author><name sortKey="Robson, Pj" uniqKey="Robson P">PJ. Robson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tashkin, Dp" uniqKey="Tashkin D">DP. Tashkin</name></author><author><name sortKey="Shapiro, Bj" uniqKey="Shapiro B">BJ. Shapiro</name></author><author><name sortKey="Lee, Ye" uniqKey="Lee Y">YE. Lee</name></author><author><name sortKey="Harper, Ce" uniqKey="Harper C">CE. Harper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tashkin, Dp" uniqKey="Tashkin D">DP. Tashkin</name></author><author><name sortKey="Calvarese, Bm" uniqKey="Calvarese B">BM. Calvarese</name></author><author><name sortKey="Simmons, Ms" uniqKey="Simmons M">MS. Simmons</name></author><author><name sortKey="Shapiro, Bj" uniqKey="Shapiro B">BJ. Shapiro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abboud, Rt" uniqKey="Abboud R">RT. Abboud</name></author><author><name sortKey="Sanders, Hd" uniqKey="Sanders H">HD. Sanders</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tashkin, Dp" uniqKey="Tashkin D">DP. Tashkin</name></author><author><name sortKey="Shapiro, Bj" uniqKey="Shapiro B">BJ. Shapiro</name></author><author><name sortKey="Frank, Im" uniqKey="Frank I">IM. Frank</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tashkin, Dp" uniqKey="Tashkin D">DP. Tashkin</name></author><author><name sortKey="Shapiro, Bj" uniqKey="Shapiro B">BJ. Shapiro</name></author><author><name sortKey="Frank, Im" uniqKey="Frank I">IM. Frank</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gong, H" uniqKey="Gong H">H. Gong</name></author><author><name sortKey="Jr" uniqKey="Jr">Jr.</name></author><author><name sortKey="Tashkin, Dp" uniqKey="Tashkin D">DP. Tashkin</name></author><author><name sortKey="Simmons, Ms" uniqKey="Simmons M">MS. Simmons</name></author><author><name sortKey="Calvarese, B" uniqKey="Calvarese B">B. Calvarese</name></author><author><name sortKey="Shapiro, Bj" uniqKey="Shapiro B">BJ. Shapiro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hartley, Jp" uniqKey="Hartley J">JP. Hartley</name></author><author><name sortKey="Nogrady, Sg" uniqKey="Nogrady S">SG. Nogrady</name></author><author><name sortKey="Seaton, A" uniqKey="Seaton A">A. Seaton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Williams, Sj" uniqKey="Williams S">SJ. Williams</name></author><author><name sortKey="Hartley, Jp" uniqKey="Hartley J">JP. Hartley</name></author><author><name sortKey="Graham, Jd" uniqKey="Graham J">JD. Graham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benowitz, Nl" uniqKey="Benowitz N">NL. Benowitz</name></author><author><name sortKey="Rosenberg, J" uniqKey="Rosenberg J">J. Rosenberg</name></author><author><name sortKey="Rogers, W" uniqKey="Rogers W">W. Rogers</name></author><author><name sortKey="Bachman, J" uniqKey="Bachman J">J. Bachman</name></author><author><name sortKey="Jones, Rt" uniqKey="Jones R">RT. Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kanakis, C" uniqKey="Kanakis C">C. Kanakis</name></author><author><name sortKey="Jr" uniqKey="Jr">Jr.</name></author><author><name sortKey="Pouget, Jm" uniqKey="Pouget J">JM. Pouget</name></author><author><name sortKey="Rosen, Km" uniqKey="Rosen K">KM. Rosen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tashkin, Dp" uniqKey="Tashkin D">DP. Tashkin</name></author><author><name sortKey="Levisman, Ja" uniqKey="Levisman J">JA. Levisman</name></author><author><name sortKey="Abbasi, As" uniqKey="Abbasi A">AS. Abbasi</name></author><author><name sortKey="Shapiro, Bj" uniqKey="Shapiro B">BJ. Shapiro</name></author><author><name sortKey="Ellis, Nm" uniqKey="Ellis N">NM. Ellis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benowitz, Nl" uniqKey="Benowitz N">NL. Benowitz</name></author><author><name sortKey="Jones, Rt" uniqKey="Jones R">RT. Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benowitz, Nl" uniqKey="Benowitz N">NL. Benowitz</name></author><author><name sortKey="Jones, Rt" uniqKey="Jones R">RT. Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goreiick, Da" uniqKey="Goreiick D">DA. GoreIick</name></author><author><name sortKey="Heishman, Sj" uniqKey="Heishman S">SJ. Heishman</name></author><author><name sortKey="Preston, Kl" uniqKey="Preston K">KL. Preston</name></author><author><name sortKey="Nelson, Ra" uniqKey="Nelson R">RA. Nelson</name></author><author><name sortKey="Moolchan, Et" uniqKey="Moolchan E">ET. Moolchan</name></author><author><name sortKey="Huestis, Ma" uniqKey="Huestis M">MA. Huestis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eisohiy, Ma" uniqKey="Eisohiy M">MA. EisohIy</name></author><author><name sortKey="Harland, E" uniqKey="Harland E">E. Harland</name></author><author><name sortKey="Murphy, Jc" uniqKey="Murphy J">JC. Murphy</name></author><author><name sortKey="Wirth, P" uniqKey="Wirth P">P. Wirth</name></author><author><name sortKey="Waller, Cw" uniqKey="Waller C">CW. Waller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Elsohly, Ma" uniqKey="Elsohly M">MA. ElSohly</name></author><author><name sortKey="Harland, Ec" uniqKey="Harland E">EC. Harland</name></author><author><name sortKey="Benigni, Da" uniqKey="Benigni D">DA. Benigni</name></author><author><name sortKey="Waller, Cw" uniqKey="Waller C">CW. Waller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buchwaid, A" uniqKey="Buchwaid A">A. BuchwaId</name></author><author><name sortKey="Derendorf, H" uniqKey="Derendorf H">H. Derendorf</name></author><author><name sortKey="Ji, F" uniqKey="Ji F">F. Ji</name></author><author><name sortKey="Nagaraja, Ny" uniqKey="Nagaraja N">NY. Nagaraja</name></author><author><name sortKey="Wu, Wm" uniqKey="Wu W">WM. Wu</name></author><author><name sortKey="Bodor, N" uniqKey="Bodor N">N. Bodor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laine, K" uniqKey="Laine K">K. Laine</name></author><author><name sortKey="Jarvinen, K" uniqKey="Jarvinen K">K. Jarvinen</name></author><author><name sortKey="Mechoulam, R" uniqKey="Mechoulam R">R. Mechoulam</name></author><author><name sortKey="Breuer, A" uniqKey="Breuer A">A. Breuer</name></author><author><name sortKey="Jarvinen, T" uniqKey="Jarvinen T">T. Jarvinen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laine, K" uniqKey="Laine K">K. Laine</name></author><author><name sortKey="Jarvinen, K" uniqKey="Jarvinen K">K. Jarvinen</name></author><author><name sortKey="Pate, Dw" uniqKey="Pate D">DW. Pate</name></author><author><name sortKey="Urtti, A" uniqKey="Urtti A">A. Urtti</name></author><author><name sortKey="Jarvinen, T" uniqKey="Jarvinen T">T. Jarvinen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pate, Dw" uniqKey="Pate D">DW. Pate</name></author><author><name sortKey="Jarvinen, K" uniqKey="Jarvinen K">K. Jarvinen</name></author><author><name sortKey="Urtti, A" uniqKey="Urtti A">A. Urtti</name></author><author><name sortKey="Jarho, P" uniqKey="Jarho P">P. Jarho</name></author><author><name sortKey="Jarvinen, T" uniqKey="Jarvinen T">T. Jarvinen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Porcella, A" uniqKey="Porcella A">A. Porcella</name></author><author><name sortKey="Casellas, P" uniqKey="Casellas P">P. Casellas</name></author><author><name sortKey="Gessa, Gl" uniqKey="Gessa G">GL. Gessa</name></author><author><name sortKey="Pani, L" uniqKey="Pani L">L. Pani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Colasanti, Bk" uniqKey="Colasanti B">BK. Colasanti</name></author><author><name sortKey="Brown, Re" uniqKey="Brown R">RE. Brown</name></author><author><name sortKey="Craig, Cr" uniqKey="Craig C">CR. Craig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Colasanti, Bk" uniqKey="Colasanti B">BK. Colasanti</name></author><author><name sortKey="Craig, Cr" uniqKey="Craig C">CR. Craig</name></author><author><name sortKey="Allara, Rd" uniqKey="Allara R">RD. Allara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coiasanti, Bk" uniqKey="Coiasanti B">BK. CoIasanti</name></author><author><name sortKey="Powell, Sr" uniqKey="Powell S">SR. Powell</name></author><author><name sortKey="Craig, Cr" uniqKey="Craig C">CR. Craig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hepier, Rs" uniqKey="Hepier R">RS. HepIer</name></author><author><name sortKey="Frank, Ir" uniqKey="Frank I">IR. Frank</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Merritt, Jc" uniqKey="Merritt J">JC. Merritt</name></author><author><name sortKey="Olsen, Jl" uniqKey="Olsen J">JL. Olsen</name></author><author><name sortKey="Armstrong, Jr" uniqKey="Armstrong J">JR. Armstrong</name></author><author><name sortKey="Mckinnon, Sm" uniqKey="Mckinnon S">SM. McKinnon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Merritt, Jc" uniqKey="Merritt J">JC. Merritt</name></author><author><name sortKey="Perry, Dd" uniqKey="Perry D">DD. Perry</name></author><author><name sortKey="Russell, Dn" uniqKey="Russell D">DN. Russell</name></author><author><name sortKey="Jones, Bf" uniqKey="Jones B">BF. Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Merritt, Jc" uniqKey="Merritt J">JC. Merritt</name></author><author><name sortKey="Crawford, Wj" uniqKey="Crawford W">WJ. Crawford</name></author><author><name sortKey="Alexander, Pc" uniqKey="Alexander P">PC. Alexander</name></author><author><name sortKey="Anduze, Al" uniqKey="Anduze A">AL. Anduze</name></author><author><name sortKey="Gelbart, Ss" uniqKey="Gelbart S">SS. Gelbart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Purneii, Wd" uniqKey="Purneii W">WD. PurneII</name></author><author><name sortKey="Gregg, Jm" uniqKey="Gregg J">JM. Gregg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Crawford, Wj" uniqKey="Crawford W">WJ. Crawford</name></author><author><name sortKey="Merritt, Jc" uniqKey="Merritt J">JC. Merritt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tomida, I" uniqKey="Tomida I">I. Tomida</name></author><author><name sortKey="Azuara Bianco, A" uniqKey="Azuara Bianco A">A. Azuara-BIanco</name></author><author><name sortKey="House, H" uniqKey="House H">H. House</name></author><author><name sortKey="Flint, M" uniqKey="Flint M">M. Flint</name></author><author><name sortKey="Pertwee, Rg" uniqKey="Pertwee R">RG. Pertwee</name></author><author><name sortKey="Robson, Pj" uniqKey="Robson P">PJ. Robson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hall, W" uniqKey="Hall W">W. Hall</name></author><author><name sortKey="Christie, M" uniqKey="Christie M">M. Christie</name></author><author><name sortKey="Currow, D" uniqKey="Currow D">D. Currow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kogan, Nm" uniqKey="Kogan N">NM. Kogan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bifulco, M" uniqKey="Bifulco M">M. Bifulco</name></author><author><name sortKey="Laezza, C" uniqKey="Laezza C">C. Laezza</name></author><author><name sortKey="Gazzerro, P" uniqKey="Gazzerro P">P. Gazzerro</name></author><author><name sortKey="Pentimalli, F" uniqKey="Pentimalli F">F. Pentimalli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aguado, T" uniqKey="Aguado T">T. Aguado</name></author><author><name sortKey="Carracedo, A" uniqKey="Carracedo A">A. Carracedo</name></author><author><name sortKey="Julien, B" uniqKey="Julien B">B. Julien</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Massi, P" uniqKey="Massi P">P. Massi</name></author><author><name sortKey="Vaccani, A" uniqKey="Vaccani A">A. Vaccani</name></author><author><name sortKey="Bianchessi, S" uniqKey="Bianchessi S">S. Bianchessi</name></author><author><name sortKey="Costa, B" uniqKey="Costa B">B. Costa</name></author><author><name sortKey="Macchi, P" uniqKey="Macchi P">P. Macchi</name></author><author><name sortKey="Parolaro, D" uniqKey="Parolaro D">D. Parolaro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Biazquez, C" uniqKey="Biazquez C">C. BIazquez</name></author><author><name sortKey="Carracedo, A" uniqKey="Carracedo A">A. Carracedo</name></author><author><name sortKey="Barrado, L" uniqKey="Barrado L">L. Barrado</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Caffarel, Mm" uniqKey="Caffarel M">MM. Caffarel</name></author><author><name sortKey="Sarrio, D" uniqKey="Sarrio D">D. Sarrio</name></author><author><name sortKey="Palacios, J" uniqKey="Palacios J">J. Palacios</name></author><author><name sortKey="Guzman, M" uniqKey="Guzman M">M. Guzman</name></author><author><name sortKey="Sanchez, C" uniqKey="Sanchez C">C. Sanchez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carracedo, A" uniqKey="Carracedo A">A. Carracedo</name></author><author><name sortKey="Gironella, M" uniqKey="Gironella M">M. Gironella</name></author><author><name sortKey="Lorente, M" uniqKey="Lorente M">M. Lorente</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jia, W" uniqKey="Jia W">W. Jia</name></author><author><name sortKey="Hegde, Vl" uniqKey="Hegde V">VL. Hegde</name></author><author><name sortKey="Singh, Np" uniqKey="Singh N">NP. Singh</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mckallip, Rj" uniqKey="Mckallip R">RJ. McKallip</name></author><author><name sortKey="Jia, W" uniqKey="Jia W">W. Jia</name></author><author><name sortKey="Schlomer, J" uniqKey="Schlomer J">J. Schlomer</name></author><author><name sortKey="Warren, Jw" uniqKey="Warren J">JW. Warren</name></author><author><name sortKey="Nagarkatti, Ps" uniqKey="Nagarkatti P">PS. Nagarkatti</name></author><author><name sortKey="Nagarkatti, M" uniqKey="Nagarkatti M">M. Nagarkatti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sarfaraz, S" uniqKey="Sarfaraz S">S. Sarfaraz</name></author><author><name sortKey="Afaq, F" uniqKey="Afaq F">F. Afaq</name></author><author><name sortKey="Adhami, Vm" uniqKey="Adhami V">VM. Adhami</name></author><author><name sortKey="Malik, A" uniqKey="Malik A">A. Malik</name></author><author><name sortKey="Mukhtar, H" uniqKey="Mukhtar H">H. Mukhtar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sarnataro, D" uniqKey="Sarnataro D">D. Sarnataro</name></author><author><name sortKey="Pisanti, S" uniqKey="Pisanti S">S. Pisanti</name></author><author><name sortKey="Santoro, A" uniqKey="Santoro A">A. Santoro</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guzman, M" uniqKey="Guzman M">M. Guzman</name></author><author><name sortKey="Duarte, Mj" uniqKey="Duarte M">MJ. Duarte</name></author><author><name sortKey="Blazquez, C" uniqKey="Blazquez C">C. Blazquez</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcclung, Ca" uniqKey="Mcclung C">CA. McClung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harper, Sj" uniqKey="Harper S">SJ. Harper</name></author><author><name sortKey="Jones, Ns" uniqKey="Jones N">NS. Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Brien, C P" uniqKey="O Brien C">C. P. O'Brien</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lader, M" uniqKey="Lader M">M. Lader</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Luetje, Cm" uniqKey="Luetje C">CM. Luetje</name></author><author><name sortKey="Wooten, J" uniqKey="Wooten J">J. Wooten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jansen, Kl" uniqKey="Jansen K">KL. Jansen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jansen, Kl" uniqKey="Jansen K">KL. Jansen</name></author><author><name sortKey="Darracot Cankovic, R" uniqKey="Darracot Cankovic R">R. Darracot-Cankovic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Linazaroso, G" uniqKey="Linazaroso G">G. Linazaroso</name></author><author><name sortKey="Van Blercom, N" uniqKey="Van Blercom N">N. van Blercom</name></author><author><name sortKey="Lasa, A" uniqKey="Lasa A">A. Lasa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greenhill, Ll" uniqKey="Greenhill L">LL. Greenhill</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karsak, M" uniqKey="Karsak M">M. Karsak</name></author><author><name sortKey="Cohen Solal, M" uniqKey="Cohen Solal M">M. Cohen-Solal</name></author><author><name sortKey="Freudenberg, J" uniqKey="Freudenberg J">J. Freudenberg</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ofek, O" uniqKey="Ofek O">O. Ofek</name></author><author><name sortKey="Karsak, M" uniqKey="Karsak M">M. Karsak</name></author><author><name sortKey="Leclerc, N" uniqKey="Leclerc N">N. Leclerc</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Begg, M" uniqKey="Begg M">M. Begg</name></author><author><name sortKey="Pacher, P" uniqKey="Pacher P">P. Pacher</name></author><author><name sortKey="Batkai, S" uniqKey="Batkai S">S. Batkai</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fride, E" uniqKey="Fride E">E. Fride</name></author><author><name sortKey="Foox, A" uniqKey="Foox A">A. Foox</name></author><author><name sortKey="Rosenberg, E" uniqKey="Rosenberg E">E. Rosenberg</name></author><author><name sortKey="Et Al" uniqKey="Et Al">et al.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Baker, D" uniqKey="Baker D">D. Baker</name></author><author><name sortKey="Pryce, G" uniqKey="Pryce G">G. Pryce</name></author><author><name sortKey="Davies, Wl" uniqKey="Davies W">WL. Davies</name></author><author><name sortKey="Hiley, Cr" uniqKey="Hiley C">CR. Hiley</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Dialogues Clin Neurosci</journal-id><journal-id journal-id-type="pmc">Dialogues Clin Neurosci</journal-id><journal-title-group><journal-title>Dialogues in Clinical Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1294-8322</issn><issn pub-type="epub">1958-5969</issn><publisher><publisher-name>Les Laboratoires Servier</publisher-name><publisher-loc>France</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18286801</article-id><article-id pub-id-type="pmc">3202504</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Cannabinoids in health and disease</article-title><trans-title-group xml:lang="es"><trans-title>Cannabinoides en la salud y en la enfermedad</trans-title></trans-title-group><trans-title-group xml:lang="fr"><trans-title>Cannabinoïdes: effets chez le sujet sain et utilisation en thérapeutique</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kogan</surname><given-names>Natalya M.</given-names></name><degrees>MSc</degrees><aff>Medicinal Chemistry and Natural Products Dept, Pharmacy School, Ein-Kerem Medical Campus, the Hebrew University of Jerusalem, Israel</aff></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mechoulam</surname><given-names>Raphael</given-names></name><degrees>PhD</degrees><xref ref-type="corresp" rid="COR2">*</xref><aff>Medicinal Chemistry and Natural Products Dept, Pharmacy School, Ein-Kerem Medical Campus, the Hebrew University of Jerusalem, Israel</aff></contrib></contrib-group><author-notes><corresp id="COR2"><label>*</label>E-mail: <email>mechou@cc.huji.ac.il</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>12</month><year>2007</year></pub-date><pmc-comment>Fake ppub date generated by PMC from publisher pub-date/@pub-type='epub-ppub' </pmc-comment>
<pub-date pub-type="ppub"><month>12</month><year>2007</year></pub-date><volume>9</volume><issue>4</issue><fpage>413</fpage><lpage>430</lpage><permissions><copyright-statement>Copyright: © 2007 LLS</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Cannabis sativa L. preparations have been used in medicine for millenia. However, concern over the dangers of abuse led to the banning of the medicinal use of marijuana in most countries in the 1930s. Only recently, marijuana and individual natural and synthetic cannabinoid receptor agonists and antagonists, as well as chemically related compounds, whose mechanism of action is still obscure, have come back to being considered of therapeutic value. However, their use is highly restricted. Despite the mild addiction to cannabis and the possible enhancement of addiction to other substances of abuse, when combined with cannabis, the therapeutic value of cannabinoids is too high to be put aside. Numerous diseases, such as anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Tourette's syndrome, Alzheimer's disease), epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders, to name just a few, are being treated or have the potential to be treated by cannabinoid agonists/antagonists/cannabinoid-related compounds. In view of the very low toxicity and the generally benign side effects of this group of compounds, neglecting or denying their clinical potential is unacceptable - instead, we need to work on the development of more selective cannabinoid receptor agonists/antagonists and related compounds, as well as on novel drugs of this family with better selectivity, distribution patterns, and pharmacokinetics, and - in cases where it is impossible to separate the desired clinical action and the psychoactivity - just to monitor these side effects carefully.</p></abstract><trans-abstract xml:lang="es"><p>Las preparaciones de Cannabis sativa L. se han empleado en medicina desde hace milenios. Sin embargo, la preocupación acerca de los peligros del abuso condujo a la prohibición de la utilización médica de la marihuana en la mayoría de los países en la década de 1930. Sólo recientemente, los agonistas y antagonistas naturales y sintéticos de los receptores de marihuana, como también compuestos químicamente relacionados, cuyo mecanismo de acción todavía es confuso, han vuelto a reconsiderar el valor terapéutico. Pero su empleo está estrictamente limitado. A pesar de la adicción leve a cannnabis y el posible incremento de la adicción a otras sustancias de abuso, cuando se combinan con cannabis, el valor terapéutico de los cannabinoides es muy alto como para no tomarlo en cuenta. Numerosas enfermedades como la anorexia, la emesis, el dolor, la inflamación, la esclerosis múltiple, trastornos neurodegenerativos (Enfermedad de Parkinson, Enfermedad de Huntington, Síndrome de Tourette, Enfermedad de Alzheimer), epilepsia, glaucoma, osteoporosis, esquizofrenia, trastornos cardiovasculares, cáncer, obesidad, y trastornos relacionados con el síndrome metabólico, por nombrar sólo algunas, están siendo tratadas o tienen el potencial de tratarse por agonistas o antagonistas de los cannabinoides o compuestos relacionados con ellos. Dada la muy baja toxicidad y los efectos secundarios generalmente benignos de este grupo de compuestos, desatender o negar su potencial clínico es inaceptable; hay que trabajar en el desarrollo de agonistas y antagonistas, y compuestos relacionados que sean más selectivos para el receptor de cannabinoides, como también de nuevos fármacos de esta familia con mejor selectividad, patrones de distribución y fármaco-cinética, y - en casos donde sea imposible separar la acción clinica deseada y la psicoactividad - igual monitorear estos efectos secundarios cuidadosamente.</p></trans-abstract><trans-abstract xml:lang="fr"><p>Depuis des millénaires, des préparations à base de Cannabis sativa L. ont été utilisées en médecine. Dans les années 1930 cependant, des inquiétudes concernant le danger lié à l'abus de cette substance ont conduit à l'interdiction de l'utilisation médicale de la marijuana dans la plupart des pays. Ce n'est que depuis peu que la marijuana et les agonistes et antagonistes des récepteurs cannabinoïdes synthétiques et naturels, ainsi que les composés chimiquement apparentés dont le mécanisme d'action est encore obscur, sont à nouveau considérés comme ayant un intérêt thérapeutique. Leur usage est cependant très limité. Malgré la dépendance modérée au cannabis et la possible stimulation de la dépendance à d'autres drogues lorsqu'elles sont associées au cannabis, la valeur thérapeutique des cannabinoïdes est trop élevée pour être négligée. De nombreuses pathologies, telles que l'anorexie, les vomissements, la douleur, l'inflammation, la sclérose en plaques, les troubles neurodégénératifs (maladie de Parkinson, chorée de Huntington, syndrome de Gilles de la Tourette, maladie d'Alzheimer), l'épilepsie, le glaucome, l'ostéoporose, la schizophrénie, les troubles cardiovasculaires, le cancer, l'obésité et les troubles liés au syndrome métabolique, pour n'en nommer que quelques-unes, sont traitées ou pourraient être traitées par des agonistes/antagonistes des cannabinoïdes, ou substances apparentées. Au regard de la très faible toxicité et des effets secondaires généralement bénins de cette classe de produits, il serait inacceptable de négliger ou de nier leur potentiel clinique. Il faut au contraire travailler au développement de récepteurs agonistes/antagonistes des cannabinoïdes et de composés apparentés sélectifs, ainsi qu'à de nouveaux médicaments de cette famille plus sélectifs, avec un mode de distribution et une pharmacocinétique meilleurs. Et lorsqu'il est impossible de séparer l'action clinique désirée et les effets psychoactifs, il est simplement nécessaire de surveiller attentivement les effets indésirables.</p></trans-abstract><kwd-group><kwd><italic>cannabinoids</italic></kwd><kwd><italic>therapeutics</italic></kwd><kwd><italic>medicinal</italic></kwd><kwd><italic>addiction</italic></kwd></kwd-group></article-meta></front><body><p><italic>Cannabis sativa L.</italic> preparations, such as marijuana, hashish, and dagga, have been used in medicine for millenia.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Investigations into the chemistry of <italic>Cannabis</italic> began in the mid-19th century, following a major trend in chemical research at the time, which centered on the quest for active natural products. Numerous alkaloids were isolated in pure form or partially characterized. Morphine, cocaine, strychnine, and many others were purified and used in medicine. However, most of the terpenoids - a major class of secondary plant metabolites, to which the plant cannabinoids also belong - were not isolated until the end of the century or even much later, and in many cases their purity was doubtful.</p><p>In 1840, Schlesinger was apparently the first investigator to obtain an active extract from the leaves and flowers of hemp.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> A few years later, Decourtive described the preparation of an ethanol extract that on evaporation of the solvent gave a dark resin, which he named “cannabin.” <sup><xref ref-type="bibr" rid="ref3">3</xref></sup> For a detailed history of early <italic>Cannabis</italic> research see ref 4. The chemical research on the plant cannabinoids and their derivatives over nearly two centuries is described in ref 5. It was, however, not until 1964 that ∆<sup>9</sup>-tetrahydrocannabinol (∆<sup>9</sup>-THC), the major psychoactive component of <italic>Cannabis</italic>, was isolated in pure form and its structure was elucidated.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Shortly thereafter it was synthesized and became widely available. These chemical advances led to an avalanche of publications on ∆<sup>9</sup>-THC, as well as on cannabidiol (CBD), a nonpsychoactive plant cannabinoid.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> However, concern about the dangers of abuse led to the banning of marijuana and its constituents for medicinal use in United States and many other countries in the 1930s and 1940s. It took decades until cannabinoids came to be considered again as compounds of therapeutic value, and even now their uses are highly restricted. Here we present an overview of the addictive and side effects of cannabinoids vs their therapeutic potential.</p><sec><title>Addiction to canabis, and the influence of cannabis on addiction to other substances</title><p>Marijuana may produce mild dependence in humans.<sup><xref ref-type="bibr" rid="ref8">8</xref>-<xref ref-type="bibr" rid="ref12">12</xref></sup> This was shown to depend on the personality type of the addicts,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> and can be successfully reversed by abstinence or treated by cognitive-behavioral therapy,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> without the occurrence of major withdrawal symptoms. Cannabinoids act on brain reward processes and reward-related behaviors by a mechanism similar to that found with other addictive drugs. In animal models they enhance electrical brain-stimulation reward in the core meso-accumbens reward circuitry of the brain and neural firing of a core dopamine (DA) component and thus elevate DA circuit. In the reward-relevant meso-accumbens DA circuit. In some animal models they produce conditioned place preference (CPP) and self-administration.<sup><xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref16">16</xref></sup> Other studies, however, find THC to be a poor reinforcer, with no or little self-administration.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup></p><p>The abuse of other substances is influenced by the cannabinoids. The cannabinoid system is involved in alcohol-consumption behavior. Cannabinoid CB1 receptor agonists have been found to specifically stimulate alcohol intake and its motivational properties in rats.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> The high ethanol preference of young mice is reduced by the cannabinoid receptor 1 (CB1) antagonist SR141716A (rimonabant) to levels observed in their CB1 knockout littermates.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Dopamine release induced by ethanol in brain was reduced by SR141716A,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> which can explain in part the antiaddictive effect of the drug. Cocaine is another substance of abuse in whose acquisition and consolidation cannabinoids may be involved. High prevalence of alcohol dependence and cannabis dependence can be found in patients with cocaine dependences.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> Marijuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers.<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> Furthermore, a recent genetic study found an association between an n triplet repeat polymorphism in the CB1 encoding <italic>CNR1</italic> gene with cocaine addiction in the African-Caribbean population.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> In another study it was found that withdrawal from repeated access or exposure to cocaine and then a reinstatement of cocaine-seeking behavior or a sensitized locomotor response to a single cocaine challenge, respectively, was potently reduced by pretreatment with rimonabant.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Similarly, acute administration of rimonabant blocked expression of nicotineinduced conditioned place preference.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Rimonabant also reduces nicotine self-administration, and may be effective not only as an aid for smoking cessation, but also in the maintenance of abstinence.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> As the endocannabinoid system plays a role in nicotine addiction,<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> the potential of cannabinoid antagonists to treat it is self-evident.<sup><xref ref-type="bibr" rid="ref29">29</xref>-<xref ref-type="bibr" rid="ref31">31</xref></sup> Opiate and CB1 receptors are coexpressed in the nucleus accumbens and dorsal striatum, and the interaction between the two systems is well known.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> The reinforcing properties of morphine and the severity of the withdrawal syndrome are strongly reduced in CB1-knockout mice<sup><xref ref-type="bibr" rid="ref33">33</xref></sup>; this observation opens an opportunity to treat opiate addiction with rimonabant, as noted with alcohol, cocaine, and nicotine addiction.<sup><xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup></p></sec><sec><title>Negative effects of cannabis other than addiction</title><p>There are some negative effects of cannabis use other than addiction, most of them related to alterations of attentional and cognitive functions or other neuropsychological and behavioral effects. Most of them are noted as a result of early-onset cannabis use (during adolescence).<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Electrophysiological measures have revealed long-term deficits in attention among cannabis users.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> In another study, impairment both in cognitive function and mood following cannabis use was noted.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> However, in another study, cannabis users and controls performed equally well in a working memory task and a selective attention task. Furthermore, cannabis users did not differ from controls in terms of overall patterns of brain activity in the regions involved in these cognitive functions.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Prenatal exposure to cannabis is associated with only minor impaired cognitive and attentional effects.<sup><xref ref-type="bibr" rid="ref40">40</xref>-<xref ref-type="bibr" rid="ref42">42</xref></sup> Cannabis use in adolescence increases the risk of schizophrenia-like psychoses.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> Cognitive dysfunction associated with long-term or heavy cannabis use is similar in many respects to the cognitive endophenotypes that have been proposed as vulnerability markers of schizophrenia.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> Also, evidence exists that cannabis use may trigger acute schizophrenic psychosis.<sup><xref ref-type="bibr" rid="ref45">45</xref>,<xref ref-type="bibr" rid="ref46">46</xref></sup> Cannabis was found to produce a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> Amotivational syndrome is a chronic psychiatric disorder characterized by a variety of changes in personality, emotions, and cognitive functions such as lack of activity, inward-turning, apathy, incoherence, blunted affect, inability to concentrate, and memory disturbance. The syndrome was first described in the 1960s among patients with a history of longtime cannabis use.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> A useful animal model for this disorder was found in rat, where the cannabis-caused catalepsy-like immobilization is related to a decrease in catecholaminergic and serotonergic neurons in the nucleus accumbens and amygdaloid nucleus, and thus can serve as a model for amotivational syndrome.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> In another study, heavy cannabis use was found to cause an amotivational syndrome in adolescents.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> The treatment of cannabis use disorders has recently been reviewed.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> However, the occurrence of amotivational syndrome as a result of cannabis exposure remains controversial.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> The data from other studies do not support the hypothesis that marijuana impairs motivation.<sup><xref ref-type="bibr" rid="ref51">51</xref>,<xref ref-type="bibr" rid="ref52">52</xref></sup> Although most of the cannabis-related negative effects relate to its neuropsychologic and behavioral effects, other negative reactions to cannabis are sometimes found. For example, cannabis can cause acute pancreatitis, although the exact mechanism remains unknown.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup></p></sec><sec><title>Therapeutic uses of cannabinoids</title><sec><title>Obesity, anorexia, emesis</title><p>Cannabis has been known for centuries to increase appetite and food consumption.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> More recently this propensity of the drug was substantiated when the CB1 receptor was shown to have a role in central appetite control, peripheral metabolism, and body weight regulation.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> Genetic variants at CB1 coding gene <italic>CNR1</italic> are associated with obesity-related phenotypes in men.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> In animals, CB1 receptor antagonism decreases motivation for palatable foods. Rimonabant administration caused suppression of the intake of a chocolate-flavored beverage over a 21-day treatment period, without any apparent development of tolerance.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> CB1 receptors were found to be preferentially involved in the reinforcing effects of sweet, as compared to a pure fat, reinforcer.<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> Rimonabant selectively reduces sweet rather than regular food intake in primates,<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> which suggests that rimonabant is more active on the hedonic rather than nutritive properties of diets.</p><p>Rimonabant leads to significant weight loss in obese human subjects. Treatment with rimonabant was also associated with beneficial effects on different metabolic parameters and cardiovascular risk factors linked with overweight.<sup><xref ref-type="bibr" rid="ref60">60</xref>,<xref ref-type="bibr" rid="ref61">61</xref></sup> In clinical trials rimonabant was found to cause a significant mean weight loss, reduction in waist circumference, increase in HDL cholesterol, reduction in triglycerides, and increase in plasma adiponectin levels.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> Patients who were switched from the rimonabant treatment to placebo after a 1-year treatment regained weight, while those who continued to receive rimonabant maintained their weight loss and favorable changes in cardiometabolic risk factors.<sup><xref ref-type="bibr" rid="ref63">63</xref>,<xref ref-type="bibr" rid="ref64">64</xref></sup> Rimonabant was shown to be safe and effective in treating the combined cardiovascular risk factors of smoking and obesity.<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> It also diminishes insulin resistance, and reduces the prevalence of metabolic syndrome. Many of the metabolic effects, including adiponectin increase, occur beyond weight loss, suggesting a direct peripheral effect of rimonabant.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> Therapy with rimonabant is also associated with favorable changes in serum lipids and an improvement in glycemie control in type 2 diabetes.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> The activity of rimonabant in the management of obesity has been described in recent reviews.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref68">68</xref></sup> It has been approved for the treatment of obesity in the European Union, and is sold under the trade name Acomplia. Surprisingly, the US Food and Drug Administration has declined to approve rimonabant, primarily due to its slight potential to enhance anxiety and suicidal thoughts. The atmosphere of consternation of possible legal action due to side effects may have led to this decision.</p><p>The other side of the same coin is anorexia. While in obese populations weight loss is the main goal, in other populations, such as patients with cancer or AIDS, it is an immense problem. Dronabinol (synthetic THC, known as Marinol and approved for the treatment of nausea and vomiting in cancer and AIDS patients) is associated with consistent improvement in appetite.<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> It was found to be safe and effective for anorexia associated with weight loss in patients with AIDS, and is associated with increased appetite, improvement in mood, and decreased nausea. In clinical trials, weight was stable in dronabinol patients, while placebo recipients lost weight.<sup><xref ref-type="bibr" rid="ref70">70</xref>,<xref ref-type="bibr" rid="ref71">71</xref></sup> Dronabinol was found to be safe and effective for treatment of HIV wasting syndrome,<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> as well as in patients with Alzheimer's disease<sup><xref ref-type="bibr" rid="ref73">73</xref></sup> and with advanced cancer,<sup><xref ref-type="bibr" rid="ref73">73</xref>,<xref ref-type="bibr" rid="ref74">74</xref></sup> The possible mechanisms of these actions have been reviewed.<sup><xref ref-type="bibr" rid="ref75">75</xref></sup> Cannabinoids have a positive effect in controlling chemotherapy-related sickness.<sup><xref ref-type="bibr" rid="ref76">76</xref></sup> They are more effective antiemetics than the dopamine receptor antagonists such as chlorpromazinetype drugs.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup> Direct comparisons with serotonin (5-HT)3 antagonists, which are widely used as antiemetics, have not been reported. However, while these antagonists are not effective in delayed vomiting, THC is known to reduce this side effect of chemotherapy.</p></sec><sec><title>Pain</title><p>Cannabis has been used for millennia as a pain-relieving substance. Evidence suggests that cannabinoids may prove useful in pain modulation by inhibiting neuronal transmission in pain pathways. Considering the pronounced antinociceptive effects produced by cannabinoids, they were proposed to be a promising therapeutic approach for the clinical management of trigeminal neuralgia.<sup><xref ref-type="bibr" rid="ref78">78</xref></sup> THC, CBD, and CBD-dimethyl heptyl (DMH) were found to block the release of serotonin from platelets induced by plasma obtained from the patients during migraine attack.<sup><xref ref-type="bibr" rid="ref79">79</xref></sup> However, in other reports cannabinoids are much less successful in pain-relieving. In a clinical trial THC did not have any significant effect on ongoing and paroxysmal pain, allodynia, quality of life, anxiety/depression scores and functional impact of pain. These results do not support an overall benefit of THC in pain and quality of life in patients with refractory neuropathic pain.<sup><xref ref-type="bibr" rid="ref80">80</xref></sup> Similarly, in an additional clinical trial, no evidence was found<sup><xref ref-type="bibr" rid="ref81">81</xref></sup> of analgesic effect of orally administered THC in postoperative pain in humans. Other studies show much better results of pain relief. When THC was given to a patient with familial Mediterranean fever, with chronic relapsing pain and gastrointestinal inflammation, a highly significant reduction in pain was noted.<sup><xref ref-type="bibr" rid="ref82">82</xref></sup> Mild improvement was noted with cannabis-based medicines for treatment of chronic pain associated with brachial plexus root avulsion.<sup><xref ref-type="bibr" rid="ref83">83</xref></sup> In neuropathic pain patients, median spontaneous pain intensity was significantly lower on THC treatment than on placebo treatment, and median pain relief score (numerical rating scale) was higher.<sup><xref ref-type="bibr" rid="ref84">84</xref></sup> It was also effective in treating central pain.<sup><xref ref-type="bibr" rid="ref85">85</xref></sup> The administration of single oral doses of THC to patients with cancer pain demonstrated a mild analgesic effect.<sup><xref ref-type="bibr" rid="ref86">86</xref>,<xref ref-type="bibr" rid="ref87">87</xref></sup> Patients who suffer from pain also tend to self-medicate with marijuana. In an anonymous cross-sectional survey, 72 (35 %) of chronic noncancer pain patients reported having used cannabis for relieving pain.<sup><xref ref-type="bibr" rid="ref88">88</xref></sup> Cannabis-treated AIDS patients reported improved appetite, muscle pain, nausea, anxiety, nerve pain, depression, and paresthesia.<sup><xref ref-type="bibr" rid="ref89">89</xref></sup> Not only THC, but also other cannabinoids can potentially affect different types of pain. Nabilone is a synthetic cannabinoid approved for treatment of severe nausea and vomiting associated with cancer chemotherapy.<sup><xref ref-type="bibr" rid="ref90">90</xref></sup> In Canada, the United States, and the United Kingdom, nabilone is marketed as Cesamet. A significant decrease in disabling spasticity-related pain of patients with chronic upper motor neuron syndrome (UMNS) was found with nabilone.<sup><xref ref-type="bibr" rid="ref91">91</xref></sup> Another cannabinoid, ajulemic acid (AJA), was effective in reducing chronic neuropathic pain,<sup><xref ref-type="bibr" rid="ref92">92</xref></sup> although cannabinoid side effects (tiredness, dry mouth, limited power of concentration, dizziness, sweating) were noted. Cannabimimetic effects with ajulemic acid in rodents have also been recorded.<sup><xref ref-type="bibr" rid="ref93">93</xref></sup></p><p>The combination of THC with the nonpsychotropic cannabis constituent CBD has a higher activity than THC alone.<sup><xref ref-type="bibr" rid="ref94">94</xref></sup> The CBD/THC buccal spray (Sativex) was found to be effective in treating neuropathic pain in multiple sclerosis (MS).<sup><xref ref-type="bibr" rid="ref95">95</xref></sup> Chronic neuropatic pain can also be treated with cannabis extracts containing THC, or CBD, or with Sativex.<sup><xref ref-type="bibr" rid="ref96">96</xref>,<xref ref-type="bibr" rid="ref97">97</xref></sup> The latter also was effective in reducing sleep disturbances in these patients and was mostly well tolerated.<sup><xref ref-type="bibr" rid="ref97">97</xref></sup> Sativex is the first cannabis-based medicine to undergo conventional clinical development and be approved as a prescription drug. It is efficacious and well tolerated in the treatment of symptoms of multiple sclerosis, notably spasticity and neuropathic pain.<sup><xref ref-type="bibr" rid="ref98">98</xref></sup> Sativex has been approved for use in neuropathic pain due to multiple sclerosis in Canada [for reviews on Sativex and on pain see refs 94, 99, and 100].</p></sec><sec><title>Multiple sclerosis, neuroprotection, inflammation</title><p>Inflammation, autoimmune response, demyelination, and axonal damage are thought to participate in the pathogenesis of MS. Increasing evidence supports the idea of a beneficial effect of cannabinoid compounds for the treatment of this disease. In clinical trials, it has been shown that cannabis derivatives are active on the pain related to MS,<sup><xref ref-type="bibr" rid="ref84">84</xref>,<xref ref-type="bibr" rid="ref85">85</xref>,<xref ref-type="bibr" rid="ref95">95</xref>,<xref ref-type="bibr" rid="ref97">97</xref>,<xref ref-type="bibr" rid="ref98">98</xref></sup> However, this is not the only positive effect of cannabinoids in this disease. In rat experimental autoimmune encephalomyelitis (EAE), a laboratory model of MS, THC, given once after disease onset, significantly reduced maximal EAE score. Reduction in the inflammatory response in the brain and spinal cord was also noted in animals treated with dexanabinol (HU-211 a nonpsychoactive synthetic cannabinoid).<sup><xref ref-type="bibr" rid="ref101">101</xref></sup> In another trial in rats, all animals treated with placebo developed severe clinical EAE and more than 98 % died, while THC-treated animals had either no clinical signs or mild signs, with delayed onset with survival greater than 95 %.<sup><xref ref-type="bibr" rid="ref102">102</xref></sup> WIN-55,212-2, another synthetic cannabinoid, also was found to ameliorate the clinical signs of EAE and to diminish cell infiltration of the spinal cord, partially through CB2.<sup><xref ref-type="bibr" rid="ref103">103</xref></sup> Using a chronic model of MS in mice, it was shown that clinical signs and axonal damage in the spinal cord were reduced by the synthetic cannabinoid HU210.<sup><xref ref-type="bibr" rid="ref104">104</xref></sup> To more fully inderstand the involvement of the endocannabinoid system in MS, the status of cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase (FAAH) enzyme in brain tissue samples obtained from MS patients was investigated. Selective glial expression of cannabinoid CB1 and CB2 receptors and FAAH enzyme was found to be induced in MS.<sup><xref ref-type="bibr" rid="ref105">105</xref></sup> In mice with chronic relapsing experimental allergic encephalomyelitis (CREAE), a chronic model of MS that reproduces many of the pathological hallmarks of the human disease, a moderate decrease in the density of CB1 receptors in the caudate-putamen, globus pallidus, and cerebellum was found. These observations may explain the efficacy of cannabinoid agonists in improving motor symptoms (spasticity, tremor, ataxia) typical of MS in both humans and animal models.<sup><xref ref-type="bibr" rid="ref106">106</xref></sup> Spasticity is a common neurologic condition in patients with MS, stroke, cerebral palsy, or an injured spinal cord. Marijuana was suggested as treatment of muscle spasticity as early as the 1980s.<sup><xref ref-type="bibr" rid="ref107">107</xref></sup> In an experiment in mice, control of spasticity in a MS model was found to be mediated by CB1, but not by CB2, cannabinoid receptors.<sup><xref ref-type="bibr" rid="ref108">108</xref></sup> In clinical trials, patients treated with THC had significant improvement in ratings of spasticity compared to placebo.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> In one case report nabilone improved muscle spasms, nocturia, and general well-being.<sup><xref ref-type="bibr" rid="ref110">110</xref></sup> In another case report, the chronic motor handicaps of an MS patient acutely improved while he smoked a marijuana cigarette.<sup><xref ref-type="bibr" rid="ref111">111</xref></sup> THC significantly reduced spasticity by clinical measurement. Responses varied, but benefit was seen in patients with tonic spasms.<sup><xref ref-type="bibr" rid="ref112">112</xref></sup> At a progressive stage of illness, oral and rectal THC reduced the spasticity, rigidity, and pain, resulting in improved active and passive mobility.<sup><xref ref-type="bibr" rid="ref113">113</xref></sup> However, in other clinical trials, cannabinoids appeared to reduce tremor but were ineffective in spasticity.<sup><xref ref-type="bibr" rid="ref114">114</xref>,<xref ref-type="bibr" rid="ref115">115</xref></sup> Moreover, in one trial marijuana smoking further impaired posture and balance in patients with spastic MS.<sup><xref ref-type="bibr" rid="ref116">116</xref></sup> The inconsistent effects noted might be due to dosedependency. Improved motor coordination was seen when patients with MS, seriously disabled with tremor and ataxia, were given oral THC.<sup><xref ref-type="bibr" rid="ref117">117</xref></sup> In another study, cannabis extract did not produce a functionally significant improvement in MS-associated tremor.<sup><xref ref-type="bibr" rid="ref118">118</xref></sup> Suppression of acquired pendular nystagmus (involuntary movement of the eyes) was seen in a patient with MS after smoking cannabis resin, but not after taking nabilone tablets or orally administered capsules containing cannabis oil.<sup><xref ref-type="bibr" rid="ref119">119</xref></sup> There are also findings suggestive of a clinical effect of cannabis on urge incontinence episodes in patients with MS.<sup><xref ref-type="bibr" rid="ref120">120</xref></sup> In the treatment of MS, as well as in pain reduction described earlier, there is a preferential effect of a THC+CBD combination (Sativex).<sup><xref ref-type="bibr" rid="ref121">121</xref></sup> A mixture of 2.5 mg THC and 0.9 mg cannabidiol (CBD) lowered spasm frequency and increased mobility, with tolerable side effects, in MS patients with persistent spasticity not responding to other drugs.<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> Oromucosal sprays of Sativex significantly reduced spasticity scores in comparison with placebo.<sup><xref ref-type="bibr" rid="ref123">123</xref></sup> Long-term use of Sativex maintains its effect in those patients who perceive initial benefit.<sup><xref ref-type="bibr" rid="ref124">124</xref></sup> Zajicek et al originally reported that cannabinoids did not have a beneficial effect on spasticity; however, there was an objective improvement in mobility and some patients reported an improvement in pain.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> Later the same group also found positive effects on muscle spasticity with prolonged treatment.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> The subject has been thoroughly reviewed.<sup><xref ref-type="bibr" rid="ref99">99</xref>,<xref ref-type="bibr" rid="ref127">127</xref>,<xref ref-type="bibr" rid="ref130">130</xref></sup></p><p>MS is not the only disease state where the neuroprotective potential of cannabinoids can be seen. In animal experiments, 2 weeks after the application of 6-hydroxydopamine, a significant depletion of dopamine contents and a reduction in tyrosine hydroxylase activity in the lesioned striatum were noted, and were accompanied by a reduction in tyrosine hydroxylase-messenger ribonucleic acid (mRNA) levels in the substantia nigra. Daily administration of THC over 2 weeks produced a significant irreversible waning in the magnitude of these changes, which may be relevant in the treatment of Parkinson's disease (see below)<sup><xref ref-type="bibr" rid="ref131">131</xref></sup> The cannabinoids have a neuroprotective activity not only in vitro but also in vivo: HU-210, a potent synthetic analog of THC, increases survival of mouse cerebellar granule cells exposed to 6-hydroxydopamine.<sup><xref ref-type="bibr" rid="ref131">131</xref></sup> In a model of experimental stroke, rimonabant reduced infarct volume by approximately 40 %. Rimonabant exerted neuroprotection independently of its cannabinoid receptor-blocking effect.<sup><xref ref-type="bibr" rid="ref132">132</xref></sup> In clinical trials, dexanabinol-treated patients achieved significantly better intracranial pressure/cerebral perfusion pressure control without jeopardizing blood pressure. A trend toward faster and better neurologic outcome was also observed.<sup><xref ref-type="bibr" rid="ref133">133</xref></sup> However, in further experiments, dexanabinol was not found to be efficacious in the treatment of traumatic brain injury<sup><xref ref-type="bibr" rid="ref134">134</xref></sup> A wide range of cannabinoids has been shown to help in pathologies affecting the central nervous system (CNS) and other diseases that are accompanied by chronic inflammation.<sup><xref ref-type="bibr" rid="ref130">130</xref>,<xref ref-type="bibr" rid="ref135">135</xref>,<xref ref-type="bibr" rid="ref136">136</xref></sup> In a rodent model of chronic brain inflammation produced by the infusion of lipopolysaccharide into the fourth ventricle of young rats, the cannabinoid agonist WIN-55212-2 reduced the number of LPS-activated microglia.<sup><xref ref-type="bibr" rid="ref137">137</xref></sup> Direct suppression of CNS autoimmune inflammation was seen by activation of CB1 receptors on neurons and CB2 receptors on autoreactive T cells.<sup><xref ref-type="bibr" rid="ref138">138</xref></sup></p><p>Atherosclerosis is a chronic inflammatory disease, and is the primary cause of heart disease and stroke in Western countries. Oral treatment with a low dose of THC inhibits atherosclerosis progression in an apolipoprotein E knockout mouse model, through pleiotropic immunomodulatory effects on lymphoid and myeloid cells. Thus, THC may be a valuable target for treating atherosclerosis.<sup><xref ref-type="bibr" rid="ref139">139</xref></sup> N-palmitoyl-ethanolamine is an endogenous endocannabinoid-like compound. Its concentrations are significantly increased in three different inflammatory and neuropathic conditions. The enhanced levels may possibly be related to a protective local anti-inflammatory and analgesic action.<sup><xref ref-type="bibr" rid="ref140">140</xref></sup> CBD has been shown to exert potent anti-inflammatory and antioxidant effects. High-glucose-induced mitochondrial superoxide generation, NF-kappaB activation, nitrotyrosine formation, iNOS and adhesion molecules ICAM-1 and VCAM-1 expression, monocyte-endothelial adhesion, transendothelial migration of monocytes, and disruption of endothelial barrier function in human coronary artery endothelial cells (HCAECs) were attenuated by CBD pretreatment.<sup><xref ref-type="bibr" rid="ref141">141</xref></sup></p><p>In experiments with obese vs lean rats, rimonabant was found to be a potent inhibitor of sensory hypersensitivity associated with CFA-induced arthritis in obese rats, in which the inflammatory reaction is more severe than in lean rats. It may thus have therapeutic potential in obesity-associated inflammatory diseases.<sup><xref ref-type="bibr" rid="ref142">142</xref></sup></p></sec><sec><title>Parkinson's disease, Huntington's disease, Tourette's syndrome, Alzheimer's disease, epilepsy</title><p><italic>Parkinson's disease (PD)</italic> is a chronic, progressive neurodegenerative disorder. The main pathological feature of PD is the degeneration of dopamine (DA)-containing neurons of the substantia nigra, which leads to severe DAergic denervation of the striatum. The irreversible loss of the DA-mediated control of striatal function leads to the typical motor symptoms observed in PD, ie, bradykinesia, tremor, and rigidity. It has been proposed that cannabinoids may have some beneficial effects in the treatment of PD.<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> In animal experiments cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro.<sup><xref ref-type="bibr" rid="ref131">131</xref></sup></p><p>The majority of PD patients undergoing levodopa therapy develop disabling motor complications (dyskinesias) within 10 years of treatment. Recent studies in animal models and in the clinic suggest that CB1 receptor antagonists could prove useful in the treatment of both parkinsonian symptoms and levodopa-induced dyskinesia, whereas CB1 receptor agonists could have value in reducing levodopa-induced dyskinesia.<sup><xref ref-type="bibr" rid="ref143">143</xref></sup> In the reserpinetreated rat model of PD, the dopamine D2 receptor agonist quinpirole caused a significant alleviation of the akinesia. This effect was significantly reduced by coinjection with the cannabinoid receptor agonist WIN 55,212-2. The simultaneous administration of the CB1 antagonist rimonabant with quinpirole and WIN 55,212-2 blocked the effect of WIN 55,212-2 on quinpirole-induced alleviation of akinesia.<sup><xref ref-type="bibr" rid="ref144">144</xref></sup> In animal experiments, chronic levodopa produced increasingly severe orolingual involuntary movements which were attenuated by WIN 55,212-2. This effect was also reversed by rimonabant.<sup><xref ref-type="bibr" rid="ref145">145</xref></sup> In other studies, rimonabant was found to possess some beneficial effects on motor inhibition typical of PD, at least in some doses. The injection of 0.1 mg/kg of rimonabant partially attenuated the hypokinesia shown by PD animals with no effects in control rats, whereas higher doses (0.5-1.0 mg/kg) were not effective.<sup><xref ref-type="bibr" rid="ref146">146</xref></sup> A nigrostriatal lesion by MPTP is associated with an increase in CB1 receptors in the basal ganglia in humans and nonhuman primates; this increase could be reversed by chronic levodopa therapy, which suggests that CB1 receptor blockade might be useful as an adjuvant for the treatment of parkinsonian motor symptoms.<sup><xref ref-type="bibr" rid="ref147">147</xref></sup> High endogenous cannabinoid levels are found in the cerebrospinal fluid of untreated PD patients.<sup><xref ref-type="bibr" rid="ref148">148</xref></sup> Administration of inhibitors of endocannabinoid degradation reduced parkinsonian motor deficits in vivo.<sup><xref ref-type="bibr" rid="ref149">149</xref></sup> Thus, both agonists and antagonists of CB receptors seem to help in some parkinsonian symptoms. In clinical trials, the cannabinoid receptor agonist nabilone significantly reduced levodopainduced dyskinesia in PD.<sup><xref ref-type="bibr" rid="ref150">150</xref></sup> THC improved motor control in a patient with musician's dystonia.<sup><xref ref-type="bibr" rid="ref151">151</xref></sup> In contrast to these findings, some studies find no effect of cannabinoids on PD: orally administered cannabis extract resulted in no objective or subjective improvement in either dyskinesias or parkinsonism,<sup><xref ref-type="bibr" rid="ref152">152</xref></sup> no significant reduction in dystonia following treatment with nabilone,<sup><xref ref-type="bibr" rid="ref153">153</xref></sup> and rimonabant could not improve parkinsonian motor disability<sup><xref ref-type="bibr" rid="ref154">154</xref></sup> However, an anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25 % of the respondents had taken cannabis and 45.9 % of these described some form of benefit.<sup><xref ref-type="bibr" rid="ref155">155</xref></sup> Thus cannabinoids seem to be able to treat at least some symptoms of neurological diseases.<sup><xref ref-type="bibr" rid="ref156">156</xref>-<xref ref-type="bibr" rid="ref158">158</xref></sup></p><p><italic>Huntington's disease (HD) or Huntington's chorea</italic> (“chorea” meaning “dance” in Greek) is a disorder characterized by a distinctive choretic movement, progressive motor disturbances, dementia, and other cognitive deficits. Neuropathologically, HD is characterized by a degeneration of medium spiny striato-efferent γ-aminobutyric acid (GABA)ergic neurons and by an atrophy of the caudate nucleus. Advanced grades of HD showed an almost total loss of CB1 receptors and a further depletion of Dl receptors in the caudate nucleus, putamen, and globus pallidus internus, and an increase in GABA<sub>A</sub> receptor binding in the globus pallidus internus.<sup><xref ref-type="bibr" rid="ref159">159</xref>,<xref ref-type="bibr" rid="ref160">160</xref></sup> Loss of cannabinoid receptors is also seen in the substantia nigra in HD.<sup><xref ref-type="bibr" rid="ref161">161</xref></sup> These findings suggest a possible therapeutic role of cannabinoid agonists in HD. Indeed, arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of HD generated by bilateral intrastriatal application of 3-nitropropionic acid (3-NP).<sup><xref ref-type="bibr" rid="ref162">162</xref></sup> The reduction in the increased ambulation exhibited by 3NP-lesioned rats in the open-field test caused by AM404 (anandamide's transport inhibitor, which also binds to vanilloid receptor 1) was reversed when the animals had been pretreated with capsazepine (VR1 antagonist), but not with SR141716A, thus suggesting a major role of VR1 receptors in the antihyperkinetic effects of AM404. However, both capsaicin (VR1 agonist) and CP55,940 (an CB1 agonist) had antihyperkinetic activity<sup><xref ref-type="bibr" rid="ref163">163</xref></sup> Quinolinic acid (QA) is an excitotoxin which, when injected into the rat striatum, reproduces many features of HD by stimulating glutamate outflow. Perfusion with WIN 55,212-2 significantly and dose-dependently prevented the increase in extracellular glutamate induced by QA. Thus, the stimulation of CB1 receptors might lead to neuroprotective effects against excitotoxic striatal toxicity.<sup><xref ref-type="bibr" rid="ref164">164</xref></sup> In a clinical trial CBD was neither symptomatically effective nor toxic in neuroleptic-free HD patients.<sup><xref ref-type="bibr" rid="ref165">165</xref></sup></p><p><italic>Tourette syndrome (TS)</italic> is a complex inherited disorder of unknown etiology, characterized by multiple motor and vocal tics. Anecdotal reports have suggested that the use of cannabis might improve tics and behavioral problems in patients with TS. Indeed, THC reduced tics in TS patients,<sup><xref ref-type="bibr" rid="ref166">166</xref></sup> without causing acute and/or long-term cognitive deficits.<sup><xref ref-type="bibr" rid="ref167">167</xref></sup> In another clinical trial, where tic severity was assessed using a self-rating scale and examiner ratings, patients also rated the severity of associated behavioral disorders. There was a significant improvement of motor tics, vocal tics and obsessive-compulsive behavior after treatment with THC. There was a significant correlation between tic improvement and maximum 11-OH-THC plasma concentration, suggesting a possible role of this THC metabolite on the positive effect of THC.<sup><xref ref-type="bibr" rid="ref168">168</xref></sup> In another, longer clinical trial, THC was also found to be effective and safe in the treatment of tics.<sup><xref ref-type="bibr" rid="ref169">169</xref></sup> In view of the positive effect of CB1 agonists in the treatment of TS, CB1 gene mutations were investigated. However, TS was not found to be caused by mutations in the <italic>CNR1</italic> gene.<sup><xref ref-type="bibr" rid="ref170">170</xref></sup></p><p><italic>Amyotrophic lateral sclerosis (ALS)</italic> is a fatal neurodegenerative disorder characterized by a selective loss of motor neurons in the spinal cord, brain stem, and motor cortex. Many effects of marijuana may be applicable to the management of ALS. These include analgesia, muscle relaxation, bronchodilation, saliva reduction, appetite stimulation, and sleep induction. In addition, its strong antioxidative and neuroprotective effects may prolong neuronal cell survival.<sup><xref ref-type="bibr" rid="ref171">171</xref></sup> Indeed, treatment of postsymptomatic, 90-day-old SOD1G93A mice (a model of ALS) with WIN 55,212-2, significantly delayed disease progression. Furthermore, genetic ablation of the FAAH enzyme, which results in raised levels of the endocannabinoid anandamide, prevented the appearance of disease signs in these mice. Surprisingly, elevation of cannabinoid levels with either WIN 55,212-2 or FAAH ablation had no effect on life span. Ablation of the CB1 receptor, in contrast, had no effect on disease onset in these mice, but significantly extended life span. Together these results show that cannabinoids have significant neuroprotective effects in this model of ALS, and suggest that these beneficial effects may be mediated by nonCB1 receptor mechanisms.<sup><xref ref-type="bibr" rid="ref172">172</xref></sup> THC was also found to delay the progression of disease.<sup><xref ref-type="bibr" rid="ref173">173</xref>,<xref ref-type="bibr" rid="ref174">174</xref></sup> Treatment with AM1241, a CB2-selective agonist, was effective at slowing signs of disease progression, when administered after onset of signs in an ALS mouse model. Administration at the onset of tremors delayed motor impairment in treated mice when compared with vehicle controls<sup><xref ref-type="bibr" rid="ref175">175</xref></sup>; moreover, AM-1241 prolonged survival in these mice.<sup><xref ref-type="bibr" rid="ref176">176</xref></sup> In a survey among ALS patients, cannabis was reported to be moderately effective in reducing symptoms of appetite loss, depression, pain, spasticity, and drooling.<sup><xref ref-type="bibr" rid="ref177">177</xref></sup> Cannabinoids were also proposed to have a role in the treatment of <italic>Alzheimer's disease (AD)</italic>. THC competitively inhibits acetylcholinesterase (AChE) and prevents AChE-induced amyloid beta-peptide (Abeta) aggregation, the key pathological marker of AD.<sup><xref ref-type="bibr" rid="ref178">178</xref></sup> THC treatment also decreased severity of disturbed behavior, and this effect persisted during the placebo period in patients who had received THC.<sup><xref ref-type="bibr" rid="ref179">179</xref></sup> Compared with baseline, THC led to a reduction in nocturnal motor activity These findings were corroborated by improvements in the Neuropsychiatrie Inventory total score, as well as in subscores for agitation, aberrant motor, and nighttime behaviors; no side effects were observed.<sup><xref ref-type="bibr" rid="ref180">180</xref></sup></p><p>Studies on <italic>cannabinoid anticonvulsant activity</italic> began in 1975, when CBD, and four CBD derivatives, (CBD-aldehyde-diacetate, 6-oxo-CBD-diacetate, 6-hydroxy-CBD-tri-acetate and 9-hydroxy-CBD-triacetate) were shown to protect against maximal electroshock convulsions in mice, to potentiate pentobarbital sleeping-time and to reduce spontaneous motor activity.<sup><xref ref-type="bibr" rid="ref181">181</xref></sup> Later additional CBD analogs were shown to be active<sup><xref ref-type="bibr" rid="ref182">182</xref>-<xref ref-type="bibr" rid="ref184">184</xref></sup> CBD was found to be an effective anticonvulsant with specificity more comparable to drugs clinically effective in major, but not in minor seizures. Furthermore, it appears that CBD enhances the anticonvulsant effects of drugs in major seizures and reduces their effects in minor seizures.<sup><xref ref-type="bibr" rid="ref185">185</xref>,<xref ref-type="bibr" rid="ref186">186</xref></sup> Hence, CBD was suggested as a drug for the treatment of children with pharmacoresistant epilepsy.<sup><xref ref-type="bibr" rid="ref187">187</xref></sup>The application of the CB1 receptor antagonists
SR141716A or AM251 to “epileptic” neurons caused the development of continuous epileptiform activity, resembling electrographic status epilepticus. The induction of status epilepticus-like activity by CB1 receptor antagonists was reversible and could be overcome by maximal concentrations of CB1 agonists.<sup><xref ref-type="bibr" rid="ref188">188</xref></sup> Arachidonyl-2'-chloroethylamide (ACEA), a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in a mouse maximal electroshock-induced seizure model.<sup><xref ref-type="bibr" rid="ref189">189</xref></sup> There are currently insufficient data to determine whether occasional or chronic marijuana use influences seizure frequency.<sup><xref ref-type="bibr" rid="ref190">190</xref></sup> In one case report, marijuana smoking was proposed to induce seizures.<sup><xref ref-type="bibr" rid="ref191">191</xref></sup> In another study, patients suffering from secondary generalized epilepsy with temporal focus treated with CBD remained almost free of convulsive crises throughout the experiment; other patients demonstrated partial improvement in their clinical condition.<sup><xref ref-type="bibr" rid="ref192">192</xref></sup></p></sec><sec><title>Bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), depression, anxiety, insomnia</title><p>Cannabis use is common in patients with <italic>bipolar disorder,</italic> and anecdotal reports suggest that some patients use marijuana to alleviate symptoms of both mania and depression.<sup><xref ref-type="bibr" rid="ref193">193</xref></sup> In a case report, one female patient found that cannabis curbed her manic rages; others described the use of cannabis as a supplement to lithium (allowing reduced consumption) or for relief of lithium's side effects.<sup><xref ref-type="bibr" rid="ref194">194</xref></sup></p><p>The effect of cannabinoids on <italic>schizophrenia</italic> is controversial. Neuropsychological results in THC-intoxicated normal volunteers exhibit strong similarities with data acquired from patients suffering from productive schizophrenic psychoses, as regards disturbances in internal regulation of perceptual processes.<sup><xref ref-type="bibr" rid="ref195">195</xref></sup> In a recent study, it was found that anandamide levels are enhanced in firstepisode schizophrenic patients, and that THC downregulates anandamide signaling.<sup><xref ref-type="bibr" rid="ref196">196</xref></sup> This observation possibly means that THC lowers endogenous production of anandamide, which may actually be a defense mechanism - presumably comparable to the known observation that administration of corticosteroids blocks corticosteroid synthesis. Data from experimental-psychological tests show that personality changes generated by schizophrenia progression are comparable to psychopathological phenomenon due to cannabis intoxication.<sup><xref ref-type="bibr" rid="ref197">197</xref></sup> In another study, psychosis, which develops or recurs in the context of cannabis use, did not have a characteristic psychopathology or mode of onset.<sup><xref ref-type="bibr" rid="ref198">198</xref></sup> First-episode schizophrenic patients with long-term cannabis consumption were significantly younger at disease onset, mostly male, and suffered more often from paranoid schizophrenia (with a better prognosis) than those without cannabis consumption.<sup><xref ref-type="bibr" rid="ref199">199</xref></sup> However, a trend towards more insight and of fewer abusive or accusatory hallucinations was seen amongst cannabis users. This argues against a distinct schizophrenia-like psychosis caused by cannabis.<sup><xref ref-type="bibr" rid="ref200">200</xref></sup> Less avolition and fewer apathy symptoms were detected in patients with schizophrenia and cannabis abuse than in those with no abuse.<sup><xref ref-type="bibr" rid="ref201">201</xref></sup> In another clinical trial, the role of CB1 receptors in schizophrenia was studied by administration of CB1 antagonist to patients. The group receiving the CB1 antagonist did not differ from the group receiving placebo on any outcome measure.<sup><xref ref-type="bibr" rid="ref202">202</xref></sup></p><p>CBD causes antipsychotic effects.<sup><xref ref-type="bibr" rid="ref203">203</xref></sup> It was found to be a safe and well-tolerated alternative treatment for schizophrenia.<sup><xref ref-type="bibr" rid="ref204">204</xref></sup> (See, however, also ref 205).</p><p><italic>Posttraumatic stress disorder (PTSD)</italic> is a term for severe psychological consequences of exposure to, or confrontation with, stressful, highly traumatic events. Cannabinoids are believed to help in such cases. AM404-treated animals showed decreased shock-induced reinstatement of fear.<sup><xref ref-type="bibr" rid="ref206">206</xref></sup> In conditioned fear and Morris water maze experiments, FAAH (-/-) mice and mice treated with the FAAH inhibitor OL-135 did not display any memory impairment or motor disruption, but did exhibit a significant increase in the rate of extinction. SRI 41716 blocked the effects of OL-135, suggesting that endogenous anandamide plays a facilitator role in extinction through a CB1 receptor mechanism of action. In contrast, THC failed to affect extinction rates, suggesting that FAAH is a more effective target facilitating extinction than a direct-acting CB1 receptor agonist.<sup><xref ref-type="bibr" rid="ref207">207</xref></sup> Acutely, the absence of CB1 receptors reduces the neuroendocrine response and does not affect the behavioral response to moderate stress. However, upon repeated stress or acute severe stress, CB1 receptor deficiency causes persistent behavioral inhibition. Repeated bell stress seemed to cause a cumulative fear in CB1 receptor knockout mice.<sup><xref ref-type="bibr" rid="ref208">208</xref></sup> In self-reports of substance use among help-seeking veterans, PTSD diagnosis was significantly associated with marijuana use.<sup><xref ref-type="bibr" rid="ref209">209</xref></sup> These observations suggest that the endocannabinoid system can be modulated to enhance emotional learning, and that endocannabinoid modulators may be therapeutically useful as adjuncts for exposure-based psychotherapies, such as those used to treat PTSD and other anxiety disorders. CB1 receptor gene polymorphism is known to modify transcription of the gene. In patients with Parkinson's disease, the presence of two long alleles, with more than 16 repeated AAT trinucleotides in the CNR1 gene, was associated with a reduced prevalence of depression.<sup><xref ref-type="bibr" rid="ref210">210</xref></sup></p><p>CBD, and some derivatives, were found to cause a selective anxiolytic effect in the elevated plus-maze, within a limited range of doses.<sup><xref ref-type="bibr" rid="ref211">211</xref>,<xref ref-type="bibr" rid="ref212">212</xref></sup> A single dose of nabilone produced only mild improvement in anxiety<sup><xref ref-type="bibr" rid="ref213">213</xref></sup>; in a repeated-dose treatment a dramatic improvement in anxiety was noted in the nabilone group.<sup><xref ref-type="bibr" rid="ref214">214</xref></sup></p><p>The effects of marijuana on human sleep patterns were noticed long ago.<sup><xref ref-type="bibr" rid="ref215">215</xref>-<xref ref-type="bibr" rid="ref217">217</xref></sup> Reduced eye movement density was seen, with some tolerance developing to this effect.<sup><xref ref-type="bibr" rid="ref218">218</xref>,<xref ref-type="bibr" rid="ref219">219</xref></sup> THC is sedative, while CBD has alerting properties as it increased awake activity and counteracted the residual sedative activity of THC.<sup><xref ref-type="bibr" rid="ref220">220</xref></sup></p></sec><sec><title>Asthma, cardiovascular disorders, glaucoma</title><p><italic>Asthma</italic> is a chronic disease of the respiratory system in which the airway occasionally constricts, becomes inflamed, and is lined with excessive amounts of mucus. In animal experiments, after methacholine-induced or exercise-induced bronchospasm, marijuana caused a prompt improvement of the bronchospasm and associated hyperinflation.<sup><xref ref-type="bibr" rid="ref221">221</xref></sup> In humans, habitual smoking of marijuana may cause mild, but significant, functional lung impairment<sup><xref ref-type="bibr" rid="ref222">222</xref></sup>; However, a mild and inconstant bronchodilatory action was found for THC.<sup><xref ref-type="bibr" rid="ref223">223</xref></sup> In other clinical trials, smoking marijuana or ingesting THC were found to increase airway conduction.<sup><xref ref-type="bibr" rid="ref224">224</xref>,<xref ref-type="bibr" rid="ref225">225</xref></sup> Other plant cannabinoids did not provide effective bronchodilation. The daily use of THC was not associated with clinical tolerance.<sup><xref ref-type="bibr" rid="ref226">226</xref></sup> THC administered in metered volumes by inhalation from an aerosol device to patients judged to be in a steady state, increased peak expiratory flow rate (PEFR) and forced expiratory volume in 1 second (FEV1) and produced bronchodilatation.<sup><xref ref-type="bibr" rid="ref227">227</xref></sup> In another study, salbutamol and THC significantly improved ventilatory function. Maximal bronchodilatation was achieved more rapidly with salbutamol, but at 1 hour both drugs were equally effective. No cardiovascular or mood disturbance was detected, and plasma total cannabinoids at 15 minutes were not detected by radioimmunoassay. The mode of action of THC differed from that of sympathomimetic drugs.<sup><xref ref-type="bibr" rid="ref228">228</xref></sup></p><p>In another study, THC induced sympathetic stimulation and parasympathetic inhibition of <italic>cardiovascular control pathways</italic>. The peak heart rate rise after THC was attenuated by atropine and by propranolol, and nearly abolished by atropine-propranolol pretreatment.<sup><xref ref-type="bibr" rid="ref229">229</xref></sup> Acute THC significantly increased heart rate, shortened pre-ejection period (PEP) and prolonged left ventricular ejection time (LVETc) without any change in afterload; it enhanced cardiac performance. Partial inhibition of this effect was achieved with prior (β-adrenergic blockade.<sup><xref ref-type="bibr" rid="ref230">230</xref></sup> In contrast, following the smoking of one to three marijuana cigarettes, the heart rate rose, cardiac output rose, stroke volume, ejection fraction, PEP and LVET did not change; thus, in long-term heavy users of cannabis, marijuana has no significant effect on myocardial contractility independent of its effect on heart rate.<sup><xref ref-type="bibr" rid="ref231">231</xref></sup> Cardiovascular effects of acute THC administration included increased sympathetic and reduced parasympathetic tone; supine tachycardia and increased blood pressure with upright hypotension were observed. With repetitive dosing supine bradycardia and decreased blood pressure with tolerance to orthostatic hypotension were observed.<sup><xref ref-type="bibr" rid="ref232">232</xref>,<xref ref-type="bibr" rid="ref233">233</xref></sup> Rimonabant attenuated the hypotensive effect of smoked marijuana in male smokers, suggesting a role for the CB1 receptor in cannabinoid hypotensive action.<sup><xref ref-type="bibr" rid="ref234">234</xref></sup></p><p>A number of studies suggest that there is a correlative, but not necessarily causal, relationship between <italic>glaucoma</italic> and systemic hypertension. Ocular hypertension (OHT) refers to any situation in which intraocular pressure is higher than normal, and is the most important risk factor for glaucoma. THC, CBN, and nabilone were active in lowering intraocular pressure (IOP) in rabbits, while CBD was inactive.<sup><xref ref-type="bibr" rid="ref235">235</xref></sup> Certain derivatives of THC were more active in lowering IOP than the parent cannabinoid<sup><xref ref-type="bibr" rid="ref236">236</xref></sup>; some topically used soft analogs that have no systemic effects were also active in IOP reduction.<sup><xref ref-type="bibr" rid="ref237">237</xref></sup> The effect on IOP of 2-AG was biphasic (ie, an initial increase in IOP followed by a reduction). In contrast, noladin ether decreased IOP immediately after topical administration, and no initial IOP increase was observed. AM251 blocked the effect on IOP of noladin ether, but did not affect the action of 2-AG.<sup><xref ref-type="bibr" rid="ref238">238</xref></sup> Topical administration of anandamide and arachidonyl propionitrileamide decreased IOP; rimonabant antagonized the IOP reduction, suggesting that cannabinoids lower IOP through CB1 receptors.<sup><xref ref-type="bibr" rid="ref239">239</xref>,<xref ref-type="bibr" rid="ref240">240</xref></sup> Significantly, higher levels of CB1 mRNA levels were found in the ciliary body than in the iris, retina, and choroid. CB2 mRNA was undetectable. This expression pattern supports a specific role for the CB1 receptor in controlling IOP.<sup><xref ref-type="bibr" rid="ref241">241</xref></sup> When delivered topically to cat eyes with osmotic minipumps, whole marijuana extract, THC and other plant cannabinoids reduced IOP, while cannabichromene was inactive. Ocular toxicity was seen after THC treatment, consisting of conjunctival erythema and chemosis as well as corneal opacification. Although these changes also occurred with marijuana extract, their intensity was much reduced. In contrast, no ocular toxicity was apparent during administration of plant cannabinoids other than THC.<sup><xref ref-type="bibr" rid="ref242">242</xref>-<xref ref-type="bibr" rid="ref244">244</xref></sup> Marijuana smoking was shown to reduce IOP as early as 1971; the effect was later confirmed.<sup><xref ref-type="bibr" rid="ref245">245</xref>-<xref ref-type="bibr" rid="ref248">248</xref></sup> The peak effect of THC on the central nervous system coincided well with the reduction in intraocular pressure induced by the drug; However, hypotonia outlasted euphoria. The results indicate that THC may have value as a hypotonizing ocular drug.<sup><xref ref-type="bibr" rid="ref249">249</xref></sup> The functional responses after THC inhalation in sitting normotensive and hypertensive patients included invariable increases in heart rate followed by substantial decreases in systolic pressure, diastolic pressure, and intraocular pressure. The intensity and duration of the arterial and ocular pressure responses to THC were greater in hypertensives than in normotensive patients; the changes in ocular pressure paralleled the changes in blood pressure in glaucoma patients.<sup><xref ref-type="bibr" rid="ref250">250</xref></sup> A single sublingual dose of THC, but not cannabidiol, reduced the IOP temporarily and was well tolerated by most patients.<sup><xref ref-type="bibr" rid="ref251">251</xref></sup></p></sec><sec><title>Cancer</title><p>The antiproliferative action of cannabinoids on cancer cells was first noticed in the 1970s. Since then cannabinoids were found to act on various cancer cell lines, through various mechanisms.<sup><xref ref-type="bibr" rid="ref252">252</xref>,<xref ref-type="bibr" rid="ref253">253</xref></sup> Cannabinoids were also found to be suppressors of angiogenesis and tumor invasion.<sup><xref ref-type="bibr" rid="ref254">254</xref></sup> Our knowledge on the anticancer activity of cannabinoids is rapidly expanding; hence only results of recent research on this topic are presented here. The cannabinoid agonists HU-210 and JWH-133 promoted glial differentiation in a CB receptor-dependent manner. Moreover, cannabinoid challenge decreased the efficiency of glioma stem-like cells to initiate glioma formation in vivo.<sup><xref ref-type="bibr" rid="ref255">255</xref></sup> The nonpsychoactive cannabidiol triggered caspase activation and oxidative stress in human glioma cells.<sup><xref ref-type="bibr" rid="ref256">256</xref></sup> Human melanomas express CB1 and CB2 cannabinoid receptors. Activation of these receptors decreased growth, proliferation, angiogenesis, and metastasis, and increased apoptosis, of melanomas in mice.<sup><xref ref-type="bibr" rid="ref257">257</xref></sup> THC, through activation of CB2 cannabinoid receptors, reduced human breast cancer cell proliferation by blocking the progression of the cell cycle and by inducing apoptosis. THC arrested cells in G2M via downregulation of Cdc2.<sup><xref ref-type="bibr" rid="ref258">258</xref></sup> Cannabinoids induced apoptosis of pancreatic tumor cells via stress protein p8 and endoplasmic reticulum stress-related genes. These effects were prevented by blockade of the CB2 cannabinoid receptor or by pharmacologic inhibition of ceramide synthesis de novo.<sup><xref ref-type="bibr" rid="ref259">259</xref></sup> THC-induced apoptosis in Jurkat leukemia T cells was found to be regulated by translocation of Bad to mitochondria.<sup><xref ref-type="bibr" rid="ref260">260</xref></sup> Exposure of leukemia cells to CBD led to CB2-mediated reduction in cell viability and induction in apoptosis (although CBD is considered not to bind to either CB1 or CB2 receptors). It is noteworthy that CBD exposure led to an increase in reactive oxygen species (ROS) production as well as an increase in the expression of the NAD(P)H oxidases Nox4 and p22(phox).<sup><xref ref-type="bibr" rid="ref261">261</xref></sup> Cannabinoid-induced apoptosis of human prostate cancer cells LNCaP proceeded through sustained activation of ERK1/2 leading to Gl cell cycle arrest.<sup><xref ref-type="bibr" rid="ref262">262</xref></sup> Rimonabant inhibited human breast cancer cell proliferation through a lipid raft-mediated mechanism.<sup><xref ref-type="bibr" rid="ref263">263</xref></sup> In a pilot phase I trial, nine patients with recurrent glioblastoma multiforme, that had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumour progression, were administered THC intratumorally. THC inhibited tumor-cell proliferation in vitro, decreased tumor-cell Ki67 immunostaining and prolonged the survival time of two of the patients.<sup><xref ref-type="bibr" rid="ref264">264</xref></sup></p></sec></sec><sec><title>Conclusion</title><p>Many drugs used today can cause addiction and are misused and abused, for example opiates,<sup><xref ref-type="bibr" rid="ref265">265</xref></sup> cocaine,<sup><xref ref-type="bibr" rid="ref266">266</xref></sup> benzodiazepines,<sup><xref ref-type="bibr" rid="ref267">267</xref></sup> barbiturates,<sup><xref ref-type="bibr" rid="ref268">268</xref></sup> cholinergic agonists,<sup><xref ref-type="bibr" rid="ref269">269</xref></sup> ketamine,<sup><xref ref-type="bibr" rid="ref270">270</xref>,<xref ref-type="bibr" rid="ref271">271</xref></sup> dopaminergic agonists,<sup><xref ref-type="bibr" rid="ref272">272</xref></sup> amphetamines,<sup><xref ref-type="bibr" rid="ref273">273</xref></sup> and others. Nevertheless they are still an important part of our pharmacopeia. Marijuana was used for centuries as a medicinal plant, but during the last century, because of its abuse and addictive potential it was taken out of clinical practice. Now, we believe that its constituents and related compounds should be brought back to clinical use. The reasons are: (i) the therapeutic potential of CB1 agonists is huge, as described in this review; (ii) for local action, topical CB1 agonists, or agonists that do not penetrate the blood-brain barrier, can be used; (iii) cannabinoids acting specifically on CB2 receptors, which cause no psychoactivity, may be used on peripheral targets (such as osteoporosis,<sup><xref ref-type="bibr" rid="ref274">274</xref>,<xref ref-type="bibr" rid="ref275">275</xref></sup> which is only one of many examples); (iv) there are additional, new cannabinoid targets distinct from the CB1/CB2 receptors<sup><xref ref-type="bibr" rid="ref276">276</xref>-<xref ref-type="bibr" rid="ref278">278</xref></sup> which do not cause psychoactivity; (v) there are cannabinoids, such as CBD, which do not cause psychoactivity, but have various therapeutic effects.</p><p>The endocannabinoid system is a very complex one and regulates numerous processes, in parallel with other wellknown systems, such as the adrenergic, cholinergic, and dopaminergic systems. Neglecting the potential clinical uses of such a system is, in our view, unacceptable; instead we need to work on more selective agonists/antagonists, more selective distribution patterns, and in cases where it is impossible to separate between the desired clinical action and the psychoactivity, to monitor these side effects carefully.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zias</surname><given-names>J.</given-names></name><name><surname>Stark</surname><given-names>H.</given-names></name><name><surname>Sellgman</surname><given-names>J.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Early medical use of cannabis.</article-title><source><italic>Nature.</italic></source><year>1993</year><volume>363</volume><fpage>215</fpage><pub-id pub-id-type="pmid">8387642</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlesinger</surname><given-names>S.</given-names></name></person-group><article-title>Untersuchung der Cannabis sativa.</article-title><source><italic>Repertorium fur die Pharmacie.</italic></source><year>1840</year><fpage>190</fpage><lpage>208</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decourtive</surname><given-names>E.</given-names></name></person-group><article-title>Note sur le haschisch.</article-title><source><italic>CR Hebd Séances Acad Sci.</italic></source><year>1848</year><volume>26</volume><fpage>509</fpage><lpage>510</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>Cannabinoid chemistry. In: Mechoulam R, ed.</article-title><source><italic>Marijuana.</italic> New York, NY; London, UK: Academic Press</source><year>1973</year><fpage>1</fpage><lpage>99</lpage></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Hanus</surname><given-names>L.</given-names></name></person-group><article-title>A historical overview of chemical research on cannabinoids.</article-title><source><italic>Chem Phys Lipids.</italic></source><year>2000</year><volume>108</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11106779</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaoni</surname><given-names>Y.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>Isolation, structure and partial synthesis of the active constituent of hashish.</article-title><source><italic>J Am Chem Soc.</italic></source><year>1964</year><volume>86</volume><fpage>1646</fpage><lpage>1647</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waller</surname><given-names>CW. JJ.</given-names></name><name><surname>Buelke</surname><given-names>J.</given-names></name><name><surname>Turner</surname><given-names>CE.</given-names></name></person-group><article-title>Marihuana, an annotated bibliography.</article-title><source><italic>Res Inst Pharmacy Sci Univ Mississippi.</italic></source><year>1976 and yearly updates.</year></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>JD.</given-names></name></person-group><article-title>Withdrawal symptoms in cannabis indica addicts.</article-title><source><italic>Lancet.</italic></source><year>1949</year><volume>2</volume><fpage>747</fpage><pub-id pub-id-type="pmid">15390694</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grinspoon</surname><given-names>L.</given-names></name><name><surname>Bakalar</surname><given-names>JB.</given-names></name><name><surname>Zimmer</surname><given-names>L.</given-names></name><name><surname>Morgan</surname><given-names>JP.</given-names></name></person-group><article-title>Marijuana addiction.</article-title><source><italic>Science.</italic></source><year>1997</year><volume>277</volume><fpage>749</fpage><lpage>author reply 750-742</lpage><pub-id pub-id-type="pmid">9273692</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaymakcalan</surname><given-names>S.</given-names></name></person-group><article-title>The addictive potential of cannabis.</article-title><source><italic>Bull Narc.</italic></source><year>1981</year><volume>33</volume><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">6272922</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RT.</given-names></name><name><surname>Benowitz</surname><given-names>N.</given-names></name><name><surname>Bachman</surname><given-names>J.</given-names></name></person-group><article-title>Clinical studies of cannabis tolerance and dependence.</article-title><source><italic>Ann N Y Acad Sci.</italic></source><year>1976</year><volume>282</volume><fpage>221</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">798533</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordstrom</surname><given-names>BR.</given-names></name><name><surname>Levin</surname><given-names>FR.</given-names></name></person-group><article-title>Treatment of cannabis use disorders: a review of the literature.</article-title><source><italic>Am J Addict.</italic></source><year>2007</year><volume>16</volume><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">17882603</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernoussi</surname><given-names>A.</given-names></name><name><surname>Brandibas</surname><given-names>G.</given-names></name></person-group><article-title>Cannabis addiction and Telic Dominance Scale.</article-title><source><italic>Encephale.</italic></source><year>2003</year><volume>29</volume><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">15029086</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budney</surname><given-names>AJ.</given-names></name><name><surname>Moore</surname><given-names>BA.</given-names></name><name><surname>Rocha</surname><given-names>HL.</given-names></name><name><surname>Higgins</surname><given-names>ST.</given-names></name></person-group><article-title>Clinical trial of abstinencebased vouchers and cognitive-behavioral therapy for cannabis dependence.</article-title><source><italic>J Consult Clin Psychol.</italic></source><year>2006</year><volume>74</volume><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">16649875</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>EL.</given-names></name></person-group><article-title>Addictive potential of cannabinoids: the underlying neurobiology.</article-title><source><italic>Chem Phys Lipids.</italic></source><year>2002</year><volume>121</volume><fpage>267</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">12505706</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>R.</given-names></name><name><surname>Rodriguez</surname><given-names>de Fonseca F.</given-names></name></person-group><article-title>Cannabinoid addiction: behavioral models and neural correlates.</article-title><source><italic>J Neurosci.</italic></source><year>2002</year><volume>22</volume><fpage>3326</fpage><lpage>3331</lpage><pub-id pub-id-type="pmid">11978807</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansbach</surname><given-names>RS.</given-names></name><name><surname>Nicholson</surname><given-names>KL.</given-names></name><name><surname>Martin</surname><given-names>BR.</given-names></name><name><surname>Balster</surname><given-names>RL.</given-names></name></person-group><article-title>Failure of Delta(9)-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys.</article-title><source><italic>Behav Pharmacol.</italic></source><year>1994</year><volume>5</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">11224271</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>G.</given-names></name><name><surname>Serra</surname><given-names>S.</given-names></name><name><surname>Vacca</surname><given-names>G.</given-names></name><name><surname>Carai</surname><given-names>MA.</given-names></name><name><surname>Gessa</surname><given-names>GL.</given-names></name></person-group><article-title>Endocannabinoid system and alcohol addiction: pharmacological studies.</article-title><source><italic>Pharmacol Biochem Behav.</italic></source><year>2005</year><volume>81</volume><fpage>369</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">15939463</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Harvey-White</surname><given-names>J.</given-names></name><name><surname>Zimmer</surname><given-names>A.</given-names></name><name><surname>Kunos</surname><given-names>G.</given-names></name></person-group><article-title>Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.</article-title><source><italic>Proc Natl Acad Sci U S A.</italic></source><year>2003</year><volume>100</volume><fpage>1393</fpage><lpage>1398</lpage><pub-id pub-id-type="pmid">12538878</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>Perrault</surname><given-names>G.</given-names></name><name><surname>Voltz</surname><given-names>C.</given-names></name><name><surname>Steinberg</surname><given-names>R.</given-names></name><name><surname>Soubrie</surname><given-names>P.</given-names></name></person-group><article-title>SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopaminereleasing effects of nicotine in rats.</article-title><source><italic>Behav Pharmacol.</italic></source><year>2002</year><volume>13</volume><fpage>451</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">12394421</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>NS.</given-names></name><name><surname>Gold</surname><given-names>MS.</given-names></name><name><surname>Klahr</surname><given-names>AL.</given-names></name></person-group><article-title>The diagnosis of alcohol and cannabis dependence (addiction) in cocaine dependence (addiction).</article-title><source><italic>Int J Addict.</italic></source><year>1990</year><volume>25</volume><fpage>735</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">2272719</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foltin</surname><given-names>RW.</given-names></name><name><surname>Fischman</surname><given-names>MW.</given-names></name><name><surname>Pippen</surname><given-names>PA.</given-names></name><name><surname>Kelly</surname><given-names>TH.</given-names></name></person-group><article-title>Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans.</article-title><source><italic>Drug Alcohol Depend.</italic></source><year>1993</year><volume>32</volume><fpage>93</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">8508730</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukas</surname><given-names>SE.</given-names></name><name><surname>Sholar</surname><given-names>M.</given-names></name><name><surname>Kouri</surname><given-names>E.</given-names></name><name><surname>Fukuzako</surname><given-names>H.</given-names></name><name><surname>Mendelson</surname><given-names>JH.</given-names></name></person-group><article-title>Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers.</article-title><source><italic>Pharmacol Biochem Behav.</italic></source><year>1994</year><volume>48</volume><fpage>715</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">7938127</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballon</surname><given-names>N.</given-names></name><name><surname>Leroy</surname><given-names>S.</given-names></name><name><surname>Roy</surname><given-names>C.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>(AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population.</article-title><source><italic>Pharmacogenomics J.</italic></source><year>2006</year><volume>6</volume><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">16314880</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filip</surname><given-names>M.</given-names></name><name><surname>Golda</surname><given-names>A.</given-names></name><name><surname>Zaniewska</surname><given-names>M.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine.</article-title><source><italic>Pharmacol Rep.</italic></source><year>2006</year><volume>58</volume><fpage>806</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">17220538</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Foll</surname><given-names>B.</given-names></name><name><surname>Goldberg</surname><given-names>SR.</given-names></name></person-group><article-title>Rimonabant, a CB1 antagonist, blocks nicotineconditioned place preferences.</article-title><source><italic>Neuroreport.</italic></source><year>2004</year><volume>15</volume><fpage>2139</fpage><lpage>2143</lpage><pub-id pub-id-type="pmid">15486497</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>Perrault</surname><given-names>G.</given-names></name><name><surname>Griebel</surname><given-names>G.</given-names></name><name><surname>Soubrie</surname><given-names>P.</given-names></name></person-group><article-title>Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).</article-title><source><italic>Neuropsychopharmacology.</italic></source><year>2005</year><volume>30</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">15292905</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castane</surname><given-names>A.</given-names></name><name><surname>Berrendero</surname><given-names>F.</given-names></name><name><surname>Maldonado</surname><given-names>R.</given-names></name></person-group><article-title>The role of the cannabinoid system in nicotine addiction.</article-title><source><italic>Pharmacol Biochem Behav.</italic></source><year>2005</year><volume>81</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">15925402</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Einecke</surname><given-names>D.</given-names></name></person-group><article-title>[A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes].</article-title><source><italic>MMW Fortschr Med.</italic></source><year>2004</year><volume>146</volume><fpage>10</fpage><lpage>11</lpage></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulds</surname><given-names>J.</given-names></name><name><surname>Burke</surname><given-names>M.</given-names></name><name><surname>Steinberg</surname><given-names>M.</given-names></name><name><surname>Williams</surname><given-names>JM.</given-names></name><name><surname>Ziedonis</surname><given-names>DM.</given-names></name></person-group><article-title>Advances in pharmacotherapy for tobacco dependence.</article-title><source><italic>Expert Opin Emerg Drugs.</italic></source><year>2004</year><volume>9</volume><fpage>39</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15155135</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelfand</surname><given-names>EV.</given-names></name><name><surname>Cannon</surname><given-names>CP.</given-names></name></person-group><article-title>Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.</article-title><source><italic>Expert Opin Investig Drugs.</italic></source><year>2006</year><volume>15</volume><fpage>307</fpage><lpage>315</lpage></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>McFarland</surname><given-names>K.</given-names></name><name><surname>Fan</surname><given-names>P.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Ueda</surname><given-names>T.</given-names></name><name><surname>Diamond</surname><given-names>I.</given-names></name></person-group><article-title>Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats.</article-title><source><italic>Proc Natl Acad Sci U S A.</italic></source><year>2006</year><volume>103</volume><fpage>7877</fpage><lpage>7882</lpage><pub-id pub-id-type="pmid">16684876</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledent</surname><given-names>C.</given-names></name><name><surname>Valverde</surname><given-names>O.</given-names></name><name><surname>Cossu</surname><given-names>G.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.</article-title><source><italic>Science.</italic></source><year>1999</year><volume>283</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">9888857</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laviolette</surname><given-names>SR.</given-names></name><name><surname>Grace</surname><given-names>AA.</given-names></name></person-group><article-title>The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction.</article-title><source><italic>Cell Mol Life Sci.</italic></source><year>2006</year><volume>63</volume><fpage>1597</fpage><lpage>1613</lpage><pub-id pub-id-type="pmid">16699809</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Foll</surname><given-names>B.</given-names></name><name><surname>Goldberg</surname><given-names>SR.</given-names></name></person-group><article-title>Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.</article-title><source><italic>J Pharmacol Exp Ther.</italic></source><year>2005</year><volume>312</volume><fpage>875</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">15525797</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solowij</surname><given-names>N.</given-names></name><name><surname>Stephens</surname><given-names>RS.</given-names></name><name><surname>Roffman</surname><given-names>RA.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cognitive functioning of longterm heavy cannabis users seeking treatment.</article-title><source><italic>JAMA.</italic></source><year>2002</year><volume>287</volume><fpage>1123</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">11879109</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klugman</surname><given-names>A.</given-names></name><name><surname>Gruzelier</surname><given-names>J.</given-names></name></person-group><article-title>Chronic cognitive impairment in users of 'ecstasy' and cannabis.</article-title><source><italic>World Psychiatry.</italic></source><year>2003</year><volume>2</volume><fpage>184</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">16946933</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadsworth</surname><given-names>EJ.</given-names></name><name><surname>Moss</surname><given-names>SC.</given-names></name><name><surname>Simpson</surname><given-names>SA.</given-names></name><name><surname>Smith</surname><given-names>AP.</given-names></name></person-group><article-title>Cannabis use, cognitive performance and mood in a sample of workers.</article-title><source><italic>J Psychopharmacol.</italic></source><year>2006</year><volume>20</volume><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16204329</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jager</surname><given-names>G.</given-names></name><name><surname>Kahn</surname><given-names>RS.</given-names></name><name><surname>Van Den Brink</surname><given-names>W.</given-names></name><name><surname>Van Ree</surname><given-names>JM.</given-names></name><name><surname>Ramsey</surname><given-names>NF.</given-names></name></person-group><article-title>Long-term effects of frequent cannabis use on working memory and attention: an fMRI study.</article-title><source><italic>Psychopharmacology (Berl).</italic></source><year>2006</year><volume>185</volume><fpage>358</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">16521034</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maj</surname><given-names>PF.</given-names></name><name><surname>Collu</surname><given-names>M.</given-names></name><name><surname>Fadda</surname><given-names>P.</given-names></name><name><surname>Cattaneo</surname><given-names>A.</given-names></name><name><surname>Racagni</surname><given-names>G.</given-names></name><name><surname>Riva</surname><given-names>MA.</given-names></name></person-group><article-title>Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone.</article-title><source><italic>Eur J Neurosci.</italic></source><year>2007</year><volume>25</volume><fpage>3305</fpage><lpage>3311</lpage><pub-id pub-id-type="pmid">17552998</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huizink</surname><given-names>AC.</given-names></name><name><surname>Mulder</surname><given-names>EJ.</given-names></name></person-group><article-title>Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring.</article-title><source><italic>Neurosci Biobehav Rev.</italic></source><year>2006</year><volume>30</volume><fpage>24</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16095697</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>PA.</given-names></name><name><surname>Smith</surname><given-names>AM.</given-names></name></person-group><article-title>A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function.</article-title><source><italic>Neurotoxicol Teratol.</italic></source><year>2001</year><volume>23</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">11274871</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>RM.</given-names></name><name><surname>Morrison</surname><given-names>PD.</given-names></name><name><surname>Henquet</surname><given-names>C.</given-names></name><name><surname>Di Forti</surname><given-names>M.</given-names></name></person-group><article-title>Cannabis, the mind and society: the hash realities.</article-title><source><italic>Nat Rev Neurosci.</italic></source><year>2007</year><volume>8</volume><fpage>885</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">17925811</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solowij</surname><given-names>N.</given-names></name><name><surname>Michie</surname><given-names>PT.</given-names></name></person-group><article-title>Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?</article-title><source><italic>J Psychiatry Neurosci.</italic></source><year>2007</year><volume>32</volume><fpage>30</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">17245472</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favrat</surname><given-names>B.</given-names></name><name><surname>Menetrey</surname><given-names>A.</given-names></name><name><surname>Augsburger</surname><given-names>M.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Two cases of “cannabis acute psychosis” following the administration of oral cannabis.</article-title><source><italic>BMC Psychiatry.</italic></source><year>2005</year><volume>5</volume><fpage>17</fpage><pub-id pub-id-type="pmid">15804348</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Souza</surname><given-names>DC.</given-names></name><name><surname>Perry</surname><given-names>E.</given-names></name><name><surname>MacDougall</surname><given-names>L.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>The psychotomimetic effects of intravenous deIta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.</article-title><source><italic>Neuropsychopharmacology.</italic></source><year>2004</year><volume>29</volume><fpage>1558</fpage><lpage>1572</lpage><pub-id pub-id-type="pmid">15173844</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>S.</given-names></name><name><surname>Wada</surname><given-names>K.</given-names></name></person-group><article-title>Amotivational syndrome in organic solvent abusers.</article-title><source><italic>Nippon Yakurigaku Zasshi.</italic></source><year>2001</year><volume>117</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">11233295</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>M.</given-names></name></person-group><article-title>Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats.</article-title><source><italic>Nippon Yakurigaku Zasshi.</italic></source><year>2001</year><volume>117</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11233294</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunving</surname><given-names>K.</given-names></name></person-group><article-title>Psychiatric aspects of cannabis use in adolescents and young adults.</article-title><source><italic>Pediatrician.</italic></source><year>1987</year><volume>14</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">3497393</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laqueille</surname><given-names>X.</given-names></name></person-group><article-title>Related, induced and associated psychiatric disorders to cannabis.</article-title><source><italic>Rev Prat.</italic></source><year>2005</year><volume>55</volume><fpage>30</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">15801394</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendelson</surname><given-names>JH.</given-names></name><name><surname>Kuehnle</surname><given-names>JC.</given-names></name><name><surname>Greenberg</surname><given-names>I.</given-names></name><name><surname>Mello</surname><given-names>NK.</given-names></name></person-group><article-title>Operant acquisition of marihuana in man.</article-title><source><italic>J Pharmacol Exp Ther.</italic></source><year>1976</year><volume>198</volume><fpage>42</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">933012</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnwell</surname><given-names>SS.</given-names></name><name><surname>Earleywine</surname><given-names>M.</given-names></name><name><surname>Wilcox</surname><given-names>R.</given-names></name></person-group><article-title>Cannabis, motivation, and life satisfaction in an internet sample.</article-title><source><italic>Subst Abuse Treat Prev Policy.</italic></source><year>2006</year><volume>1</volume><fpage>2</fpage><pub-id pub-id-type="pmid">16722561</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wargo</surname><given-names>KA.</given-names></name><name><surname>Geveden</surname><given-names>BN.</given-names></name><name><surname>McConnell</surname><given-names>VJ.</given-names></name></person-group><article-title>Cannabinoid-induced pancreatitis: a case series.</article-title><source><italic>JOP.</italic></source><year>2007</year><volume>8</volume><fpage>579</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">17873462</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkham</surname><given-names>TC.</given-names></name></person-group><article-title>Endocannabinoids in the regulation of appetite and body weight.</article-title><source><italic>Behav Pharmacol.</italic></source><year>2005</year><volume>16</volume><fpage>297</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">16148436</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkham</surname><given-names>TC.</given-names></name><name><surname>Tucci</surname><given-names>SA.</given-names></name></person-group><article-title>Endocannabinoids in appetite control and the treatment of obesity.</article-title><source><italic>CNS Neurol Disord Drug Targets.</italic></source><year>2006</year><volume>5</volume><fpage>272</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">16787229</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>P.</given-names></name><name><surname>Strazzullo</surname><given-names>P.</given-names></name><name><surname>Cappuccio</surname><given-names>FP.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men.</article-title><source><italic>J Clin Endocrinol Metab.</italic></source><year>2007</year></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gessa</surname><given-names>GL.</given-names></name><name><surname>Orru</surname><given-names>A.</given-names></name><name><surname>Lai</surname><given-names>P.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats.</article-title><source><italic>Psychopharmacology (Berl).</italic></source><year>2006</year><volume>185</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">16491428</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>SJ.</given-names></name><name><surname>Dykstra</surname><given-names>LA.</given-names></name></person-group><article-title>The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940).</article-title><source><italic>Behav Pharmacol.</italic></source><year>2005</year><volume>16</volume><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">16148442</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simiand</surname><given-names>J.</given-names></name><name><surname>Keane</surname><given-names>M.</given-names></name><name><surname>Keane</surname><given-names>PE.</given-names></name><name><surname>Soubrie</surname><given-names>P.</given-names></name></person-group><article-title>SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.</article-title><source><italic>Behav Pharmacol.</italic></source><year>1998</year><volume>9</volume><fpage>179</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">10065938</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carai</surname><given-names>MA.</given-names></name><name><surname>Colombo</surname><given-names>G</given-names></name><name><surname>Maccioni</surname><given-names>P.</given-names></name><name><surname>Gessa</surname><given-names>GL.</given-names></name></person-group><article-title>Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.</article-title><source><italic>CNS Drug Rev</italic></source><year>2006</year><volume>12</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">16958983</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagotto</surname><given-names>U.</given-names></name><name><surname>Pasquali</surname><given-names>R.</given-names></name></person-group><article-title>Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.</article-title><source><italic>Lancet.</italic></source><year>2005</year><volume>365</volume><fpage>1363</fpage><lpage>1364</lpage><pub-id pub-id-type="pmid">15836868</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Despres</surname><given-names>JP.</given-names></name><name><surname>Golay</surname><given-names>A.</given-names></name><name><surname>Sjostrom</surname><given-names>L.</given-names></name></person-group><article-title>Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.</article-title><source><italic>N Engl J Med.</italic></source><year>2005</year><volume>353</volume><fpage>2121</fpage><lpage>2134</lpage><pub-id pub-id-type="pmid">16291982</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pi-Sunyer</surname><given-names>FX.</given-names></name><name><surname>Aronne</surname><given-names>LJ.</given-names></name><name><surname>Heshmati</surname><given-names>HM.</given-names></name><name><surname>Devin</surname><given-names>J.</given-names></name><name><surname>Rosenstock</surname><given-names>J.</given-names></name></person-group><article-title>Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.</article-title><source><italic>JAMA.</italic></source><year>2006</year><volume>295</volume><fpage>761</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">16478899</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Gaal</surname><given-names>LF.</given-names></name><name><surname>Rissanen</surname><given-names>AM.</given-names></name><name><surname>Scheen</surname><given-names>AJ.</given-names></name><name><surname>Ziegler</surname><given-names>O.</given-names></name><name><surname>Rossner</surname><given-names>S.</given-names></name></person-group><article-title>Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.</article-title><source><italic>Lancet.</italic></source><year>2005</year><volume>365</volume><fpage>1389</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">15836887</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleland</surname><given-names>JG.</given-names></name><name><surname>Ghosh</surname><given-names>J.</given-names></name><name><surname>Freemantle</surname><given-names>N.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCDHeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure.</article-title><source><italic>Eur J Heart Fail.</italic></source><year>2004</year><volume>6</volume><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">15182777</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheen</surname><given-names>AJ.</given-names></name><name><surname>Van Gaal</surname><given-names>LG.</given-names></name><name><surname>Despres</surname><given-names>JP.</given-names></name><name><surname>Pi-Sunyer</surname><given-names>X.</given-names></name><name><surname>Golay</surname><given-names>A.</given-names></name><name><surname>Hanotin</surname><given-names>C.</given-names></name></person-group><article-title>Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies.</article-title><source><italic>Rev Med Suisse.</italic></source><year>2006</year><volume>2</volume><fpage>1916</fpage><lpage>1923</lpage><pub-id pub-id-type="pmid">16972542</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>H.</given-names></name><name><surname>Singer</surname><given-names>P.</given-names></name></person-group><article-title>Rimonabant in obese patients with type 2 diabetes.</article-title><source><italic>Lancet.</italic></source><year>2007</year><volume>369</volume><fpage>553</fpage><lpage>554; author reply 554-555</lpage><pub-id pub-id-type="pmid">17307091</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>PN.</given-names></name><name><surname>Pathak</surname><given-names>R.</given-names></name></person-group><article-title>Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.</article-title><source><italic>Am J Health Syst Pharm.</italic></source><year>2007</year><volume>64</volume><fpage>481</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">17322160</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beal</surname><given-names>JE.</given-names></name><name><surname>Olson</surname><given-names>R.</given-names></name><name><surname>Lefkowitz</surname><given-names>L.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.</article-title><source><italic>J Pain Symptom Manage.</italic></source><year>1997</year><volume>14</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">9223837</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beal</surname><given-names>JE.</given-names></name><name><surname>Olson</surname><given-names>R.</given-names></name><name><surname>Laubenstein</surname><given-names>L.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.</article-title><source><italic>J Pain Symptom Manage.</italic></source><year>1995</year><volume>10</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">7730690</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorter</surname><given-names>R.</given-names></name><name><surname>Seefried</surname><given-names>M.</given-names></name><name><surname>Volberding</surname><given-names>P.</given-names></name></person-group><article-title>Dronabinol effects on weight in patients with HIV infection.</article-title><source><italic>AIDS.</italic></source><year>1992</year><volume>6</volume><fpage>127</fpage><pub-id pub-id-type="pmid">1311935</pub-id></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timpone</surname><given-names>JG.</given-names></name><name><surname>Wright</surname><given-names>DJ.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRl 004 Study Group. Division of AIDS Treatment Research Initiative.</article-title><source><italic>AIDS Res Hum Retroviruses.</italic></source><year>1997</year><volume>13</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">9071430</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>F.</given-names></name><name><surname>Klaschik</surname><given-names>E.</given-names></name></person-group><article-title>Cannabinoids in the treatment of the cachexiaanorexia syndrome in palliative care patients.</article-title><source><italic>Schmerz.</italic></source><year>2004</year><volume>18</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">15221423</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>K.</given-names></name><name><surname>Walsh</surname><given-names>D.</given-names></name><name><surname>Deeter</surname><given-names>P.</given-names></name><name><surname>Sheehan</surname><given-names>F.</given-names></name></person-group><article-title>A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia.</article-title><source><italic>J Palliat Care.</italic></source><year>1994</year><volume>10</volume><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">8035251</pub-id></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>BR.</given-names></name><name><surname>Wiley</surname><given-names>JL.</given-names></name></person-group><article-title>Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.</article-title><source><italic>J Support Oncol.</italic></source><year>2004</year><volume>2</volume><fpage>305</fpage><lpage>314; discussion 314-306</lpage><pub-id pub-id-type="pmid">15357514</pub-id></element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrahamov</surname><given-names>A.</given-names></name><name><surname>Abrahamov</surname><given-names>A.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>An efficient new cannabinoid antiemetic in pediatric oncology.</article-title><source><italic>Life Sci.</italic></source><year>1995</year><volume>56</volume><fpage>2097</fpage><lpage>2102</lpage><pub-id pub-id-type="pmid">7776837</pub-id></element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tramer</surname><given-names>MR.</given-names></name><name><surname>Carroll</surname><given-names>D.</given-names></name><name><surname>Campbell</surname><given-names>FA.</given-names></name><name><surname>Reynolds</surname><given-names>DJ.</given-names></name><name><surname>Moore</surname><given-names>RA.</given-names></name><name><surname>McQuay</surname><given-names>HJ.</given-names></name></person-group><article-title>Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.</article-title><source><italic>BMJ.</italic></source><year>2001</year><volume>323</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">11440936</pub-id></element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>YC.</given-names></name><name><surname>Huang</surname><given-names>CC.</given-names></name><name><surname>Hsu</surname><given-names>KS.</given-names></name></person-group><article-title>Therapeutic potential of cannabinoids in trigeminal neuralgia.</article-title><source><italic>Curr Drug Targets CNS Neurol Disord.</italic></source><year>2004</year><volume>3</volume><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">15578967</pub-id></element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volfe</surname><given-names>Z.</given-names></name><name><surname>Dvilansky</surname><given-names>A.</given-names></name><name><surname>Nathan</surname><given-names>I.</given-names></name></person-group><article-title>Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients.</article-title><source><italic>Int J Clin Pharmacol Res.</italic></source><year>1985</year><volume>5</volume><fpage>243</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">2997048</pub-id></element-citation></ref><ref id="ref80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attal</surname><given-names>N.</given-names></name><name><surname>Brasseur</surname><given-names>L.</given-names></name><name><surname>Guirimand</surname><given-names>D.</given-names></name><name><surname>Clermond-Gnamien</surname><given-names>S.</given-names></name><name><surname>Atlami</surname><given-names>S.</given-names></name><name><surname>Bouhassira</surname><given-names>D.</given-names></name></person-group><article-title>Are oral cannabinoids safe and effective in refractory neuropathic pain?</article-title><source><italic>Eur J Pain.</italic></source><year>2004</year><volume>8</volume><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">14987627</pub-id></element-citation></ref><ref id="ref81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buggy</surname><given-names>DJ.</given-names></name><name><surname>Toogood</surname><given-names>L.</given-names></name><name><surname>Marie</surname><given-names>S.</given-names></name><name><surname>Sharpe</surname><given-names>P.</given-names></name><name><surname>Lambert</surname><given-names>DG.</given-names></name><name><surname>Rowbotham</surname><given-names>DJ.</given-names></name></person-group><article-title>Lack of analgesic efficacy of oral deIta-9-tetrahydrocannabinol in postoperative pain.</article-title><source><italic>Pain.</italic></source><year>2003</year><volume>106</volume><fpage>169</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">14581124</pub-id></element-citation></ref><ref id="ref82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holdcroft</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>M.</given-names></name><name><surname>Jacklin</surname><given-names>A.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Pain relief with oral cannabinoids in familial Mediterranean fever.</article-title><source><italic>Anaesthesia.</italic></source><year>1997</year><volume>52</volume><fpage>483</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">9165969</pub-id></element-citation></ref><ref id="ref83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>JS.</given-names></name><name><surname>Symonds</surname><given-names>C.</given-names></name><name><surname>Birch</surname><given-names>R.</given-names></name></person-group><article-title>Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.</article-title><source><italic>Pain.</italic></source><year>2004</year><volume>112</volume><fpage>299</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">15561385</pub-id></element-citation></ref><ref id="ref84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svendsen</surname><given-names>KB.</given-names></name><name><surname>Jensen</surname><given-names>TS.</given-names></name><name><surname>Bach</surname><given-names>FW.</given-names></name></person-group><article-title>Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.</article-title><source><italic>BMJ.</italic></source><year>2004</year><volume>329</volume><fpage>253</fpage><pub-id pub-id-type="pmid">15258006</pub-id></element-citation></ref><ref id="ref85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svendsen</surname><given-names>KB.</given-names></name><name><surname>Jensen</surname><given-names>TS.</given-names></name><name><surname>Bach</surname><given-names>FW.</given-names></name></person-group><article-title>Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis - secondary publication.</article-title><source><italic>Ugeskr Laeger.</italic></source><year>2005</year><volume>167</volume><fpage>2772</fpage><lpage>2774</lpage><pub-id pub-id-type="pmid">16014264</pub-id></element-citation></ref><ref id="ref86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noyes</surname><given-names>R.</given-names></name><name><surname>Jr.</surname></name><name><surname>Brunk</surname><given-names>SF.</given-names></name><name><surname>Avery</surname><given-names>DA.</given-names></name><name><surname>Canter</surname><given-names>AC.</given-names></name></person-group><article-title>The analgesic properties of deIta-9-tetrahydrocannabinol and codeine.</article-title><source><italic>Clin Pharmacol Ther.</italic></source><year>1975</year><volume>18</volume><fpage>84</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">50159</pub-id></element-citation></ref><ref id="ref87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noyes</surname><given-names>R.</given-names></name><name><surname>Jr.</surname></name><name><surname>Brunk</surname><given-names>SF.</given-names></name><name><surname>Baram</surname><given-names>DA.</given-names></name><name><surname>Canter</surname><given-names>A.</given-names></name></person-group><article-title>Analgesic effect of deIta-9-tetrahydrocannabinol.</article-title><source><italic>J Clin Pharmacol.</italic></source><year>1975</year><volume>15</volume><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">1091664</pub-id></element-citation></ref><ref id="ref88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>MA.</given-names></name><name><surname>Doyle</surname><given-names>CR.</given-names></name><name><surname>Woods</surname><given-names>R.</given-names></name><name><surname>Lynch</surname><given-names>ME.</given-names></name><name><surname>Clark</surname><given-names>AJ.</given-names></name></person-group><article-title>Cannabis use for chronic non-cancer pain: results of a prospective survey.</article-title><source><italic>Pain.</italic></source><year>2003</year><volume>102</volume><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">12620613</pub-id></element-citation></ref><ref id="ref89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woolridge</surname><given-names>E.</given-names></name><name><surname>Barton</surname><given-names>S.</given-names></name><name><surname>Samuel</surname><given-names>J.</given-names></name><name><surname>Osorio</surname><given-names>J.</given-names></name><name><surname>Dougherty</surname><given-names>A.</given-names></name><name><surname>Holdcroft</surname><given-names>A.</given-names></name></person-group><article-title>Cannabis use in HIV for pain and other medical symptoms.</article-title><source><italic>J Pain Symptom Manage.</italic></source><year>2005</year><volume>29</volume><fpage>358</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">15857739</pub-id></element-citation></ref><ref id="ref90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlach</surname><given-names>DM.</given-names></name><name><surname>Shir</surname><given-names>Y.</given-names></name><name><surname>Ware</surname><given-names>MA.</given-names></name></person-group><article-title>Experience with the synthetic cannabinoid nabilone in chronic noncancer pain.</article-title><source><italic>Pain Med.</italic></source><year>2006</year><volume>7</volume><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">16533193</pub-id></element-citation></ref><ref id="ref91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wissel</surname><given-names>J.</given-names></name><name><surname>Haydn</surname><given-names>T.</given-names></name><name><surname>MuIIer</surname><given-names>J.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial.</article-title><source><italic>J Neurol.</italic></source><year>2006</year><volume>253</volume><fpage>1337</fpage><lpage>1341</lpage><pub-id pub-id-type="pmid">16988792</pub-id></element-citation></ref><ref id="ref92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karst</surname><given-names>M.</given-names></name><name><surname>Salim</surname><given-names>K.</given-names></name><name><surname>Burstein</surname><given-names>S.</given-names></name><name><surname>Conrad</surname><given-names>I.</given-names></name><name><surname>Hoy</surname><given-names>L.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name></person-group><article-title>Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.</article-title><source><italic>JAMA.</italic></source><year>2003</year><volume>290</volume><fpage>1757</fpage><lpage>1762</lpage><pub-id pub-id-type="pmid">14519710</pub-id></element-citation></ref><ref id="ref93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vann</surname><given-names>RE.</given-names></name><name><surname>Cook</surname><given-names>CD.</given-names></name><name><surname>Martin</surname><given-names>BR.</given-names></name><name><surname>Jenny</surname><given-names>L.</given-names></name><name><surname>Wiley</surname><given-names>JL.</given-names></name></person-group><article-title>Cannabimimetic properties of ajulemic acid.</article-title><source><italic>J Pharmacol Exp Ther.</italic></source><year>2007</year><volume>320</volume><fpage>678</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">17105826</pub-id></element-citation></ref><ref id="ref94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>E.</given-names></name><name><surname>Guy</surname><given-names>GW.</given-names></name></person-group><article-title>A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.</article-title><source><italic>Med Hypotheses.</italic></source><year>2006</year><volume>66</volume><fpage>234</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">16209908</pub-id></element-citation></ref><ref id="ref95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iskedjian</surname><given-names>M.</given-names></name><name><surname>Bereza</surname><given-names>B.</given-names></name><name><surname>Gordon</surname><given-names>A.</given-names></name><name><surname>Piwko</surname><given-names>C.</given-names></name><name><surname>Einarson</surname><given-names>TR.</given-names></name></person-group><article-title>Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.</article-title><source><italic>Curr Med Res Opin.</italic></source><year>2007</year><volume>23</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">17257464</pub-id></element-citation></ref><ref id="ref96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notcutt</surname><given-names>W.</given-names></name><name><surname>Price</surname><given-names>M.</given-names></name><name><surname>Miller</surname><given-names>R.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.</article-title><source><italic>Anaesthesia.</italic></source><year>2004</year><volume>59</volume><fpage>440</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">15096238</pub-id></element-citation></ref><ref id="ref97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rog</surname><given-names>DJ.</given-names></name><name><surname>Nurmikko</surname><given-names>TJ.</given-names></name><name><surname>Friede</surname><given-names>T.</given-names></name><name><surname>Young</surname><given-names>CA.</given-names></name></person-group><article-title>Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.</article-title><source><italic>Neurology.</italic></source><year>2005</year><volume>65</volume><fpage>812</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">16186518</pub-id></element-citation></ref><ref id="ref98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>MP.</given-names></name></person-group><article-title>Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.</article-title><source><italic>Exp Opin Pharmacother.</italic></source><year>2006</year><volume>7</volume><fpage>607</fpage><lpage>615</lpage></element-citation></ref><ref id="ref99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>J.</given-names></name></person-group><article-title>Combined cannabinoid therapy via an oromucosal spray.</article-title><source><italic>Drugs Today (Bare).</italic></source><year>2006</year><volume>42</volume><fpage>495</fpage><lpage>503</lpage></element-citation></ref><ref id="ref100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>M.</given-names></name><name><surname>Beaulieu</surname><given-names>P.</given-names></name></person-group><article-title>Cannabinoids for the treatment of pain: An update on recent clinical trials.</article-title><source><italic>Pain Res Manag.</italic></source><year>2005</year><volume>10 (suppl A)</volume><fpage>27A</fpage><lpage>30A</lpage></element-citation></ref><ref id="ref101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achiron</surname><given-names>A.</given-names></name><name><surname>Miron</surname><given-names>S.</given-names></name><name><surname>Lavie</surname><given-names>V.</given-names></name><name><surname>Margalit</surname><given-names>R.</given-names></name><name><surname>Biegon</surname><given-names>A.</given-names></name></person-group><article-title>Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis.</article-title><source><italic>J Neuroimmunol.</italic></source><year>2000</year><volume>102</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10626663</pub-id></element-citation></ref><ref id="ref102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyman</surname><given-names>WD.</given-names></name><name><surname>Sonett</surname><given-names>JR.</given-names></name><name><surname>Brosnan</surname><given-names>CF.</given-names></name><name><surname>Elkin</surname><given-names>R.</given-names></name><name><surname>Bornstein</surname><given-names>MB.</given-names></name></person-group><article-title>Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.</article-title><source><italic>J Neuroimmunol.</italic></source><year>1989</year><volume>23</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">2542370</pub-id></element-citation></ref><ref id="ref103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>AJ.</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>P.</given-names></name><name><surname>Galve-Roperh</surname><given-names>I.</given-names></name><name><surname>Garcia-Merino</surname><given-names>A.</given-names></name></person-group><article-title>R-(+)-[2,3-Dihydro-5-methyI-3-(4-morphoIinyImethyI)-pyrroIo-[1,2,3-de]-1,4-benzoxazin-6-yI]-1-naphta!enyImethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.</article-title><source><italic>Biochem Pharmacol.</italic></source><year>2006</year><volume>72</volume><fpage>1697</fpage><lpage>1706</lpage><pub-id pub-id-type="pmid">17007821</pub-id></element-citation></ref><ref id="ref104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Docagne</surname><given-names>F.</given-names></name><name><surname>Muneton</surname><given-names>V.</given-names></name><name><surname>Clemente</surname><given-names>D.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.</article-title><source><italic>Mol Cell Neurosci.</italic></source><year>2007</year><volume>34</volume><fpage>551</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">17229577</pub-id></element-citation></ref><ref id="ref105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benito</surname><given-names>C.</given-names></name><name><surname>Romero</surname><given-names>JP.</given-names></name><name><surname>Tolon</surname><given-names>RM.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.</article-title><source><italic>J Neurosci.</italic></source><year>2007</year><volume>27</volume><fpage>2396</fpage><lpage>2402</lpage><pub-id pub-id-type="pmid">17329437</pub-id></element-citation></ref><ref id="ref106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabranes</surname><given-names>A.</given-names></name><name><surname>Pryce</surname><given-names>G.</given-names></name><name><surname>Baker</surname><given-names>D.</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J.</given-names></name></person-group><article-title>Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice.</article-title><source><italic>Brain Res.</italic></source><year>2006</year><volume>1107</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">16822488</pub-id></element-citation></ref><ref id="ref107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petro</surname><given-names>DJ.</given-names></name></person-group><article-title>Marihuana as a therapeutic agent for muscle spasm or spasticity.</article-title><source><italic>Psychosomatics.</italic></source><year>1980</year><volume>21</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">7360860</pub-id></element-citation></ref><ref id="ref108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pryce</surname><given-names>G.</given-names></name><name><surname>Baker</surname><given-names>D.</given-names></name></person-group><article-title>Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.</article-title><source><italic>Br J Pharmacol.</italic></source><year>2007</year><volume>150</volume><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">17220914</pub-id></element-citation></ref><ref id="ref109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>UngerIeider</surname><given-names>JT.</given-names></name><name><surname>Andyrsiak</surname><given-names>T.</given-names></name><name><surname>Fairbanks</surname><given-names>L.</given-names></name><name><surname>Ellison</surname><given-names>GW.</given-names></name><name><surname>Myers</surname><given-names>LW.</given-names></name></person-group><article-title>Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.</article-title><source><italic>Adv Alcohol Subst Abuse.</italic></source><year>1987</year><volume>7</volume><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">2831701</pub-id></element-citation></ref><ref id="ref110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martyn</surname><given-names>CN.</given-names></name><name><surname>lllis</surname><given-names>LS.</given-names></name><name><surname>Thom</surname><given-names>J.</given-names></name></person-group><article-title>Nabilone in the treatment of multiple sclerosis.</article-title><source><italic>Lancet.</italic></source><year>1995</year><volume>345</volume><fpage>579</fpage><pub-id pub-id-type="pmid">7776785</pub-id></element-citation></ref><ref id="ref111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meinck</surname><given-names>HM.</given-names></name><name><surname>Schonle</surname><given-names>PW.</given-names></name><name><surname>Conrad</surname><given-names>B.</given-names></name></person-group><article-title>Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.</article-title><source><italic>J Neurol.</italic></source><year>1989</year><volume>236</volume><fpage>120</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">2709054</pub-id></element-citation></ref><ref id="ref112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petro</surname><given-names>DJ.</given-names></name><name><surname>Ellenberger</surname><given-names>C.</given-names></name><name><surname>Jr.</surname></name></person-group><article-title>Treatment of human spasticity with delta-9-tetrahydrocannabinol.</article-title><source><italic>J Clin Pharmacol.</italic></source><year>1981</year><volume>21</volume><fpage>413S</fpage><lpage>416S</lpage><pub-id pub-id-type="pmid">6271839</pub-id></element-citation></ref><ref id="ref113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenneisen</surname><given-names>R.</given-names></name><name><surname>Egli</surname><given-names>A.</given-names></name><name><surname>Elsohly</surname><given-names>MA.</given-names></name><name><surname>Henn</surname><given-names>V.</given-names></name><name><surname>Spiess</surname><given-names>Y.</given-names></name></person-group><article-title>The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.</article-title><source><italic>Int J Clin Pharmacol Ther.</italic></source><year>1996</year><volume>34</volume><fpage>446</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">8897084</pub-id></element-citation></ref><ref id="ref114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>M.</given-names></name><name><surname>Mostert</surname><given-names>J.</given-names></name><name><surname>Heersema</surname><given-names>D.</given-names></name><name><surname>De Keyser</surname><given-names>J.</given-names></name></person-group><article-title>Tremor in multiple sclerosis.</article-title><source><italic>J Neurol.</italic></source><year>2007</year><volume>254</volume><fpage>133</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">17318714</pub-id></element-citation></ref><ref id="ref115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killestein</surname><given-names>J.</given-names></name><name><surname>Hoogervorst</surname><given-names>EL.</given-names></name><name><surname>Reif</surname><given-names>M.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Safety, tolerability, and efficacy of orally administered cannabinoids in MS.</article-title><source><italic>Neurology.</italic></source><year>2002</year><volume>58</volume><fpage>1404</fpage><lpage>1407</lpage><pub-id pub-id-type="pmid">12011290</pub-id></element-citation></ref><ref id="ref116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>HS.</given-names></name><name><surname>Werness</surname><given-names>SA.</given-names></name><name><surname>Pugh</surname><given-names>JE.</given-names></name><name><surname>Andrus</surname><given-names>RO.</given-names></name><name><surname>Anderson</surname><given-names>DJ.</given-names></name><name><surname>Domino</surname><given-names>EF.</given-names></name></person-group><article-title>Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers.</article-title><source><italic>Clin Pharmacol Ther.</italic></source><year>1994</year><volume>55</volume><fpage>324</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">8143398</pub-id></element-citation></ref><ref id="ref117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clifford</surname><given-names>DB.</given-names></name></person-group><article-title>Tetrahydrocannabinol for tremor in multiple sclerosis.</article-title><source><italic>Ann Neurol.</italic></source><year>1983</year><volume>13</volume><fpage>669</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">6309074</pub-id></element-citation></ref><ref id="ref118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>P.</given-names></name><name><surname>Bain</surname><given-names>PG.</given-names></name><name><surname>Glickman</surname><given-names>S.</given-names></name><name><surname>Carroll</surname><given-names>C.</given-names></name><name><surname>Zajicek</surname><given-names>J.</given-names></name></person-group><article-title>The effect of cannabis on tremor in patients with multiple sclerosis.</article-title><source><italic>Neurology.</italic></source><year>2004</year><volume>62</volume><fpage>1105</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">15079008</pub-id></element-citation></ref><ref id="ref119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schon</surname><given-names>F.</given-names></name><name><surname>Hart</surname><given-names>PE.</given-names></name><name><surname>Hodgson</surname><given-names>TL.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis.</article-title><source><italic>Neurology.</italic></source><year>1999</year><volume>53</volume><fpage>2209</fpage><lpage>2210</lpage><pub-id pub-id-type="pmid">10599815</pub-id></element-citation></ref><ref id="ref120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>RM.</given-names></name><name><surname>Adekanmi</surname><given-names>O.</given-names></name><name><surname>Waterfield</surname><given-names>MR.</given-names></name><name><surname>Waterfield</surname><given-names>AE.</given-names></name><name><surname>Wright</surname><given-names>D.</given-names></name><name><surname>Zajicek</surname><given-names>J.</given-names></name></person-group><article-title>The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMSLUTS).</article-title><source><italic>Int Urogynecol J Pelvic Floor Dysfunct.</italic></source><year>2006</year><volume>17</volume><fpage>636</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">16552618</pub-id></element-citation></ref><ref id="ref121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PF.</given-names></name></person-group><article-title>GW-1000. GW Pharmaceuticals.</article-title><source><italic>Curr Opin Investig Drugs.</italic></source><year>2004</year><volume>5</volume><fpage>748</fpage><lpage>754</lpage></element-citation></ref><ref id="ref122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaney</surname><given-names>C.</given-names></name><name><surname>Heinzel-Gutenbrunner</surname><given-names>M.</given-names></name><name><surname>Jobin</surname><given-names>P.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.</article-title><source><italic>Mult Scler.</italic></source><year>2004</year><volume>10</volume><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">15327040</pub-id></element-citation></ref><ref id="ref123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wade</surname><given-names>DT.</given-names></name><name><surname>Makela</surname><given-names>P.</given-names></name><name><surname>Robson</surname><given-names>P.</given-names></name><name><surname>House</surname><given-names>H.</given-names></name><name><surname>Bateman</surname><given-names>C.</given-names></name></person-group><article-title>Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.</article-title><source><italic>Mult Scler.</italic></source><year>2004</year><volume>10</volume><fpage>434</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">15327042</pub-id></element-citation></ref><ref id="ref124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wade</surname><given-names>DT.</given-names></name><name><surname>Makela</surname><given-names>PM.</given-names></name><name><surname>House</surname><given-names>H.</given-names></name><name><surname>Bateman</surname><given-names>C.</given-names></name><name><surname>Robson</surname><given-names>P.</given-names></name></person-group><article-title>Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.</article-title><source><italic>Mult Scler.</italic></source><year>2006</year><volume>12</volume><fpage>639</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">17086911</pub-id></element-citation></ref><ref id="ref125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zajicek</surname><given-names>J.</given-names></name><name><surname>Fox</surname><given-names>P.</given-names></name><name><surname>Sanders</surname><given-names>H.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.</article-title><source><italic>Lancet.</italic></source><year>2003</year><volume>362</volume><fpage>1517</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">14615106</pub-id></element-citation></ref><ref id="ref126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zajicek</surname><given-names>JP.</given-names></name><name><surname>Sanders</surname><given-names>HP.</given-names></name><name><surname>Wright</surname><given-names>DE.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.</article-title><source><italic>J Neurol Neurosurg Psychiatry.</italic></source><year>2005</year><volume>76</volume><fpage>1664</fpage><lpage>1669</lpage><pub-id pub-id-type="pmid">16291891</pub-id></element-citation></ref><ref id="ref127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BifuIco</surname><given-names>M.</given-names></name><name><surname>Laezza</surname><given-names>C.</given-names></name><name><surname>Malfitano</surname><given-names>AM.</given-names></name></person-group><article-title>From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches.</article-title><source><italic>Mult Scler.</italic></source><year>2007</year><volume>13</volume><fpage>133</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">17294623</pub-id></element-citation></ref><ref id="ref128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BowIing</surname><given-names>A.</given-names></name></person-group><article-title>Cannabinoids in MS - are we any closer to knowing how best to use them?</article-title><source><italic>Mult Scler.</italic></source><year>2006</year><volume>12</volume><fpage>523</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">17086895</pub-id></element-citation></ref><ref id="ref129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maccarrone</surname><given-names>M.</given-names></name><name><surname>Battista</surname><given-names>N.</given-names></name><name><surname>Centonze</surname><given-names>D.</given-names></name></person-group><article-title>The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.</article-title><source><italic>Prog Neurobiol.</italic></source><year>2007</year><volume>81</volume><fpage>349</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">17276576</pub-id></element-citation></ref><ref id="ref130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mestre</surname><given-names>L.</given-names></name><name><surname>Correa</surname><given-names>F.</given-names></name><name><surname>Docagne</surname><given-names>F.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabinoid system and neuroinflammation: therapeutic perspectives in multiple sclerosis.</article-title><source><italic>Rev Neurol.</italic></source><year>2006</year><volume>43</volume><fpage>541</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">17072810</pub-id></element-citation></ref><ref id="ref131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lastres-Becker</surname><given-names>I.</given-names></name><name><surname>Molina-Holgado</surname><given-names>F.</given-names></name><name><surname>Ramos</surname><given-names>JA.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J.</given-names></name></person-group><article-title>Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.</article-title><source><italic>Neurobiol Dis.</italic></source><year>2005</year><volume>19</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">15837565</pub-id></element-citation></ref><ref id="ref132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>C.</given-names></name><name><surname>Schomacher</surname><given-names>M.</given-names></name><name><surname>Berger</surname><given-names>C.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra.</article-title><source><italic>Acta Neuropathol (Berl).</italic></source><year>2006</year><volume>112</volume><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">16871404</pub-id></element-citation></ref><ref id="ref133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>KnoIler</surname><given-names>N.</given-names></name><name><surname>Levi</surname><given-names>L.</given-names></name><name><surname>Shoshan</surname><given-names>I.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial.</article-title><source><italic>Crit Care Med.</italic></source><year>2002</year><volume>30</volume><fpage>548</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">11990913</pub-id></element-citation></ref><ref id="ref134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maas</surname><given-names>AI.</given-names></name><name><surname>Murray</surname><given-names>G.</given-names></name><name><surname>Henney</surname><given-names>H.</given-names></name><name><surname>3rd.</surname></name><name><surname>et al.</surname></name></person-group><article-title>Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.</article-title><source><italic>Lancet Neurol.</italic></source><year>2006</year><volume>5</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">16361021</pub-id></element-citation></ref><ref id="ref135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>TW.</given-names></name></person-group><article-title>Cannabinoid-based drugs as anti-inflammatory therapeutics.</article-title><source><italic>Nat Rev Immunol.</italic></source><year>2005</year><volume>5</volume><fpage>400</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">15864274</pub-id></element-citation></ref><ref id="ref136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>L.</given-names></name><name><surname>Stella</surname><given-names>N.</given-names></name></person-group><article-title>Cannabinoids and neuroinflammation.</article-title><source><italic>Br J Pharmacol.</italic></source><year>2004</year><volume>141</volume><fpage>775</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">14757702</pub-id></element-citation></ref><ref id="ref137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchalant</surname><given-names>Y.</given-names></name><name><surname>Rosi</surname><given-names>S.</given-names></name><name><surname>Wenk</surname><given-names>GL.</given-names></name></person-group><article-title>Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation.</article-title><source><italic>Neuroscience.</italic></source><year>2007</year><volume>144</volume><fpage>1516</fpage><lpage>1522</lpage><pub-id pub-id-type="pmid">17178196</pub-id></element-citation></ref><ref id="ref138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maresz</surname><given-names>K.</given-names></name><name><surname>Pryce</surname><given-names>G.</given-names></name><name><surname>Ponomarev</surname><given-names>ED.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB(1) on neurons and CB(2) on autoreactive T cells.</article-title><source><italic>Nat Med.</italic></source><year>2007</year><volume>13</volume><fpage>492</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">17401376</pub-id></element-citation></ref><ref id="ref139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffens</surname><given-names>S.</given-names></name><name><surname>Veillard</surname><given-names>NR.</given-names></name><name><surname>Arnaud</surname><given-names>C.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.</article-title><source><italic>Nature.</italic></source><year>2005</year><volume>434</volume><fpage>782</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">15815632</pub-id></element-citation></ref><ref id="ref140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darmani</surname><given-names>NA.</given-names></name><name><surname>Izzo</surname><given-names>AA.</given-names></name><name><surname>Degenhardt</surname><given-names>B.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Involvement of the cannabimimetic compound, N-palmitoyl-ethanoIamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies.</article-title><source><italic>Neuropharmacology.</italic></source><year>2005</year><volume>48</volume><fpage>1154</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">15910891</pub-id></element-citation></ref><ref id="ref141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajesh</surname><given-names>M.</given-names></name><name><surname>Mukhopadhyay</surname><given-names>P.</given-names></name><name><surname>Batkai</surname><given-names>S.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption.</article-title><source><italic>Am J Physiol Heart Ore Physiol.</italic></source><year>2007</year><volume>293</volume><fpage>H909</fpage><lpage>H918</lpage></element-citation></ref><ref id="ref142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croci</surname><given-names>T.</given-names></name><name><surname>Zarini</surname><given-names>E.</given-names></name></person-group><article-title>Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats.</article-title><source><italic>Br J Pharmacol.</italic></source><year>2007</year><volume>150</volume><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">17245360</pub-id></element-citation></ref><ref id="ref143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brotchie</surname><given-names>JM.</given-names></name></person-group><article-title>CB1 cannabinoid receptor signalling in Parkinson's disease.</article-title><source><italic>Curr Opin Pharmacol.</italic></source><year>2003</year><volume>3</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">12550742</pub-id></element-citation></ref><ref id="ref144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maneuf</surname><given-names>YP.</given-names></name><name><surname>Crossman</surname><given-names>AR.</given-names></name><name><surname>Brotchie</surname><given-names>JM.</given-names></name></person-group><article-title>The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.</article-title><source><italic>Exp Neurol.</italic></source><year>1997</year><volume>148</volume><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">9398468</pub-id></element-citation></ref><ref id="ref145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>B.</given-names></name><name><surname>Asbrock</surname><given-names>N.</given-names></name><name><surname>Kathuria</surname><given-names>S.</given-names></name><name><surname>Piomelli</surname><given-names>D.</given-names></name><name><surname>Giuffrida</surname><given-names>A.</given-names></name></person-group><article-title>Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.</article-title><source><italic>Eur J Neurosci.</italic></source><year>2003</year><volume>18</volume><fpage>1607</fpage><lpage>1614</lpage><pub-id pub-id-type="pmid">14511339</pub-id></element-citation></ref><ref id="ref146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>S.</given-names></name><name><surname>Scorticati</surname><given-names>C.</given-names></name><name><surname>Garcia-Arencibia</surname><given-names>M.</given-names></name><name><surname>de Miguel</surname><given-names>R.</given-names></name><name><surname>Ramos</surname><given-names>JA.</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J.</given-names></name></person-group><article-title>Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.</article-title><source><italic>Brain Res.</italic></source><year>2006</year><volume>1073-1074</volume><fpage>209</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">16412990</pub-id></element-citation></ref><ref id="ref147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lastres-Becker</surname><given-names>I.</given-names></name><name><surname>Cebeira</surname><given-names>M.</given-names></name><name><surname>de Ceballos</surname><given-names>ML.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.</article-title><source><italic>Eur J Neurosci.</italic></source><year>2001</year><volume>14</volume><fpage>1827</fpage><lpage>1832</lpage><pub-id pub-id-type="pmid">11860478</pub-id></element-citation></ref><ref id="ref148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisani</surname><given-names>A.</given-names></name><name><surname>Fezza</surname><given-names>F.</given-names></name><name><surname>Galati</surname><given-names>S.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients.</article-title><source><italic>Ann Neurol.</italic></source><year>2005</year><volume>57</volume><fpage>777</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">15852389</pub-id></element-citation></ref><ref id="ref149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreitzer</surname><given-names>AC.</given-names></name><name><surname>Malenka</surname><given-names>RC.</given-names></name></person-group><article-title>Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.</article-title><source><italic>Nature.</italic></source><year>2007</year><volume>445</volume><fpage>643</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">17287809</pub-id></element-citation></ref><ref id="ref150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieradzan</surname><given-names>KA.</given-names></name><name><surname>Fox</surname><given-names>SH.</given-names></name><name><surname>Hill</surname><given-names>M.</given-names></name><name><surname>Dick</surname><given-names>JP.</given-names></name><name><surname>Crossman</surname><given-names>AR.</given-names></name><name><surname>Brotchie</surname><given-names>JM.</given-names></name></person-group><article-title>Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.</article-title><source><italic>Neurology.</italic></source><year>2001</year><volume>57</volume><fpage>2108</fpage><lpage>2111</lpage><pub-id pub-id-type="pmid">11739835</pub-id></element-citation></ref><ref id="ref151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabusch</surname><given-names>HC.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name><name><surname>AltenmuIIer</surname><given-names>E.</given-names></name></person-group><article-title>DeIta9-tetrahydrocannabinol improves motor control in a patient with musician's dystonia.</article-title><source><italic>Mov Disord.</italic></source><year>2004</year><volume>19</volume><fpage>990</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">15300675</pub-id></element-citation></ref><ref id="ref152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>CB.</given-names></name><name><surname>Bain</surname><given-names>PG.</given-names></name><name><surname>Teare</surname><given-names>L.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.</article-title><source><italic>Neurology.</italic></source><year>2004</year><volume>63</volume><fpage>1245</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">15477546</pub-id></element-citation></ref><ref id="ref153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>SH.</given-names></name><name><surname>Kellett</surname><given-names>M.</given-names></name><name><surname>Moore</surname><given-names>AP.</given-names></name><name><surname>Crossman</surname><given-names>AR.</given-names></name><name><surname>Brotchie</surname><given-names>JM.</given-names></name></person-group><article-title>Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.</article-title><source><italic>Mov Disord.</italic></source><year>2002</year><volume>17</volume><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">11835452</pub-id></element-citation></ref><ref id="ref154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesnage</surname><given-names>V.</given-names></name><name><surname>Houeto</surname><given-names>JL.</given-names></name><name><surname>Bonnet</surname><given-names>AM.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.</article-title><source><italic>Clin Neuropharmacol.</italic></source><year>2004</year><volume>27</volume><fpage>108</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">15190231</pub-id></element-citation></ref><ref id="ref155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venderova</surname><given-names>K.</given-names></name><name><surname>Ruzicka</surname><given-names>E.</given-names></name><name><surname>Vorisek</surname><given-names>V.</given-names></name><name><surname>Visnovsky</surname><given-names>P.</given-names></name></person-group><article-title>Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms.</article-title><source><italic>Mov Disord.</italic></source><year>2004</year><volume>19</volume><fpage>1102</fpage><lpage>1106</lpage><pub-id pub-id-type="pmid">15372606</pub-id></element-citation></ref><ref id="ref156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AIsasua</surname><given-names>del Valle A.</given-names></name></person-group><article-title>Implication of cannabinoids in neurological diseases.</article-title><source><italic>Cell Mol Neurobiol.</italic></source><year>2006</year><volume>26</volume><fpage>579</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">16699878</pub-id></element-citation></ref><ref id="ref157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lastres-Becker</surname><given-names>I.</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J.</given-names></name></person-group><article-title>An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments.</article-title><source><italic>Curr Med Chem.</italic></source><year>2006</year><volume>13</volume><fpage>3705</fpage><lpage>3718</lpage><pub-id pub-id-type="pmid">17168732</pub-id></element-citation></ref><ref id="ref158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevcik</surname><given-names>J.</given-names></name><name><surname>Masek</surname><given-names>K.</given-names></name></person-group><article-title>Potential role of cannabinoids in Parkinson's disease.</article-title><source><italic>Drugs Aging.</italic></source><year>2000</year><volume>16</volume><fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">10939305</pub-id></element-citation></ref><ref id="ref159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>M.</given-names></name><name><surname>Dragunow</surname><given-names>M.</given-names></name><name><surname>Faull</surname><given-names>RL.</given-names></name></person-group><article-title>The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.</article-title><source><italic>Neuroscience.</italic></source><year>2000</year><volume>97</volume><fpage>505</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">10828533</pub-id></element-citation></ref><ref id="ref160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richfield</surname><given-names>EK.</given-names></name><name><surname>Herkenham</surname><given-names>M.</given-names></name></person-group><article-title>Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus.</article-title><source><italic>Ann Neurol.</italic></source><year>1994</year><volume>36</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">7944290</pub-id></element-citation></ref><ref id="ref161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>M.</given-names></name><name><surname>Faull</surname><given-names>RL.</given-names></name><name><surname>Dragunow</surname><given-names>M.</given-names></name></person-group><article-title>Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.</article-title><source><italic>Neuroscience.</italic></source><year>1993</year><volume>56</volume><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">8255419</pub-id></element-citation></ref><ref id="ref162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lago</surname><given-names>E.</given-names></name><name><surname>Urbani</surname><given-names>P.</given-names></name><name><surname>Ramos</surname><given-names>JA.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J.</given-names></name></person-group><article-title>Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.</article-title><source><italic>Brain Res.</italic></source><year>2005</year><volume>1050</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">15975564</pub-id></element-citation></ref><ref id="ref163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lastres-Becker</surname><given-names>I.</given-names></name><name><surname>de Miguel</surname><given-names>R.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Makriyannis</surname><given-names>A.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J.</given-names></name></person-group><article-title>Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.</article-title><source><italic>J Neurochem.</italic></source><year>2003</year><volume>84</volume><fpage>1097</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">12603833</pub-id></element-citation></ref><ref id="ref164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pintor</surname><given-names>A.</given-names></name><name><surname>Tebano</surname><given-names>MT.</given-names></name><name><surname>Martire</surname><given-names>A.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.</article-title><source><italic>Neuropharmacology.</italic></source><year>2006</year><volume>51</volume><fpage>1004</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">16895732</pub-id></element-citation></ref><ref id="ref165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consroe</surname><given-names>P.</given-names></name><name><surname>Laguna</surname><given-names>J.</given-names></name><name><surname>AHender</surname><given-names>J.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Controlled clinical trial of cannabidiol in Huntington's disease.</article-title><source><italic>Pharmacol Biochem Behav.</italic></source><year>1991</year><volume>40</volume><fpage>701</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">1839644</pub-id></element-citation></ref><ref id="ref166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MulIer-Vahl</surname><given-names>KR.</given-names></name></person-group><article-title>Cannabinoids reduce symptoms of Tourette's syndrome.</article-title><source><italic>Expert Opin Pharmacother.</italic></source><year>2003</year><volume>4</volume><fpage>1717</fpage><lpage>1725</lpage><pub-id pub-id-type="pmid">14521482</pub-id></element-citation></ref><ref id="ref167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller-Vahl</surname><given-names>KR.</given-names></name><name><surname>Prevedel</surname><given-names>H.</given-names></name><name><surname>Theloe</surname><given-names>K.</given-names></name><name><surname>Kolbe</surname><given-names>H.</given-names></name><name><surname>Emrich</surname><given-names>HM.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name></person-group><article-title>Treatment of Tourette syndrome with deIta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance.</article-title><source><italic>Neuropsychopharmacology.</italic></source><year>2003</year><volume>28</volume><fpage>384</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">12589392</pub-id></element-citation></ref><ref id="ref168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MuIIer-VahI</surname><given-names>KR.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name><name><surname>Koblenz</surname><given-names>A.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.</article-title><source><italic>Pharmacopsychiatry.</italic></source><year>2002</year><volume>35</volume><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11951146</pub-id></element-citation></ref><ref id="ref169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MuIIer-Vahl</surname><given-names>KR.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name><name><surname>Prevedel</surname><given-names>H.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.</article-title><source><italic>J Clin Psychiatry.</italic></source><year>2003</year><volume>64</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">12716250</pub-id></element-citation></ref><ref id="ref170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gadzicki</surname><given-names>D.</given-names></name><name><surname>MuIIer-Vahl</surname><given-names>KR.</given-names></name><name><surname>Heller</surname><given-names>D.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene.</article-title><source><italic>Am J Med Genet B Neuropsychiatr Genet.</italic></source><year>2004</year><volume>127</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">15108190</pub-id></element-citation></ref><ref id="ref171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>GT.</given-names></name><name><surname>Rosen</surname><given-names>BS.</given-names></name></person-group><article-title>Marijuana in the management of amyotrophic lateral sclerosis.</article-title><source><italic>Am J Hosp Palliat Care.</italic></source><year>2001</year><volume>18</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">11467101</pub-id></element-citation></ref><ref id="ref172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilsland</surname><given-names>LG.</given-names></name><name><surname>Dick</surname><given-names>JR.</given-names></name><name><surname>Pryce</surname><given-names>G.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice.</article-title><source><italic>Faseb J.</italic></source><year>2006</year><volume>20</volume><fpage>1003</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">16571781</pub-id></element-citation></ref><ref id="ref173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raman</surname><given-names>C.</given-names></name><name><surname>McAllister</surname><given-names>SD.</given-names></name><name><surname>Rizvi</surname><given-names>G.</given-names></name><name><surname>Patel</surname><given-names>SG.</given-names></name><name><surname>Moore</surname><given-names>DH.</given-names></name><name><surname>Abood</surname><given-names>ME.</given-names></name></person-group><article-title>Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid.</article-title><source><italic>Amyotroph Lateral Scler Other Motor Neuron Disord.</italic></source><year>2004</year><volume>5</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">15204022</pub-id></element-citation></ref><ref id="ref174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weydt</surname><given-names>P.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Witting</surname><given-names>A.</given-names></name><name><surname>MoIIer</surname><given-names>T.</given-names></name><name><surname>Stella</surname><given-names>N.</given-names></name><name><surname>Kliot</surname><given-names>M.</given-names></name></person-group><article-title>Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival.</article-title><source><italic>Amyotroph Lateral Scler Other Motor Neuron Disord.</italic></source><year>2005</year><volume>6</volume><fpage>182</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">16183560</pub-id></element-citation></ref><ref id="ref175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Moore</surname><given-names>DH.</given-names></name><name><surname>Makriyannis</surname><given-names>A.</given-names></name><name><surname>Abood</surname><given-names>ME.</given-names></name></person-group><article-title>AM 1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis.</article-title><source><italic>Eur J Pharmacol.</italic></source><year>2006</year><volume>542</volume><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">16781706</pub-id></element-citation></ref><ref id="ref176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoemaker</surname><given-names>JL.</given-names></name><name><surname>Seely</surname><given-names>KA.</given-names></name><name><surname>Reed</surname><given-names>RL.</given-names></name><name><surname>Crow</surname><given-names>JP.</given-names></name><name><surname>Prather</surname><given-names>PL.</given-names></name></person-group><article-title>The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.</article-title><source><italic>J Neurochem.</italic></source><year>2007</year><volume>101</volume><fpage>87</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">17241118</pub-id></element-citation></ref><ref id="ref177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amtmann</surname><given-names>D.</given-names></name><name><surname>Weydt</surname><given-names>P.</given-names></name><name><surname>Johnson</surname><given-names>KL.</given-names></name><name><surname>Jensen</surname><given-names>MP.</given-names></name><name><surname>Carter</surname><given-names>GT.</given-names></name></person-group><article-title>Survey of cannabis use in patients with amyotrophic lateral sclerosis.</article-title><source><italic>Am J Hosp Palliat Care.</italic></source><year>2004</year><volume>21</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">15055508</pub-id></element-citation></ref><ref id="ref178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eubanks</surname><given-names>LM.</given-names></name><name><surname>Rogers</surname><given-names>CJ.</given-names></name><name><surname>Beuscher</surname><given-names>AE. 4th.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>A molecular link between the active component of marijuana and Alzheimer's disease pathology.</article-title><source><italic>Mol Pharm.</italic></source><year>2006</year><volume>3</volume><fpage>773</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">17140265</pub-id></element-citation></ref><ref id="ref179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>VoIicer</surname><given-names>L.</given-names></name><name><surname>Stelly</surname><given-names>M.</given-names></name><name><surname>Morris</surname><given-names>J.</given-names></name><name><surname>McLaughlin</surname><given-names>J.</given-names></name><name><surname>Volicer</surname><given-names>BJ.</given-names></name></person-group><article-title>Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease.</article-title><source><italic>Int J Geriatr Psychiatry.</italic></source><year>1997</year><volume>12</volume><fpage>913</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">9309469</pub-id></element-citation></ref><ref id="ref180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>WaIther</surname><given-names>S.</given-names></name><name><surname>Mahlberg</surname><given-names>R.</given-names></name><name><surname>Eichmann</surname><given-names>U.</given-names></name><name><surname>Kunz</surname><given-names>D.</given-names></name></person-group><article-title>DeIta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.</article-title><source><italic>Psychopharmacology (Berl).</italic></source><year>2006</year><volume>185</volume><fpage>524</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">16521031</pub-id></element-citation></ref><ref id="ref181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlini</surname><given-names>EA.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Lander</surname><given-names>N.</given-names></name></person-group><article-title>Anticonvulsant activity of four oxygenated cannabidiol derivatives.</article-title><source><italic>Res Commun Chem Pathol Pharmacol.</italic></source><year>1975</year><volume>12</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">1188178</pub-id></element-citation></ref><ref id="ref182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consroe</surname><given-names>P.</given-names></name><name><surname>Martin</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>V.</given-names></name></person-group><article-title>Antiepileptic potential of cannabidiol analogs.</article-title><source><italic>J Clin Pharmacol.</italic></source><year>1981</year><volume>21</volume><fpage>428S</fpage><lpage>436S</lpage><pub-id pub-id-type="pmid">7298873</pub-id></element-citation></ref><ref id="ref183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>AR.</given-names></name><name><surname>Consroe</surname><given-names>P.</given-names></name><name><surname>Kane</surname><given-names>W.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Structure-anticonvulsant activity relationships of cannabidiol analogs.</article-title><source><italic>NIDA Res Monogr.</italic></source><year>1987</year><volume>79</volume><fpage>48</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">3125480</pub-id></element-citation></ref><ref id="ref184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ames</surname><given-names>FR.</given-names></name><name><surname>Cridland</surname><given-names>S.</given-names></name></person-group><article-title>Anticonvulsant effect of cannabidiol.</article-title><source><italic>S Afr Med J.</italic></source><year>1986</year><volume>69</volume><fpage>14</fpage><pub-id pub-id-type="pmid">3941934</pub-id></element-citation></ref><ref id="ref185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consroe</surname><given-names>P.</given-names></name><name><surname>Wolkin</surname><given-names>A.</given-names></name></person-group><article-title>Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.</article-title><source><italic>J Pharmacol Exp Ther.</italic></source><year>1977</year><volume>201</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">850145</pub-id></element-citation></ref><ref id="ref186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consroe</surname><given-names>PF.</given-names></name><name><surname>Wolkin</surname><given-names>AL.</given-names></name></person-group><article-title>Anticonvulsant interaction of cannabidiol and ethosuximide in rats.</article-title><source><italic>J Pharm Pharmacol.</italic></source><year>1977</year><volume>29</volume><fpage>500</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">19602</pub-id></element-citation></ref><ref id="ref187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortesi</surname><given-names>M.</given-names></name><name><surname>Fusar-Poli</surname><given-names>P.</given-names></name></person-group><article-title>Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy.</article-title><source><italic>Med Hypotheses.</italic></source><year>2007</year><volume>68</volume><fpage>920</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">17112679</pub-id></element-citation></ref><ref id="ref188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshpande</surname><given-names>LS.</given-names></name><name><surname>Sombati</surname><given-names>S.</given-names></name><name><surname>Blair</surname><given-names>RE.</given-names></name><name><surname>Carter</surname><given-names>DS.</given-names></name><name><surname>Martin</surname><given-names>BR.</given-names></name><name><surname>DeLorenzo</surname><given-names>RJ.</given-names></name></person-group><article-title>Cannabinoid CB1 receptor antagonists cause status epilepticus-Iike activity in the hippocampal neuronal culture model of acquired epilepsy.</article-title><source><italic>Neurosci Lett.</italic></source><year>2007</year><volume>411</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">17110038</pub-id></element-citation></ref><ref id="ref189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luszczki</surname><given-names>JJ.</given-names></name><name><surname>Czuczwar</surname><given-names>P.</given-names></name><name><surname>Cioczek-Czuczwar</surname><given-names>A.</given-names></name><name><surname>Czuczwar</surname><given-names>SJ.</given-names></name></person-group><article-title>Arachidonyl-2'-chIoroethyIamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.</article-title><source><italic>Eur J Pharmacol.</italic></source><year>2006</year><volume>547</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">16930590</pub-id></element-citation></ref><ref id="ref190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>E.</given-names></name><name><surname>Devinsky</surname><given-names>O.</given-names></name></person-group><article-title>Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy.</article-title><source><italic>Epilepsia.</italic></source><year>2001</year><volume>42</volume><fpage>1266</fpage><lpage>1272</lpage><pub-id pub-id-type="pmid">11737161</pub-id></element-citation></ref><ref id="ref191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeler</surname><given-names>MH.</given-names></name><name><surname>Reifler</surname><given-names>CB.</given-names></name></person-group><article-title>Grand mal convulsions subsequent to marijuana use. Case report.</article-title><source><italic>Dis Nerv Syst.</italic></source><year>1967</year><volume>28</volume><fpage>474</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">5006458</pub-id></element-citation></ref><ref id="ref192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>JM.</given-names></name><name><surname>Carlini</surname><given-names>EA.</given-names></name><name><surname>Pereira</surname><given-names>AE.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Chronic administration of cannabidiol to healthy volunteers and epileptic patients.</article-title><source><italic>Pharmacology.</italic></source><year>1980</year><volume>21</volume><fpage>175</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">7413719</pub-id></element-citation></ref><ref id="ref193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashton</surname><given-names>CH.</given-names></name><name><surname>Moore</surname><given-names>PB.</given-names></name><name><surname>Gallagher</surname><given-names>P.</given-names></name><name><surname>Young</surname><given-names>AH.</given-names></name></person-group><article-title>Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.</article-title><source><italic>J Psychopharmacol.</italic></source><year>2005</year><volume>19</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">15888515</pub-id></element-citation></ref><ref id="ref194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grinspoon</surname><given-names>L.</given-names></name><name><surname>Bakalar</surname><given-names>JB.</given-names></name></person-group><article-title>The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research.</article-title><source><italic>J Psychoactive Drugs.</italic></source><year>1998</year><volume>30</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">9692379</pub-id></element-citation></ref><ref id="ref195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emrich</surname><given-names>HM.</given-names></name><name><surname>Leweke</surname><given-names>FM.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name></person-group><article-title>Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.</article-title><source><italic>Pharmacol Biochem Behav.</italic></source><year>1997</year><volume>56</volume><fpage>803</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">9130308</pub-id></element-citation></ref><ref id="ref196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leweke</surname><given-names>FM.</given-names></name><name><surname>Giuffrida</surname><given-names>A.</given-names></name><name><surname>Koethe</surname><given-names>D.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use.</article-title><source><italic>Schizophr Res.</italic></source><year>2007</year><volume>94</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">17566707</pub-id></element-citation></ref><ref id="ref197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenchadze</surname><given-names>VG.</given-names></name><name><surname>Chkoniia</surname><given-names>ED.</given-names></name></person-group><article-title>Clinical features of cannabis psychosis in schizophrenia patients.</article-title><source><italic>Georgian Med News.</italic></source><year>2006</year><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">16980745</pub-id></element-citation></ref><ref id="ref198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>PK.</given-names></name><name><surname>Jones</surname><given-names>P.</given-names></name><name><surname>Harvey</surname><given-names>I.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabis and acute psychosis.</article-title><source><italic>Schizophr Res.</italic></source><year>1994</year><volume>13</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">7986773</pub-id></element-citation></ref><ref id="ref199"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jockers-Scherubl</surname><given-names>MC.</given-names></name></person-group><article-title>Schizophrenia and cannabis consumption: epidemiology and clinical symptoms.</article-title><source><italic>Prax Kinderpsychol Kinderpsychiatr.</italic></source><year>2006</year><volume>55</volume><fpage>533</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">17058779</pub-id></element-citation></ref><ref id="ref200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BoydeII</surname><given-names>J.</given-names></name><name><surname>Dean</surname><given-names>K.</given-names></name><name><surname>Dutta</surname><given-names>R.</given-names></name><name><surname>Giouroukou</surname><given-names>E.</given-names></name><name><surname>Fearon</surname><given-names>P.</given-names></name><name><surname>Murray</surname><given-names>R.</given-names></name></person-group><article-title>A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis.</article-title><source><italic>Schizophr Res.</italic></source><year>2007</year><volume>93</volume><fpage>203</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">17462864</pub-id></element-citation></ref><ref id="ref201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubertret</surname><given-names>C.</given-names></name><name><surname>Bidard</surname><given-names>I.</given-names></name><name><surname>Ades</surname><given-names>J.</given-names></name><name><surname>Gorwood</surname><given-names>P.</given-names></name></person-group><article-title>Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction.</article-title><source><italic>Schizophr Res.</italic></source><year>2006</year><volume>86</volume><fpage>284</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">16806837</pub-id></element-citation></ref><ref id="ref202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meltzer</surname><given-names>HY.</given-names></name><name><surname>Arvanitis</surname><given-names>L.</given-names></name><name><surname>Bauer</surname><given-names>D.</given-names></name><name><surname>Rein</surname><given-names>W.</given-names></name></person-group><article-title>Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.</article-title><source><italic>Am J Psychiatry.</italic></source><year>2004</year><volume>161</volume><fpage>975</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">15169685</pub-id></element-citation></ref><ref id="ref203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuardi</surname><given-names>AW.</given-names></name><name><surname>Morais</surname><given-names>SL.</given-names></name><name><surname>Guimaraes</surname><given-names>FS.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>Antipsychotic effect of cannabidiol.</article-title><source><italic>J Clin Psychiatry.</italic></source><year>1995</year><volume>56</volume><fpage>485</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">7559378</pub-id></element-citation></ref><ref id="ref204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuardi</surname><given-names>AW.</given-names></name><name><surname>Crippa</surname><given-names>JA.</given-names></name><name><surname>Hallak</surname><given-names>JE.</given-names></name><name><surname>Moreira</surname><given-names>FA.</given-names></name><name><surname>Guimaraes</surname><given-names>FS.</given-names></name></person-group><article-title>Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.</article-title><source><italic>Braz J Med Biol Res.</italic></source><year>2006</year><volume>39</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">16612464</pub-id></element-citation></ref><ref id="ref205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuardi</surname><given-names>AW.</given-names></name><name><surname>Hallak</surname><given-names>JE.</given-names></name><name><surname>Dursun</surname><given-names>SM.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabidiol monotherapy for treatment-resistant schizophrenia.</article-title><source><italic>J Psychopharmacol.</italic></source><year>2006</year><volume>20</volume><fpage>683</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">16401651</pub-id></element-citation></ref><ref id="ref206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chhatwal</surname><given-names>JP.</given-names></name><name><surname>Davis</surname><given-names>M.</given-names></name><name><surname>Maguschak</surname><given-names>KA.</given-names></name><name><surname>Ressler</surname><given-names>KJ.</given-names></name></person-group><article-title>Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear.</article-title><source><italic>Neuropsychopharmacology.</italic></source><year>2005</year><volume>30</volume><fpage>516</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">15637635</pub-id></element-citation></ref><ref id="ref207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varvel</surname><given-names>SA.</given-names></name><name><surname>Wise</surname><given-names>LE.</given-names></name><name><surname>Niyuhire</surname><given-names>F.</given-names></name><name><surname>Cravatt</surname><given-names>BF.</given-names></name><name><surname>Lichtman</surname><given-names>AH.</given-names></name></person-group><article-title>Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task.</article-title><source><italic>Neuropsychopharmacology.</italic></source><year>2007</year><volume>32</volume><fpage>1032</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">17047668</pub-id></element-citation></ref><ref id="ref208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fride</surname><given-names>E.</given-names></name><name><surname>Suris</surname><given-names>R.</given-names></name><name><surname>Weidenfeld</surname><given-names>J.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group><article-title>Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice.</article-title><source><italic>Behav Pharmacol.</italic></source><year>2005</year><volume>16</volume><fpage>431</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">16148448</pub-id></element-citation></ref><ref id="ref209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calhoun</surname><given-names>PS.</given-names></name><name><surname>Sampson</surname><given-names>WS.</given-names></name><name><surname>Bosworth</surname><given-names>HB.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder.</article-title><source><italic>J Consult Clin Psychol.</italic></source><year>2000</year><volume>68</volume><fpage>923</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">11068979</pub-id></element-citation></ref><ref id="ref210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrero</surname><given-names>FJ.</given-names></name><name><surname>Ampuero</surname><given-names>I.</given-names></name><name><surname>Morales</surname><given-names>B.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).</article-title><source><italic>Pharmacogenomics J.</italic></source><year>2005</year><volume>5</volume><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">15668727</pub-id></element-citation></ref><ref id="ref211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimaraes</surname><given-names>FS.</given-names></name><name><surname>Chiaretti</surname><given-names>TM.</given-names></name><name><surname>Graeff</surname><given-names>FG.</given-names></name><name><surname>Zuardi</surname><given-names>AW.</given-names></name></person-group><article-title>Antianxiety effect of cannabidiol in the elevated plus-maze.</article-title><source><italic>Psychopharmacology (Berl).</italic></source><year>1990</year><volume>100</volume><fpage>558</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">1969666</pub-id></element-citation></ref><ref id="ref212"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimaraes</surname><given-names>FS.</given-names></name><name><surname>de Aguiar</surname><given-names>JC.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Breuer</surname><given-names>A.</given-names></name></person-group><article-title>Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze.</article-title><source><italic>Gen Pharmacol.</italic></source><year>1994</year><volume>25</volume><fpage>161</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">7913072</pub-id></element-citation></ref><ref id="ref213"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>RM.</given-names></name><name><surname>Uhlenhuth</surname><given-names>EH.</given-names></name><name><surname>Hartel</surname><given-names>FW.</given-names></name><name><surname>Schuster</surname><given-names>CR.</given-names></name><name><surname>Fischman</surname><given-names>MW.</given-names></name></person-group><article-title>A single dose study of nabilone, a synthetic cannabinoid.</article-title><source><italic>Psychopharmacology (Berl).</italic></source><year>1980</year><volume>71</volume><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">6108592</pub-id></element-citation></ref><ref id="ref214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabre</surname><given-names>LF.</given-names></name><name><surname>McLendon</surname><given-names>D.</given-names></name></person-group><article-title>The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety.</article-title><source><italic>J Clin Pharmacol.</italic></source><year>1981</year><volume>21</volume><fpage>377S</fpage><lpage>382S</lpage><pub-id pub-id-type="pmid">6117575</pub-id></element-citation></ref><ref id="ref215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barratt</surname><given-names>ES.</given-names></name><name><surname>Beaver</surname><given-names>W.</given-names></name><name><surname>White</surname><given-names>R.</given-names></name></person-group><article-title>The effects of marijuana on human sleep patterns.</article-title><source><italic>Biol Psychiatry.</italic></source><year>1974</year><volume>8</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">4361028</pub-id></element-citation></ref><ref id="ref216"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freemon</surname><given-names>FR.</given-names></name></person-group><article-title>Effects of marihuana on sleeping states.</article-title><source><italic>JAMA.</italic></source><year>1972</year><volume>220</volume><fpage>1364</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">4336774</pub-id></element-citation></ref><ref id="ref217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pivik</surname><given-names>RT.</given-names></name><name><surname>Zarcone</surname><given-names>V.</given-names></name><name><surname>Dement</surname><given-names>WC.</given-names></name><name><surname>Hollister</surname><given-names>LE.</given-names></name></person-group><article-title>DeIta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns.</article-title><source><italic>Clin Pharmacol Ther.</italic></source><year>1972</year><volume>13</volume><fpage>426</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">4337346</pub-id></element-citation></ref><ref id="ref218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname><given-names>I.</given-names></name><name><surname>Jones</surname><given-names>R.</given-names></name><name><surname>Walker</surname><given-names>J.</given-names></name><name><surname>Cavness</surname><given-names>C.</given-names></name><name><surname>Floyd</surname><given-names>T.</given-names></name></person-group><article-title>Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns.</article-title><source><italic>Clin Pharmacol Ther.</italic></source><year>1976</year><volume>19</volume><fpage>782</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">178475</pub-id></element-citation></ref><ref id="ref219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname><given-names>I.</given-names></name><name><surname>Jones</surname><given-names>R.</given-names></name><name><surname>Walker</surname><given-names>JM.</given-names></name><name><surname>Cavness</surname><given-names>C.</given-names></name><name><surname>March</surname><given-names>J.</given-names></name></person-group><article-title>Effects of high dosage deIta-9-tetrahydrocannabinol on sleep patterns in man.</article-title><source><italic>Clin Pharmacol Ther.</italic></source><year>1975</year><volume>17</volume><fpage>458</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">164314</pub-id></element-citation></ref><ref id="ref220"><label>220</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>AN.</given-names></name><name><surname>Turner</surname><given-names>C.</given-names></name><name><surname>Stone</surname><given-names>BM.</given-names></name><name><surname>Robson</surname><given-names>PJ.</given-names></name></person-group><article-title>Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults.</article-title><source><italic>J Clin Psychopharmacol.</italic></source><year>2004</year><volume>24</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">15118485</pub-id></element-citation></ref><ref id="ref221"><label>221</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP.</given-names></name><name><surname>Shapiro</surname><given-names>BJ.</given-names></name><name><surname>Lee</surname><given-names>YE.</given-names></name><name><surname>Harper</surname><given-names>CE.</given-names></name></person-group><article-title>Effects of smoked marijuana in experimentally induced asthma.</article-title><source><italic>Am Rev Respir Dis.</italic></source><year>1975</year><volume>112</volume><fpage>377</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">1099949</pub-id></element-citation></ref><ref id="ref222"><label>222</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP.</given-names></name><name><surname>Calvarese</surname><given-names>BM.</given-names></name><name><surname>Simmons</surname><given-names>MS.</given-names></name><name><surname>Shapiro</surname><given-names>BJ.</given-names></name></person-group><article-title>Respiratory status of seventy-four habitual marijuana smokers.</article-title><source><italic>Chest.</italic></source><year>1980</year><volume>78</volume><fpage>699</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">7428453</pub-id></element-citation></ref><ref id="ref223"><label>223</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abboud</surname><given-names>RT.</given-names></name><name><surname>Sanders</surname><given-names>HD.</given-names></name></person-group><article-title>Effect of oral administration of delta-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects.</article-title><source><italic>Chest.</italic></source><year>1976</year><volume>70</volume><fpage>480</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">789025</pub-id></element-citation></ref><ref id="ref224"><label>224</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP.</given-names></name><name><surname>Shapiro</surname><given-names>BJ.</given-names></name><name><surname>Frank</surname><given-names>IM.</given-names></name></person-group><article-title>Acute effects of smoked marijuana and oral delta-9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects.</article-title><source><italic>Am Rev Respir Dis.</italic></source><year>1974</year><volume>109</volume><fpage>420</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">4816823</pub-id></element-citation></ref><ref id="ref225"><label>225</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP.</given-names></name><name><surname>Shapiro</surname><given-names>BJ.</given-names></name><name><surname>Frank</surname><given-names>IM.</given-names></name></person-group><article-title>Acute pulmonary physiologic effects of smoked marijuana and oral 9 -tetrahydrocannabinol in healthy young men.</article-title><source><italic>N Engl J Med.</italic></source><year>1973</year><volume>289</volume><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">4718513</pub-id></element-citation></ref><ref id="ref226"><label>226</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>H.</given-names></name><name><surname>Jr.</surname></name><name><surname>Tashkin</surname><given-names>DP.</given-names></name><name><surname>Simmons</surname><given-names>MS.</given-names></name><name><surname>Calvarese</surname><given-names>B.</given-names></name><name><surname>Shapiro</surname><given-names>BJ.</given-names></name></person-group><article-title>Acute and subacute bronchial effects of oral cannabinoids.</article-title><source><italic>Clin Pharmacol Ther.</italic></source><year>1984</year><volume>35</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">6690168</pub-id></element-citation></ref><ref id="ref227"><label>227</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartley</surname><given-names>JP.</given-names></name><name><surname>Nogrady</surname><given-names>SG.</given-names></name><name><surname>Seaton</surname><given-names>A.</given-names></name></person-group><article-title>Bronchodilator effect of deltaltetrahydrocannabinol.</article-title><source><italic>Br J Clin Pharmacol.</italic></source><year>1978</year><volume>5</volume><fpage>523</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">656294</pub-id></element-citation></ref><ref id="ref228"><label>228</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>SJ.</given-names></name><name><surname>Hartley</surname><given-names>JP.</given-names></name><name><surname>Graham</surname><given-names>JD.</given-names></name></person-group><article-title>Bronchodilator effect of deltaltetrahydrocannabinol administered by aerosol of asthmatic patients.</article-title><source><italic>Thorax.</italic></source><year>1976</year><volume>31</volume><fpage>720</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">797044</pub-id></element-citation></ref><ref id="ref229"><label>229</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benowitz</surname><given-names>NL.</given-names></name><name><surname>Rosenberg</surname><given-names>J.</given-names></name><name><surname>Rogers</surname><given-names>W.</given-names></name><name><surname>Bachman</surname><given-names>J.</given-names></name><name><surname>Jones</surname><given-names>RT.</given-names></name></person-group><article-title>Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms.</article-title><source><italic>Clin Pharmacol Ther.</italic></source><year>1979</year><volume>25</volume><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">428189</pub-id></element-citation></ref><ref id="ref230"><label>230</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanakis</surname><given-names>C.</given-names></name><name><surname>Jr.</surname></name><name><surname>Pouget</surname><given-names>JM.</given-names></name><name><surname>Rosen</surname><given-names>KM.</given-names></name></person-group><article-title>The effects of deIta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade.</article-title><source><italic>Circulation.</italic></source><year>1976</year><volume>53</volume><fpage>703</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">1253395</pub-id></element-citation></ref><ref id="ref231"><label>231</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP.</given-names></name><name><surname>Levisman</surname><given-names>JA.</given-names></name><name><surname>Abbasi</surname><given-names>AS.</given-names></name><name><surname>Shapiro</surname><given-names>BJ.</given-names></name><name><surname>Ellis</surname><given-names>NM.</given-names></name></person-group><article-title>Short-term effects of smoked marihuana on left ventricular function in man.</article-title><source><italic>Chest.</italic></source><year>1977</year><volume>72</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">326498</pub-id></element-citation></ref><ref id="ref232"><label>232</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benowitz</surname><given-names>NL.</given-names></name><name><surname>Jones</surname><given-names>RT.</given-names></name></person-group><article-title>Cardiovascular effects of prolonged delta-9tetrahydrocannabinol ingestion.</article-title><source><italic>Clin Pharmacol Ther.</italic></source><year>1975</year><volume>18</volume><fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">1164818</pub-id></element-citation></ref><ref id="ref233"><label>233</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benowitz</surname><given-names>NL.</given-names></name><name><surname>Jones</surname><given-names>RT.</given-names></name></person-group><article-title>Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man.</article-title><source><italic>J Clin Pharmacol.</italic></source><year>1981</year><volume>21</volume><fpage>214S</fpage><lpage>223S</lpage><pub-id pub-id-type="pmid">6271827</pub-id></element-citation></ref><ref id="ref234"><label>234</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>GoreIick</surname><given-names>DA.</given-names></name><name><surname>Heishman</surname><given-names>SJ.</given-names></name><name><surname>Preston</surname><given-names>KL.</given-names></name><name><surname>Nelson</surname><given-names>RA.</given-names></name><name><surname>Moolchan</surname><given-names>ET.</given-names></name><name><surname>Huestis</surname><given-names>MA.</given-names></name></person-group><article-title>The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers.</article-title><source><italic>Am Heart J.</italic></source><year>2006</year><volume>151</volume><fpage>754 e751</fpage><lpage>754 e755</lpage></element-citation></ref><ref id="ref235"><label>235</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>EisohIy</surname><given-names>MA.</given-names></name><name><surname>Harland</surname><given-names>E.</given-names></name><name><surname>Murphy</surname><given-names>JC.</given-names></name><name><surname>Wirth</surname><given-names>P.</given-names></name><name><surname>Waller</surname><given-names>CW.</given-names></name></person-group><article-title>Cannabinoids in glaucoma: a primary screening procedure.</article-title><source><italic>J Clin Pharmacol.</italic></source><year>1981</year><volume>21</volume><fpage>472S</fpage><lpage>478S</lpage><pub-id pub-id-type="pmid">6271842</pub-id></element-citation></ref><ref id="ref236"><label>236</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ElSohly</surname><given-names>MA.</given-names></name><name><surname>Harland</surname><given-names>EC.</given-names></name><name><surname>Benigni</surname><given-names>DA.</given-names></name><name><surname>Waller</surname><given-names>CW.</given-names></name></person-group><article-title>Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit.</article-title><source><italic>Curr Eye Res.</italic></source><year>1984</year><volume>3</volume><fpage>841</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">6329602</pub-id></element-citation></ref><ref id="ref237"><label>237</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BuchwaId</surname><given-names>A.</given-names></name><name><surname>Derendorf</surname><given-names>H.</given-names></name><name><surname>Ji</surname><given-names>F.</given-names></name><name><surname>Nagaraja</surname><given-names>NY.</given-names></name><name><surname>Wu</surname><given-names>WM.</given-names></name><name><surname>Bodor</surname><given-names>N.</given-names></name></person-group><article-title>Soft cannabinoid analogues as potential anti-glaucoma agents.</article-title><source><italic>Pharmazie.</italic></source><year>2002</year><volume>57</volume><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">11878185</pub-id></element-citation></ref><ref id="ref238"><label>238</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laine</surname><given-names>K.</given-names></name><name><surname>Jarvinen</surname><given-names>K.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Breuer</surname><given-names>A.</given-names></name><name><surname>Jarvinen</surname><given-names>T.</given-names></name></person-group><article-title>Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.</article-title><source><italic>Invest Ophthalmol Vis Sci.</italic></source><year>2002</year><volume>43</volume><fpage>3216</fpage><lpage>3222</lpage><pub-id pub-id-type="pmid">12356827</pub-id></element-citation></ref><ref id="ref239"><label>239</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laine</surname><given-names>K.</given-names></name><name><surname>Jarvinen</surname><given-names>K.</given-names></name><name><surname>Pate</surname><given-names>DW.</given-names></name><name><surname>Urtti</surname><given-names>A.</given-names></name><name><surname>Jarvinen</surname><given-names>T.</given-names></name></person-group><article-title>Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides.</article-title><source><italic>Invest Ophthalmol Vis Sci.</italic></source><year>2002</year><volume>43</volume><fpage>393</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">11818382</pub-id></element-citation></ref><ref id="ref240"><label>240</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pate</surname><given-names>DW.</given-names></name><name><surname>Jarvinen</surname><given-names>K.</given-names></name><name><surname>Urtti</surname><given-names>A.</given-names></name><name><surname>Jarho</surname><given-names>P.</given-names></name><name><surname>Jarvinen</surname><given-names>T.</given-names></name></person-group><article-title>Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits.</article-title><source><italic>Curr Eye Res.</italic></source><year>1995</year><volume>14</volume><fpage>791</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">8529418</pub-id></element-citation></ref><ref id="ref241"><label>241</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porcella</surname><given-names>A.</given-names></name><name><surname>Casellas</surname><given-names>P.</given-names></name><name><surname>Gessa</surname><given-names>GL.</given-names></name><name><surname>Pani</surname><given-names>L.</given-names></name></person-group><article-title>Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana.</article-title><source><italic>Brain Res Mol Brain Res.</italic></source><year>1998</year><volume>58</volume><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">9685662</pub-id></element-citation></ref><ref id="ref242"><label>242</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colasanti</surname><given-names>BK.</given-names></name><name><surname>Brown</surname><given-names>RE.</given-names></name><name><surname>Craig</surname><given-names>CR.</given-names></name></person-group><article-title>Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol.</article-title><source><italic>Gen Pharmacol.</italic></source><year>1984</year><volume>15</volume><fpage>479</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">6098513</pub-id></element-citation></ref><ref id="ref243"><label>243</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colasanti</surname><given-names>BK.</given-names></name><name><surname>Craig</surname><given-names>CR.</given-names></name><name><surname>Allara</surname><given-names>RD.</given-names></name></person-group><article-title>Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol.</article-title><source><italic>Exp Eye Res.</italic></source><year>1984</year><volume>39</volume><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">6499952</pub-id></element-citation></ref><ref id="ref244"><label>244</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>CoIasanti</surname><given-names>BK.</given-names></name><name><surname>Powell</surname><given-names>SR.</given-names></name><name><surname>Craig</surname><given-names>CR.</given-names></name></person-group><article-title>Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene.</article-title><source><italic>Exp Eye Res.</italic></source><year>1984</year><volume>38</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">6323206</pub-id></element-citation></ref><ref id="ref245"><label>245</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>HepIer</surname><given-names>RS.</given-names></name><name><surname>Frank</surname><given-names>IR.</given-names></name></person-group><article-title>Marihuana smoking and intraocular pressure.</article-title><source><italic>Jama.</italic></source><year>1971</year><volume>217</volume><fpage>1392</fpage></element-citation></ref><ref id="ref246"><label>246</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname><given-names>JC.</given-names></name><name><surname>Olsen</surname><given-names>JL.</given-names></name><name><surname>Armstrong</surname><given-names>JR.</given-names></name><name><surname>McKinnon</surname><given-names>SM.</given-names></name></person-group><article-title>Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas.</article-title><source><italic>J Pharm Pharmacol.</italic></source><year>1981</year><volume>33</volume><fpage>40</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">6114151</pub-id></element-citation></ref><ref id="ref247"><label>247</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname><given-names>JC.</given-names></name><name><surname>Perry</surname><given-names>DD.</given-names></name><name><surname>Russell</surname><given-names>DN.</given-names></name><name><surname>Jones</surname><given-names>BF.</given-names></name></person-group><article-title>Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma.</article-title><source><italic>J Clin Pharmacol.</italic></source><year>1981</year><volume>21</volume><fpage>467S</fpage><lpage>471S</lpage><pub-id pub-id-type="pmid">6271841</pub-id></element-citation></ref><ref id="ref248"><label>248</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname><given-names>JC.</given-names></name><name><surname>Crawford</surname><given-names>WJ.</given-names></name><name><surname>Alexander</surname><given-names>PC.</given-names></name><name><surname>Anduze</surname><given-names>AL.</given-names></name><name><surname>Gelbart</surname><given-names>SS.</given-names></name></person-group><article-title>Effect of marihuana on intraocular and blood pressure in glaucoma.</article-title><source><italic>Ophthalmology.</italic></source><year>1980</year><volume>87</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">7053160</pub-id></element-citation></ref><ref id="ref249"><label>249</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>PurneII</surname><given-names>WD.</given-names></name><name><surname>Gregg</surname><given-names>JM.</given-names></name></person-group><article-title>DeIta(9)-tetrahydrocannabinoI, euphoria and intraocular pressure in man.</article-title><source><italic>Ann Ophthalmol.</italic></source><year>1975</year><volume>7</volume><fpage>921</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">1147519</pub-id></element-citation></ref><ref id="ref250"><label>250</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>WJ.</given-names></name><name><surname>Merritt</surname><given-names>JC.</given-names></name></person-group><article-title>Effects of tetrahydrocannabinol on arterial and intraocular hypertension.</article-title><source><italic>IntJ Clin Pharmacol Biopharm.</italic></source><year>1979</year><volume>17</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">468444</pub-id></element-citation></ref><ref id="ref251"><label>251</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomida</surname><given-names>I.</given-names></name><name><surname>Azuara-BIanco</surname><given-names>A.</given-names></name><name><surname>House</surname><given-names>H.</given-names></name><name><surname>Flint</surname><given-names>M.</given-names></name><name><surname>Pertwee</surname><given-names>RG.</given-names></name><name><surname>Robson</surname><given-names>PJ.</given-names></name></person-group><article-title>Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.</article-title><source><italic>J Glaucoma.</italic></source><year>2006</year><volume>15</volume><fpage>349</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">16988594</pub-id></element-citation></ref><ref id="ref252"><label>252</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>W.</given-names></name><name><surname>Christie</surname><given-names>M.</given-names></name><name><surname>Currow</surname><given-names>D.</given-names></name></person-group><article-title>Cannabinoids and cancer: causation, remediation, and palliation.</article-title><source><italic>Lancet Oncol.</italic></source><year>2005</year><volume>6</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15629274</pub-id></element-citation></ref><ref id="ref253"><label>253</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kogan</surname><given-names>NM.</given-names></name></person-group><article-title>Cannabinoids and cancer.</article-title><source><italic>Mini Rev Med Chem.</italic></source><year>2005</year><volume>5</volume><fpage>941</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">16250836</pub-id></element-citation></ref><ref id="ref254"><label>254</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bifulco</surname><given-names>M.</given-names></name><name><surname>Laezza</surname><given-names>C.</given-names></name><name><surname>Gazzerro</surname><given-names>P.</given-names></name><name><surname>Pentimalli</surname><given-names>F.</given-names></name></person-group><article-title>Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review).</article-title><source><italic>Oncol Rep.</italic></source><year>2007</year><volume>17</volume><fpage>813</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">17342320</pub-id></element-citation></ref><ref id="ref255"><label>255</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguado</surname><given-names>T.</given-names></name><name><surname>Carracedo</surname><given-names>A.</given-names></name><name><surname>Julien</surname><given-names>B.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis.</article-title><source><italic>J Biol Chem.</italic></source><year>2007</year><volume>282</volume><fpage>6854</fpage><lpage>6862</lpage><pub-id pub-id-type="pmid">17202146</pub-id></element-citation></ref><ref id="ref256"><label>256</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massi</surname><given-names>P.</given-names></name><name><surname>Vaccani</surname><given-names>A.</given-names></name><name><surname>Bianchessi</surname><given-names>S.</given-names></name><name><surname>Costa</surname><given-names>B.</given-names></name><name><surname>Macchi</surname><given-names>P.</given-names></name><name><surname>Parolaro</surname><given-names>D.</given-names></name></person-group><article-title>The nonpsychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells.</article-title><source><italic>Cell Mol Life Sci.</italic></source><year>2006</year><volume>63</volume><fpage>2057</fpage><lpage>2066</lpage><pub-id pub-id-type="pmid">16909207</pub-id></element-citation></ref><ref id="ref257"><label>257</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BIazquez</surname><given-names>C.</given-names></name><name><surname>Carracedo</surname><given-names>A.</given-names></name><name><surname>Barrado</surname><given-names>L.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabinoid receptors as novel targets for the treatment of melanoma.</article-title><source><italic>FASEB J.</italic></source><year>2006</year><volume>20</volume><fpage>2633</fpage><lpage>2635</lpage><pub-id pub-id-type="pmid">17065222</pub-id></element-citation></ref><ref id="ref258"><label>258</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffarel</surname><given-names>MM.</given-names></name><name><surname>Sarrio</surname><given-names>D.</given-names></name><name><surname>Palacios</surname><given-names>J.</given-names></name><name><surname>Guzman</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>C.</given-names></name></person-group><article-title>Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.</article-title><source><italic>Cancer Res.</italic></source><year>2006</year><volume>66</volume><fpage>6615</fpage><lpage>6621</lpage><pub-id pub-id-type="pmid">16818634</pub-id></element-citation></ref><ref id="ref259"><label>259</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carracedo</surname><given-names>A.</given-names></name><name><surname>Gironella</surname><given-names>M.</given-names></name><name><surname>Lorente</surname><given-names>M.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.</article-title><source><italic>Cancer Res.</italic></source><year>2006</year><volume>66</volume><fpage>6748</fpage><lpage>6755</lpage><pub-id pub-id-type="pmid">16818650</pub-id></element-citation></ref><ref id="ref260"><label>260</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>W.</given-names></name><name><surname>Hegde</surname><given-names>VL.</given-names></name><name><surname>Singh</surname><given-names>NP.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria.</article-title><source><italic>Mol Cancer Res.</italic></source><year>2006</year><volume>4</volume><fpage>549</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">16908594</pub-id></element-citation></ref><ref id="ref261"><label>261</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKallip</surname><given-names>RJ.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name><name><surname>Schlomer</surname><given-names>J.</given-names></name><name><surname>Warren</surname><given-names>JW.</given-names></name><name><surname>Nagarkatti</surname><given-names>PS.</given-names></name><name><surname>Nagarkatti</surname><given-names>M.</given-names></name></person-group><article-title>Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.</article-title><source><italic>Mol Pharmacol.</italic></source><year>2006</year><volume>70</volume><fpage>897</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">16754784</pub-id></element-citation></ref><ref id="ref262"><label>262</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarfaraz</surname><given-names>S.</given-names></name><name><surname>Afaq</surname><given-names>F.</given-names></name><name><surname>Adhami</surname><given-names>VM.</given-names></name><name><surname>Malik</surname><given-names>A.</given-names></name><name><surname>Mukhtar</surname><given-names>H.</given-names></name></person-group><article-title>Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest.</article-title><source><italic>J Biol Chem.</italic></source><year>2006</year><volume>281</volume><fpage>39480</fpage><lpage>39491</lpage><pub-id pub-id-type="pmid">17068343</pub-id></element-citation></ref><ref id="ref263"><label>263</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarnataro</surname><given-names>D.</given-names></name><name><surname>Pisanti</surname><given-names>S.</given-names></name><name><surname>Santoro</surname><given-names>A.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.</article-title><source><italic>Mol Pharmacol.</italic></source><year>2006</year><volume>70</volume><fpage>1298</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">16822929</pub-id></element-citation></ref><ref id="ref264"><label>264</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>M.</given-names></name><name><surname>Duarte</surname><given-names>MJ.</given-names></name><name><surname>Blazquez</surname><given-names>C.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.</article-title><source><italic>Br J Cancer.</italic></source><year>2006</year><volume>95</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">16804518</pub-id></element-citation></ref><ref id="ref265"><label>265</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClung</surname><given-names>CA.</given-names></name></person-group><article-title>The molecular mechanisms of morphine addiction.</article-title><source><italic>Rev Neurosci.</italic></source><year>2006</year><volume>17</volume><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">17139840</pub-id></element-citation></ref><ref id="ref266"><label>266</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>SJ.</given-names></name><name><surname>Jones</surname><given-names>NS.</given-names></name></person-group><article-title>Cocaine: what role does it have in current ENT practice? A review of the current literature.</article-title><source><italic>J Laryngol Otol.</italic></source><year>2006</year><volume>120</volume><fpage>808</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">16848922</pub-id></element-citation></ref><ref id="ref267"><label>267</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>C. P.</given-names></name></person-group><article-title>Benzodiazepine use, abuse, and dependence.</article-title><source><italic>J Clin Psychiatry.</italic></source><year>2005</year><volume>66 SuppI 2</volume><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15762817</pub-id></element-citation></ref><ref id="ref268"><label>268</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lader</surname><given-names>M.</given-names></name></person-group><article-title>Anxiolytic drugs: dependence, addiction and abuse.</article-title><source><italic>Eur Neuropsychopharmacol.</italic></source><year>1994</year><volume>4</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">7919947</pub-id></element-citation></ref><ref id="ref269"><label>269</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luetje</surname><given-names>CM.</given-names></name><name><surname>Wooten</surname><given-names>J.</given-names></name></person-group><article-title>Clinical manifestations of transdermal scopolamine addiction.</article-title><source><italic>Ear Nose Throat J.</italic></source><year>1996</year><volume>75</volume><fpage>210</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">8935644</pub-id></element-citation></ref><ref id="ref270"><label>270</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>KL.</given-names></name></person-group><article-title>A review of the nonmedical use of ketamine: use, users and consequences.</article-title><source><italic>J Psychoactive Drugs.</italic></source><year>2000</year><volume>32</volume><fpage>419</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">11210204</pub-id></element-citation></ref><ref id="ref271"><label>271</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>KL.</given-names></name><name><surname>Darracot-Cankovic</surname><given-names>R.</given-names></name></person-group><article-title>The nonmedical use of ketamine, part two: A review of problem use and dependence.</article-title><source><italic>J Psychoactive Drugs.</italic></source><year>2001</year><volume>33</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">11476262</pub-id></element-citation></ref><ref id="ref272"><label>272</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linazaroso</surname><given-names>G.</given-names></name><name><surname>van Blercom</surname><given-names>N.</given-names></name><name><surname>Lasa</surname><given-names>A.</given-names></name></person-group><article-title>[Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].</article-title><source><italic>Neurologia.</italic></source><year>2004</year><volume>19</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">15088161</pub-id></element-citation></ref><ref id="ref273"><label>273</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenhill</surname><given-names>LL.</given-names></name></person-group><article-title>The science of stimulant abuse.</article-title><source><italic>Pediatr Ann.</italic></source><year>2006</year><volume>35</volume><fpage>552</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">16986449</pub-id></element-citation></ref><ref id="ref274"><label>274</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karsak</surname><given-names>M.</given-names></name><name><surname>Cohen-Solal</surname><given-names>M.</given-names></name><name><surname>Freudenberg</surname><given-names>J.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Cannabinoid receptor type 2 gene is associated with human osteoporosis.</article-title><source><italic>Hum Mol Genet.</italic></source><year>2005</year><volume>14</volume><fpage>3389</fpage><lpage>3396</lpage><pub-id pub-id-type="pmid">16204352</pub-id></element-citation></ref><ref id="ref275"><label>275</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ofek</surname><given-names>O.</given-names></name><name><surname>Karsak</surname><given-names>M.</given-names></name><name><surname>Leclerc</surname><given-names>N.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Peripheral cannabinoid receptor, CB2, regulates bone mass.</article-title><source><italic>Proc Natl Acad Sci U S A.</italic></source><year>2006</year><volume>103</volume><fpage>696</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">16407142</pub-id></element-citation></ref><ref id="ref276"><label>276</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begg</surname><given-names>M.</given-names></name><name><surname>Pacher</surname><given-names>P.</given-names></name><name><surname>Batkai</surname><given-names>S.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Evidence for novel cannabinoid receptors.</article-title><source><italic>Pharmacol Ther.</italic></source><year>2005</year><volume>106</volume><fpage>133</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">15866316</pub-id></element-citation></ref><ref id="ref277"><label>277</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fride</surname><given-names>E.</given-names></name><name><surname>Foox</surname><given-names>A.</given-names></name><name><surname>Rosenberg</surname><given-names>E.</given-names></name><name><surname>et al.</surname></name></person-group><article-title>Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a “CB3” receptor.</article-title><source><italic>Eur J Pharmacol.</italic></source><year>2003</year><volume>461</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12568912</pub-id></element-citation></ref><ref id="ref278"><label>278</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>D.</given-names></name><name><surname>Pryce</surname><given-names>G.</given-names></name><name><surname>Davies</surname><given-names>WL.</given-names></name><name><surname>Hiley</surname><given-names>CR.</given-names></name></person-group><article-title>In silico patent searching reveals a new cannabinoid receptor.</article-title><source><italic>Trends Pharmacol Sci.</italic></source><year>2006</year><volume>27</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16318877</pub-id></element-citation></ref></ref-list><glossary><title>Selected abbreviations and acronyms</title><def-list id="DL1"><def-item><term>ALS</term><def><p>amyotrophic lateral sclerosis</p></def></def-item><def-item><term>CBD</term><def><p>cannabidiol</p></def></def-item><def-item><term>DA</term><def><p>dopamine</p></def></def-item><def-item><term>HD</term><def><p>Huntington's disease</p></def></def-item><def-item><term>IOP</term><def><p>intraocular pressure</p></def></def-item><def-item><term>MS</term><def><p>multiple sclerosis</p></def></def-item><def-item><term>PD</term><def><p>Parkinson's stress disorder</p></def></def-item><def-item><term>PTSD</term><def><p>post-traumatic stress disorder</p></def></def-item><def-item><term>THC</term><def><p>tetrahydrocannabinol</p></def></def-item></def-list></glossary></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/DanceTherParkinsonV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0002769 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0002769 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= DanceTherParkinsonV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.35. |  |